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Nanoparticles are currently being developed as delivery vehicles for therapeutic and contrast imaging agents.
Polymersomes (mesoscopic polymer vesicles) possess a number of attractive biomaterial properties, including
greater biocompatibility, prolonged circulation times, and increased mechanical stability, that make them ideal
for these applications. The polymersome architecture, with its large hydrophilic reservoir and thick
hydrophobic lamellar membrane, provides significant storage capacity for water soluble and insoluble
substances.
The primary thesis aims are to develop multi-functional polymersomes for combination therapeutic
applications, as well as simultaneous therapeutic and diagnostic applications. These multi-functional vesicles
are capable of simultaneously loading both therapeutic agents, such as doxorubicin and combretastatin, and
optical imaging agents, such as porphyrin-based near infrared (NIR) fluorophores, into their hydrophobic and
hydrophilic regions.
Doxorubicin, an anti-neoplastic agent, was encapsulated into PEO-b-PCL polymersomes and its release was
characterized in situ. In vitro and in vivo studies confirmed the therapeutic potential of doxorubicin loaded
polymersomes. Furthermore, the in vitro therapeutic efficacy of polymersomes loaded with combretastatin,
an anti-vascular agent, was established with and without co-doxorubicin loading. The co-encapsulation of
DOX and combretastatin into polymeric vesicles, generates a multi-functional drug loaded polymersome with
the potential to eliminate tumorigenic cells an endothelial cells, respectively.
The use of near infrared (NIR) emissive porphyrin polymersomes, loaded with porphyrin, for biodistribution
studies, to non-invasively track the location of the polymersomes in tumor bearing mice was demonstrated
using a noninvasive small animal optical imaging instrument which detects NIR fluorescence signal. Passive
accumulation of drug loaded NIR-emissive polymersomes in tumor tissues of mice, as well as other organs,
was observed. The study findings suggest the potential utility of NIR-emissive porphyrin polymersome in
clinical diagnostic applications. Furthermore, preliminary results utilizing drug loaded porphyrin
polymersomes to retard tumor growth and monitor vesicle location suggest these vesicles may have great
future clinical utility.
The ability to load components into the polymersome membrane and core shows enormous promise for
future dual modality polymersomes with potential to be nanostructured biomaterials for future theranostic
applications which provide both therapy and diagnosis.
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ABSTRACT 
POLYMERSOMES: MULTI-FUNCTIONAL TOOLS FOR IN VIVO CANCER 
THERANOSTIC APPLICATIONS 
Dalia Hope Levine 
Dr. Daniel A. Hammer 
 Nanoparticles are currently being developed as delivery vehicles for therapeutic 
and contrast imaging agents.  Polymersomes (mesoscopic polymer vesicles) possess a 
number of attractive biomaterial properties, including greater biocompatibility, prolonged 
circulation times, and increased mechanical stability, that make them ideal for these 
applications. The polymersome architecture, with its large hydrophilic reservoir and thick 
hydrophobic lamellar membrane, provides significant storage capacity for water soluble 
and insoluble substances.  
 The primary thesis aims are to develop multi-functional polymersomes for 
combination therapeutic applications, as well as simultaneous therapeutic and diagnostic 
applications.  These multi-functional vesicles are capable of simultaneously loading both 
therapeutic agents, such as doxorubicin and combretastatin, and optical imaging agents, 
such as porphyrin-based near infrared (NIR) fluorophores, into their hydrophobic and 
hydrophilic regions.   
 Doxorubicin, an anti-neoplastic agent, was encapsulated into PEO-b-PCL 
polymersomes and its release was characterized in situ.  In vitro and in vivo studies 
confirmed the therapeutic potential of doxorubicin loaded polymersomes.   Furthermore, 
x 
the in vitro therapeutic efficacy of polymersomes loaded with combretastatin, an anti-
vascular agent, was established with and without co-doxorubicin loading.  The co-
encapsulation of DOX and combretastatin into polymeric vesicles, generates a multi-
functional drug loaded polymersome with the potential to eliminate tumorigenic cells an 
endothelial cells, respectively.   
 The use of near infrared (NIR) emissive porphyrin polymersomes, loaded with 
porphyrin, for biodistribution studies, to non-invasively track the location of the 
polymersomes in tumor bearing mice was demonstrated using a noninvasive small animal 
optical imaging instrument which detects NIR fluorescence signal.  Passive accumulation 
of drug loaded NIR-emissive polymersomes in tumor tissues of mice, as well as other 
organs, was observed.  The study findings suggest the potential utility of NIR-emissive 
porphyrin polymersome in clinical diagnostic applications.   Furthermore, preliminary 
results utilizing drug loaded porphyrin polymersomes to retard tumor growth and monitor 
vesicle location suggest these vesicles may have great future clinical utility.   
 The ability to load components into the polymersome membrane and core shows 
enormous promise for future dual modality polymersomes with potential to be 
nanostructured biomaterials for future theranostic applications which provide both 
therapy and diagnosis.   
xi 
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1.1 BACKGROUND:  INTRODUCTION TO POLYMERSOMES 
 Nanosized carriers are prime candidates for the delivery of highly toxic or 
hydrophobic therapeutic agents.  These delivery vehicles have the potential to augment 
the pharmacodynamic and pharmacokinetic profiles of drug molecules, thereby 
enhancing the therapeutic efficacy of the pharmaceutical agents [1].  Further, 
encapsulating the drug molecule in a delivery system can increase in vivo stability, extend 
its blood circulation time, and further provide a means for controlling the release of the 
agent [1].  Moreover, the delivery system can alter the biodistribution of the drug 
molecule by allowing the agent to accumulate at the tumor site, either passively or 
actively with targeting [1].  In addition to their role in therapeutic drug delivery, by 
serving as diagnostics tools, nanosized carriers can deliver imaging agents to detect and 
non-invasively diagnose disease.  Combining these two ideas, the marriage of the drug 
delivery and imaging in one vehicle leads to the generation of a nanocarrier for 
theranostics—therapeutics and diagnostics.   
 Polymersomes, polymer vesicles self-assembled from a diverse array of synthetic 
amphiphilic block-copolymers containing hydrophilic and hydrophobic blocks [2-4], 
have been shown to possess superior biomaterial properties, including greater stability 
and storage capabilities [5-7], as well as prolonged circulation time, as compared to 
liposomes (vesicles derived from phospholipids) [8].  A particularly attractive storage 
feature, highlighted in Figure 1.1, is the large hydrophobic core of the polymersome 
membrane, which follows from the membrane-forming amphiphilic polymers being 
larger than conventional phospholipids [9]. Further, block copolymer chemistries can be 
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tuned through polymer synthesis to yield polymersomes with diverse functionality [10].  
 A vast majority of vesicles made of synthetic copolymers have dense 
polyethylene oxide (PEO) outer shells, which affords them “stealth” like character that 
may lead to increased circulation times and in vivo biocompatibility [5].  Thus, although 
liposomes are presently used in various biotechnological and pharmaceutical applications 
to improve therapeutic indices and enhance cellular uptake [4], it appears that 
polymersomes can offer superior advantages for future clinical therapeutic and diagnostic  
imaging applications. 
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Figure 1.1- Schematic representations of NIR-emissive polymersomes.  
(A) In aqueous solution, amphiphilic diblock copolymers of polyethyleneoxide-1,2 
polybutadiene (PEO30-PBD46) self-assemble into polymer vesicles (polymersomes) 
with the hydrophobic PBD tails orienting end-to-end to form bilayer membranes.  
The depicted unilamellar polymersome displays an excised cross-sectional slice 
illustrating the bilayer PBD membrane (gray) containing the hydrophobic 
(porphinato)zinc(II) (PZn)-based near-IR fluorophores (NIRFs, red). (B) CAChe-
generated sectional schematic of the NIR-emissive polymersome membrane 
indicating the molecular dimensions of: (i) the PBD component of the bilayer (9.6 
nm); (ii) the large, dispersed PZn-based NIRFs (2.1-to-5.4 nm); and, (iii) a typical 
liposome membrane (3-4 nm) comprised of phospholipids (1-stearoyl-2-oleoyl-sn-
Glycero-3-Phosopho-choline – SOPC). (C) Chemical structures of NIR fluorophores 
PZn2-PZn5.  Copyright (2005) National Academy of Sciences, U.S.A. [9] 
In aqueous solutions, amphiphilic block copolymers can self-assemble into 
mesoscopic structures (≤200nm-50µm in diameter) [3].  The ratio of hydrophilic to 
hydrophobic block volume fraction determines whether micelles (spherical, prolate, or 
oblate), or vesicles (polymersomes) will form [2, 11-13].  As a general rule, however, a 
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ratio of hydrophilic block to total polymer mass of approximately ≤ 35% ± 10% yields 
membrane structures, while copolymers with ratios greater than 45% generally form 
micelles; those with ratios less than 25% form inverted microstructures [14].    Micellar 
structures have been used as intracellular and systemic delivery systems [15-18] but 
present significant limitations when compared to polymersomes. In aqueous solutions, 
they can only encapsulate hydrophobic molecules unless strong binding or covalent 
linking strategies are incorporated for sequestering aqueous-soluble components.  
In contrast to micelles, polymersomes can simultaneously encapsulate hydrophilic 
components in their aqueous interior and hydrophobic molecules within their thick 
lamellar membranes [10].  In addition, biologically active ligands, such as antibodies, can 
be readily conjugated to the exterior brush surface to target the vesicles or to provide a 
therapeutic response [19-22].  These properties of the vesicle architecture (Figure 1.2) 
effectively create a multimodal platform, which can be used for therapeutic (drug 
delivery) and/or diagnostic (imaging) applications.   
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Figure 1.2- General application of polymersome architecture in theranostics.  
Schematic representation of polymersome assembly illustrating three possible 
applications, namely optical imaging, drug delivery, and targeted- therapy.   
Although vesicles can be targeted to specific sites using biologically active 
ligands, the anatomical and pathophysiological abnormalities of tumor tissue alone can be 
utilized to aid in the localized delivery of macromolecules [23].  The tumor vasculature, 
characterized by irregularly shaped, dilated, defective, and/or leaky blood vessels, 
disorganized endothelial cells with fenestrations, as well as other abnormalities, allows 
for the passive accumulation of macromolecules at the tumor site [24].  Further, due to 
poor lymphatic drainage, nanoparticles can accumulate and remain at the tumor site  even 
in the absence of a targeting moiety [25].  This phenomenon is known as the enhanced 
permeability and retention (EPR) effect and makes it possible to achieve high local 
concentrations of macromolecules at the tumor site without specific targeting [24].  
However, a question that has yet to be addressed with polymersomes is how much 
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additional accumulation is possible with targeting.  
1.2 DIBLOCK CO-POLYMERS AND AMPHIPHILIC MOLECULES FORMING 
VESICLES AND RELEASE MECHANISMS  
 In addition to yielding robust multi-compartment vesicles, some of block co-
polymer formulations that have demonstrated promise for controlled release of 
pharmaceuticals.  
 Initial polymersome research by Hammer and Discher used poly(ethylene oxide)-
block-poly(ethylethylene) (PEO-b-PEE) diblock copolymers to demonstrate the 
formation of polymersomes in aqueous solution, as well as to characterize the vesicle’s 
material and physical properties [3].  Additional work in the field has led to the synthesis 
of a number of biocompatible PEO-based amphiphilic block copolymers that form 
aqueous vesicles dispersions, including poly(ethylene oxide)-block-poly(butadiene) 
(PEO-b-PBD) [7].  
A significant limitation of these polymers for in vivo therapeutics is that they are 
not biodegradable and likely not fully biocompatible.  In an effort to create vesicles that 
degrade and release their contents in vivo, PEO-b-PBD polymers have been blended with 
hydrolysable block copolymers, such as poly(ethylene oxide)-block-poly(lactic acid) 
(PEO-b-PLA) or poly(ethylene oxide)-block-poly(caprolactone) (PEO-b-PCL); these 
vesicles have been shown to undergo hydrolytic degradation intracellularly (in the acidic 
environment of the endolysosomal compartment), leading to release of the 
polymersomes’ encapsulates [26-28].  Cryo-TEM images and dynamic light scattering 
measurements serve to demonstrate that nanoscale phase transitions occur in these blends 
8 
as the polyester backbone of the vesicles’ hydrolytic components degrade over time; the 
intact vesicle begins to form pores, which leads to the transition to worm-like micelles 
and ultimately leads to the formation of spherical micelles [27].  Further, it has been 
shown that the release rate of encapsulates in blended polymersomes increases linearly 
with increasing mole ratio of hydrolysable polymer [26].  While these studies represent a 
reasonable first step in the development of polymersomes for therapy, it is critical to 
overcome the hurdle of in vivo toxicity presented by the residual PEO-b-PBD in these 
structures. 
Recently, efforts in our group have focused on the development of self-assembled 
polymersomes from fully-biodegradable synthetic amphiphiles.  The ability to generate 
self-assembled, fully-bioresorbable vesicles comprised of an amphiphilic diblock 
copolymer consisting of two previously FDA-approved building blocks, poly(ethylene 
oxide) (PEO) and poly(caprolactone) (PCL), has been demonstrated by Ghoroghchian 
and coworkers [10].  Unlike polymersomes formed from the blending of “bio-inert” and 
hydrolysable block copolymers [26], these fully-bioresorbable PEO-b-PCL vesicles 
undergo acid catalyzed hydrolysis of their ester linkages and degrade without leaving any 
potentially toxic byproducts [10, 29]. We have demonstrated the release of doxorubicin 
from these systems with time-constants of 18-24 hours, depending on pH; in vivo testing 
of these polymersomes for delivery is underway as further discussed in Chapter 2.  
In contrast to acid catalyzed hydrolysis of the polymer backbone, which occurs on 
the order of hours to days, pH triggered contents release, using block copolymers whose 
solubility in aqueous solutions is dependent upon solution pH, can occur much more 
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rapidly [30].  Borchert and colleagues generated polymersomes comprised of poly(2-
vinylpyridine)-block-poly(ethylene oxide) (P2VP-b-PEO) copolymers and showed that 
the resultant vesicles disassemble in acidic solutions and quickly and completely release 
their contents;  this dissolution is due to the protonation of the P2VP block in acidic 
solutions (below pH 5) which converts the previously hydrophobic block into a water 
soluble polymer [30].  
Cerritelli and colleagues have designed and characterized a diblock copolymer of 
poly(ethylene glycol) (PEG) and poly(propylene sulfide) (PPS) with a reduction sensitive 
disulfide link between the two blocks (PEG-SS-PSS); they demonstrated the ability of 
this block copolymer to form polymer vesicles which burst within a few minutes of 
endocytosis due to the reductive environment in the endosome [31].  In addition to 
diblock copolymers, various other polymeric amphiphiles can form vesicles in aqueous 
solutions.  Napoli et al. synthesized a triblock copolymer of poly(ethylene glycol)-block-
poly(propylene sulfur)-block-poly(ethylene glycol) (PEG-b-PPS-b-PEG) [32], which at 
dilute concentrations forms polymeric vesicles [33, 34].  Napoli and colleagues then 
demonstrated that vesicles comprised of this triblock copolymer could be destabilized by 
the oxidation of the hydrophobic PPS block; when oxidized, PPS is first converted to 
poly(propylene sulphoxide) and subsequently converted to poly(propylene sulfone), both 
of which are more hydrophilic than PPS [35].  This change in hydrophobicity of the 
“hydrophobic” block alters the ratio of hydrophobic block to total polymer mass, leading 
to changes in morphology of the self-assembled structures from vesicles, to worm-like 
micelles, to spherical micelles, and finally to unimolecular micelles [35].  These 
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polymers present the promise of biodegradability, due to oxidation of the hydrophobic 
chain into small molecules solutes that can be readily cleared [32]. 
 Another possibility to generate fully biodegradable vesicles is to utilize 
polypeptides as their composite amphiphiles. Vesicles and micelles comprised of 
polypeptide block copolymers can mimic the shape and biological performance of natural 
vesicles and micelles [36].  Sun et al. synthesized various diblock copolypeptides of 
poly(L-lysine)-block-poly(L-phenylalanine) (PLL-b-PPA) which spontaneously self-
assemble into giant vesicles in aqueous solutions [36].    
 In addition to vesicle generation using block co-polymers, amphiphilic Janus-
dendrimers have demonstrated the ability to self-assembly into regular structures ranging 
from dendritic spherical vesicles to cubosomes.  The mechanical stability of the 
dendrosomes suggest they may be useful for in vivo applications.   
1.3 THERAPEUTIC APPLICATIONS OF POLYMERSOMES 
Currently, many compounds with toxic side effects or low bioavailability hold 
extraordinary promise as potential therapeutic agents.  However, limited bioavailability 
of hydrophobic compounds and/or toxic side effects of these molecules can render their 
therapeutic value ineffective.  Further, the ability of the therapeutic agents to reach the 
target site can be limited by the body’s clearance.    Thus, the development of a 
polymeric delivery vehicle with specifically tuned pharmacokinetics, which can 
encapsulate and release highly toxic therapeutic agents for concentrated local delivery, 
should greatly increase therapeutic efficacy.   
Doxorubicin (DOX) is an amphipathic anti-neoplastic agent that shows much 
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promise in cancer therapy, both alone and in conjunction with antibodies and peptides 
[37] and other chemotherapeutics [27] and pharmaceuticals [38].  One of the major 
limitations associated with administration of this chemotherapeutic agent is cardiac 
myocyte toxicity [39].  However, utilizing drug carriers to deliver doxorubicin can 
alleviate some of the associated cardio-toxicity by altering the pharmacodistribution of 
the drug, thereby reducing the drug concentration in the heart [39].  Delivery of 
doxorubicin in liposomes has been shown to extend the circulation time and alter the 
pharmacodynamics of doxorubicin in such a way as to decrease its toxicity while still 
maintaining its anticancer activity [39].   Using active loading methods originally 
developed for liposomes, doxorubicin can be efficiently loaded into the aqueous center 
[10, 26, 40] of polymer vesicles.   
 Paclitaxel (taxol), an anticancer agent, whose therapeutic efficacy is limited by its 
poor aqueous solubility [41] is currently administered in a mixture of Cremophor EL 
(polyoxyethylated castor oil) and dehydrated ethanol [42] to increase bioavailability.  
Systemic administration of taxol is associated with several negative side effects in 
patients including dyspnea, hypotension, bronchospasm, urticaria, and erythematous 
rashes [42].  In addition, the formulation agent (Cremophor EL) used to solubilize the 
hydrophobic taxol is believed to be responsible for inducing the hypersensitivity 
reactions observed in patients [42].  As a result, various aqueous formulations of taxol 
have been examined to decrease toxic side effects and increase water solubility.  Li et al. 
demonstrated the ability to load taxol into the hydrophobic bilayer of PEO-b-PBD 
polymer vesicles and thus increase the water solubility of this drug while maintaining its 
cytotoxic properties [43].   
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 Combination therapy involves the administration of different classes of 
chemotherapeutics to a patient in order to treat the disease; this approach has been shown 
to be generally effective and many cancer treatment regimes employ such multi-drug 
therapy.  A combination regime of DOX and TAX has been shown clinically to retard 
tumor growth more effectively in comparison to the administration of a single agent 
alone [44].  A reasonable hypothesis is that the synergistic effect of these two drugs 
would be increased when both drugs are administered in the same delivery vehicle, as 
this would ensure delivery of the drug molecules in prescribed ratios to a given target at 
the same time; Ahmed et al. demonstrated the ability to co-encapsulate DOX and TAX 
into polymer vesicles and showed the increased synergistic effect when DOX and TAX 
are in the same polymersome [27, 28].  PEG-b-PLA/PEG-b-PBD blended polymer 
vesicles were loaded with DOX in their hydrophilic reservoir and TAX in their 
hydrophobic bilayer, and were administered in vivo; the results demonstrate a higher 
maximum tolerated dose (MTD), as well as increased tumor shrinkage and maintenance, 
when both agents are administered in vesicles rather than as free drugs [27].  Since there 
are a wide variety of both hydrophilic and hydrophobic pharmaceuticals, this paradigm is 
generally applicable to creating other polymersome-formulations for combination 
therapy. Ultimately, as mentioned before, further work to combine these pharmaceuticals 
within a safe and fully biodegradable formulation is necessary. 
In addition to small molecules, peptides, proteins, and nucleic acids have been 
encapsulated in block copolymer assemblies.  Lee et al. successfully encapsulated 
myoglobin, hemoglobin, and albumin in PEO-b-PBD based polymer vesicles at varying 
degrees of encapsulation efficiency [5].  Arifin and Palmer further demonstrated that 
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bovine hemoglobin (Hb) could be encapsulated inside PEO-b-PBD polymer vesicles with 
oxygen affinities similar to those of human red blood cells; they demonstrated that these 
“polymersomes-encapuslated hemoglobin” (PEH) dispersions could store and transport 
Hb and potentially act as in vivo oxygen therapeutics [45].  The ability to encapsulate 
proteins within polymersomes provides a promise for future protein therapies, which are 
currently facing delivery obstacles.  
1.4 DIANGNOSTIC APPLICATIONS FOR POLYMERSOMES 
The ability to non-invasively image nanoparticles in vivo is a major advantage in 
determining their biodistribution and developing these delivery vehicles for both 
therapeutic and diagnostic applications. Biodistribution studies with polymersomes, in 
particular, would be greatly aided by the encapsulation of an imaging agent in the 
vesicles; this would enable non-invasive monitoring of the location of vesicles during 
drug delivery without the need to sacrifice the animal. Although nanoparticles have been 
used with a spectrum of different imaging modalities including PET [46, 47] and MRI 
[48-50], here we will focus on polymersomes that encapsulate fluorescent agents for 
optical imaging. Because light scattering decreases with increasing wavelength, and 
hemoglobin and water absorption spectra have their nadir in the near infrared (NIR) 
spectral region, much work has been focused on developing NIR contrast agents for in 
vivo imaging studies [9].  To this end, Ghoroghchian et al. have successfully loaded 
porphyrin-based near infrared fluorophores (NIRFs) into the hydrophobic bilayer 
membranes of PEO-b-PBD [9, 10, 51, 52], PEO-b-PCL [52], PEO-b-PEE [52], and 
poly(ethylene oxide)-block-poly(methylcaprolactone) (PEO-b-PmCL) [52] 
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polymersomes.   
Studies using PEO-b-PBD polymersomes have shown that porphyrin-based 
NIRFs, when encapsulated in polymersomes, are able to generate a signal with enough 
intensity to penetrate through 1 cm of a solid tumor [9].  Further, when these NIR-
emissive nanopolymersomes are injected into the tail-vein of mice, the biodistribution of 
the nanoparticles can be tracked in vivo via non-invasive NIR fluorescence-based optical 
imaging [53].  Combining drug delivery with imaging will allow for the continuous non-
invasive monitoring of drug-loaded nanopolymersomes in vivo, obviating the need to 
sacrifice animals at each time point to determine basic pharmacokinetic and 
biodistribution profiles, thereby greatly reducing animal load.   
In addition to developing drug delivery applications, NIR-emissive polymersomes 
have also been shown to be useful for ex vivo cellular labeling and in vivo cellular 
tracking.  Dendritic cells (DCs) play an important role in the immune response and have 
shown potent anticancer activity, leading to DC-based vaccines research [54].  Current 
progress in DC-based vaccines has been, however, limited by various factors [54], some 
of which could be overcome by the development of imaging methods for in vivo DC 
tracking [19].  Christian et al. have demonstrated the ability to label DCs ex vivo with 
polymersomes encapsulating porphyrin-based NIRFs; the TAT peptide, as will be 
discussed in greater detail below, was conjugated to these NIR-emissive polymersome to 
facilitate efficient uptake of polymer vesicles by DCs [19].  Christian and colleagues 
determined that DC surface-associated polymersomes shed over the first 24 to 48 hours; 
but polymer vesicles that were fully internalized by the DCs remained stably incorporated 
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over 3 days [19].  They further showed that the NIR-emissive-polymersome-labeled DCs, 
when administered into the foot pad of mice, traffic to the nearest lymph node (popliteal 
lymph node) and could be tracked in vivo via optical imaging over 33 days [55]. They 
further showed that dendritic cells are sequestered in the liver when the cells are 
delivered intravenously (42), indicating that the mode of dendritic cell delivery will be 
critical for the effectiveness of cancer immunotherapy.  These results suggest that 
polymer vesicles can be employed for cell tracking in longitudinal studies and could thus 
assist in the further development of cell-based vaccines.  Overall, the results in this 
section demonstrate that the loading of imaging agents, such as porphyrin-based NIRFs, 
into the polymersome bilayer creates soft matter optical imaging agents suitable for in 
vitro diagnosis and deep-tissue imaging, non-invasive biodistribution and 
pharmacokinetic studies, as well as in vivo cellular tracking. 
An alternative imaging modality that can be used to image polymer vesicles is 
diagnostic ultrasound.  Zhou et al. prepared air-encapsulated polymersomes via 
lyophilization and rehydration of previously formed polymer vesicles [56].  The polymer 
bubbles were imaged using a Pie Medical Scanner 350 and were visualized as bright 
spots, validating the acoustic activity of air-encapsulated polymersomes [56].  These 
results show that polymer vesicles hold promise in the realm of ultrasound imaging as 
well as optical imaging. 
1.5 POLYMERSOME SURFACE MODIFICATIONS FOR ENHANCED DELIVERY 
AND THERAPY  
 Biologically-active molecules conjugated to the surfaces of polymersomes can be 
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used to direct these nanoparticles to sites of disease and inflammation.  Modifying 
polymer vesicles with biological ligands enables targeting of upregulated receptors and 
molecules on affected cells in vitro and in vivo, thereby enhancing the nanoparticles’ EPR 
effect and further mitigating the potential toxic side effects of systemic delivery.  
Additionally, chemotherapeutics, when used in conjunction with molecular targeting 
agents, can have a synergistic effect [57].  In addition to therapeutic applications, over the 
past two decades the use of anticancer antibodies against molecular targets has been 
developed for tumor imaging applications [37].  Polymer vesicles can be directed to 
specific sites in vivo by conjugation of targeting moieties to the end group of their 
hydrophilic polymer block (usually PEO).  It is important to recognize that the 
conjugation of ligands to the polymersome surfaces can alter the composite polymer 
amphiphiles’ hydrophilic-block-to-total-mass ratio leading to a change in structural 
morphology (e.g. from vesicles to micelles).   
 Using a modular biotin-avidin chemistry, Lin and colleagues functionalized 
polymer vesicles with anti-ICAM-1 antibody to target ICAM-1 (intercellular adhesion 
molecule-1) [21], a molecule that is upregulated on endothelial cells during 
inflammation.  Using micropipette aspiration, they measured the adhesiveness of these 
functionalized polymer vesicles to ICAM-1 immobilized on the surface of polystyrene 
beads and determined that the adhesion strength is linearly proportional to the surface 
density of the anti-ICAM-1 molecules on the polymersome [21].  This finding is in 
contrast to their earlier adhesion experiments carried out with functionalized biotinylated 
polymersomes and avidin coated beads [22], suggesting that the adhesiveness of 
functionalized vesicles is not only dependent on surface density, but also upon the 
17 
presentation/orientation of the targeting molecules on the vesicle surface [21].   
 Additionally, sialyl lewisX (sLeX), a selectin ligand, has been conjugated to 
polymer vesicles using similar biotin-avidin modular chemistry as previously described 
(Hammer et al., in press, Faraday-Discussions 139).  In addition to ICAM-1 molecules, 
selectins are also upregulated at sites of inflammation [21].  In an effort to create 
“leukopolymersomes,” i.e. polymersomes that mimic the adhesive properties of 
leukocytes, dual functionalized vesicles of sLex and anti-ICAM-1 have been made by the 
Hammer lab.  The investigators were able to measure firm and rolling adhesion of anti-
ICAM-1-, sLex-, and anti-ICAM-1/sLex conjugated polymersomes under flow along 
ICAM-1, P-selectin, and ICAM-1/Pselectin coated surfaces, respectively, at venous shear 
rates.  It is believed that dual functionalized leukopolymersomes will be able to serve as 
targeting agents to bring both therapeutics (drugs) and diagnostics (imaging agents) to 
sites of inflammation [21].   
 Meng and co-workers functionalized polymersomes comprised of PEG-block-
poly(ester) and PEG-block-poly(carbonate) diblock copolymers with anti-human IgG (a-
HIgG) or anti-human serum albumin (a-HSA) [6].   a-HIgG and a-HSA were either 
conjugated to the polymersome through covalent attachment to carboxyl groups on the 
vesicle surface or by attachment to protein G, which was covalently attached to the 
polymersome surface via the carboxyl groups; using imaging surface plasmon resonance 
(iSPR), they determined that immobilization of antibodies on the vesicle surface through 
protein G is preferred for targeting [6].  iSPR was further used to demonstrate the 
potential of antibody functionalized vesicles for targeting antigens  [6].   
In addition to targeting, these biologically active ligands can aid in cellular uptake 
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[58].  As previously mentioned, Christian et al. demonstrated that the highly cationic 
HIV-derived TAT peptide, when coupled to NIR-emissive polymersomes, enhances 
cellular delivery of polymer vesicles to dendritic cells while moderately affecting cell 
viability [19].  Intracellular uptake of polymersomes was dependent upon their 
concentration and incubation time in solution; viability was affected by these factors as 
well [19].  
We have recently attempted to conjugate small anti-HER2/neu peptidomimetics, 
designed by Murali and coworkers [57], to polymersomes in order to further develop 
these nanoparticles for both clinical breast cancer diagnosis (NIR-emissive 
polymersomes) and therapy (e.g. with and without doxorubicin incorporation).  In 
comparison to normal epithelial tissues, over-expression of the HER2 protein, a member 
of the epidermal growth factor (EGFR) or HER family, has been seen in approximately 
30% of breast, ovarian, and colon cancers [37, 57].  A family of anti-HER2/neu peptides 
(AHNPs) designed by Murali et al. has a potency on par with that of the full-length 
monoclonal antibody (Herceptin®; Genentech, San Francisco, CA) and demonstrates 
biochemical and biological properties predictive of clinical therapeutic response [57].  It 
has been demonstrated that AHNP prevents tumor growth of transformed T6-17 cells, in 
which HER2/neu is over-expressed, in vivo and in vitro [57].  However, the relatively 
short half-life of peptides and proteins in vivo is one challenge that still remains to be 
overcome when using such agents for therapeutic applications [59].  To overcome the 
challenge of rapid clearance, “stealth” or “sterically stabilized” nanoparticles, such as 
pegylated liposomes, have been employed to deliver peptides [60].  Thus, linking AHNP 
to a nanoparticle surface can greatly improve the pharmacokinetics of the small peptide 
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and allow for targeting as well as improved therapeutic efficacy.   
Ghoroghchian et al. observed changes in polymersome morphology from vesicles 
to micelles post-conjugation of the AHNP peptides to PEO-b-PBD vesicles [53]. 
Vesicles, as well as small spherical micelles, not present in aqueous suspensions of the 
functionalized and unfunctionalized diblock copolymer without peptide, were observed in 
the polymersome suspension post AHNP conjugation [53].  Since these micelles were not 
seen in cryoTEM images of the pure or unfunctionalized polymer, it is probable that they 
are comprised of peptide-conjugated polymer; furthermore, it is hypothesized that the 
vesicles in the suspension consist of polymer not conjugated to AHNP peptide [53].  
Peptide-conjugated vesicle generation with less hydrophobic AHNP peptide family 
members were also attempted and again resulted in phase separation of the diblock 
copolymer-peptide “triblock” from the diblocks [53].  Our interpretation of these results 
is that the underlying polymer material needs to be redesigned to accommodate peptides 
and preserve vesicular structure in order to develop AHNP polymersomes fit for clinical 
diagnostic and therapeutic applications.         
1.6 FUTURE DIRECTIONS 
 Polymersomes are new and valuable tools for both disease diagnosis and therapy.  
Our view is that the enhanced stability and tunability of polymersomes will ultimately 
lead to the development of effective carriers for in vivo drug delivery, molecular imaging, 
and cellular mimicry that extend well beyond what has thus far been achieved with 
phospholipid vesicles.  
In pharmacodelivery, the potential to co-encapsulate two drug molecules in the 
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same polymersome enables combination therapies and eliminates the need to individually 
administer two separate drug formulations.  As such, polymersome may not only be more 
effective in treating recurrent, resistant, or residual tumors, but may also be more 
convenient for patient administration and treatment tolerance.  It is also possible to make 
separate polymersome formulations, each with different drugs or with different dosing 
that deliver drugs in a sequence, as needed for the particular type of disease that is being 
treated. Additionally, localizing therapeutics to the site of intent, either through passive 
accumulation (EPR effect) or with targeting ligands, can enable administration of higher 
doses of drug while minimizing the toxic side effects of systemic delivery.  Further, the 
ability to image polymer vesicles during delivery will offer numerous advantages for 
understanding the mechanisms of therapy as well as efficiently designing drug delivery 
regimens in small animal models. Aside from the demonstration of the activity of multi-
modal polymersomes with existing block copolymers, we believe that further 
developments in polymer design will extend the applicability of polymersomes to 
different drugs and imaging modalities.  
 In addition to targeted therapeutic drug delivery, targeting ligands can be used to 
direct diagnostic agents to tumors sites, assisting in in vivo diagnostic imaging.  Air-
encapsulated polymeric vesicles facilitate nanodiagnostics using ultrasound.  Further, the 
encapsulation of both porphyrin-based near-infrared fluorophores and air into the same 
vesicle should yield a multi-modal polymersome, where both ultrasound and optical 
imaging can be performed concurrently thereby enhancing tumor imaging. Finally, we 
have presented evidence that ultrasonics can be used as a delivery tool; and, thus, we see 
promise for simultaneous clinical diagnostic imaging and in vivo therapeutic drug 
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delivery with the correct polymer formulations.    
1.7 SPECIFIC AIMS 
1.7.1 Aim 1:  To load physiologically relevant therapeutic molecules and imaging 
agents into the fully bioresorbable polymersome center and thick lamellar membrane 
and characterize the kinetics of drug release from the polymersome 
• Aim 1.a) Load clinically relevant anti-cancer therapeutic into the hydrophilic 
interior of the polymersome and characterize the kinetics of drug release from the 
core.   
• Aim 1.b) Load clinically relevant anti-angiogenic therapeutic/vascular disrupting 
agent (VDA) into the hydrophobic bilayer.   
• Aim 1.c) Co-load both therapeutic agents into one polymersome for the 
simultaneous delivery of a vascular disrupting agent and chemotherapeutic. 
• Aim 1.d) Co-encapsulate a therapeutic agent, doxorubicin, into the vesicle core 
and a near infrared imaging agent, porphyrin into the bilayer of the same 
polymersome for biodistribution studies.   
1.7.2 Aim 2:  To demonstrate the potential use of amphiphilic Janus-dendrimers for in 
vivo drug delivery applications 
• Aim 2.a) Load doxorubicin, an anti-neoplastic agent, into the aqueous core of 
dendrosomes, vesicles self assembled from dendrimers and characterize the 
release.   
• Aim 2.b) Determine the dendrosome effects on cell viability using Human Vein 
Endothelial Cells (HUVECs). 
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1.7.3 Aim 3. To use the drug loaded polymersome and porphyrin incorporated 
polymersomes to study the in vitro effects of polymersomes using HUVECs and SK-
BR-3 tumorigenic cells  
• Aim 3.a) Determine the effects of unloaded polymersome on cell viability. 
• Aim 3.b) Determine the cellular uptake of polymersome by HUVECs and SK-
BR-3 Cells. 
• Aim 3.c) Determine the effects of drug loaded polymersomes on cell viability 
when cultured separately and in co-culture. 
1.7.4. Aim 4. To demonstrate the in vivo potential of polymersome for imaging and 
drug delivery applications using athymic nude mice with xenograft tumors  
• Aim 4.a) Determine the biodistribution of polymersome and establish their in vivo 
potential as imaging agents for in vivo deep tissue optical imaging. 
• Aim 4.b) Demonstrate the anti-tumor effect of drug loaded polymersomes on 
tumor suppression in vivo.   
• Aim 4.c) Highlight the potential of drug and imaging agent loaded vesicles for 
theranostic applications. 
1.8 ORGANIZATION OF THE THESIS 
1.8.1 Chapter 1 
 This chapter provides a brief introduction into the various vesicles self assembled 
from diblock copolymers and other amphiphilic building blocks, such as dendrimers.  
Particular detail is given to polymersomes self assembled from diblock copolymers.  The 
motivation for development and characterization of these vesicles is elaborated upon by 
describing their potential for therapeutic applications through delivery of pharmaceutical 
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agents within the core and bilayer and attachment of biologically active ligands to the 
brush surface.  Furthermore, the use of vesicles for diagnostic applications is discussed 
and provides additional motivation for their development as biological tools.  Lastly, the 
potential for these vesicles to combine both therapy and diagnosis into one vesicles is 
briefly discussed.  These ideas will be further explored throughout the body of this thesis.   
1.8.2 Chapter 2 
 The generation of a fully bioresorbable polymersome capable of simultaneously 
delivering a vascular disrupting agent, combretastatin, and a chemotherapeutic, 
doxorubicin, is described.  Furthermore, the method of loading doxorubicin into vesicles 
self-assembled from a variety of diblock copolymers and its release are discussed.  The 
ability to encapsulate each pharmaceutical agent separately as well as in concert is 
highlights the enormous promise for using polymersomes as multi-drug delivery agents 
for the eradication of tumorigenic cells and endothelial cells.   
1.8.3 Chapter 3 
 The formation of self-assembled monodispersed vesicles from amphiphilic Janus-
dendrimers, dendrosomes, is introduced.  In addition, the ability to load doxorubicin into 
these vesicles is demonstrated and the release kinetics of the drug at various pHs is 
established.  Furthermore, the viability effects of these dendrosomes on HUVECs were 
investigated and viability results demonstrate that the uptake of dendrosomes is well 
tolerated by the HUVECs at short times. 
1.8.4 Chapter 4 
 This chapter discusses the generation of a near infrared (NIR) emissive 
polymersome, a self-assembled polymer vesicles loaded with porphyrin in its 
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hydrophobic compartment and highlights the special properties of these fluorophores that 
render them useful for in vivo deep tissue optical imaging applications.  Furthermore, the 
loading of doxorubicin into porphyrin incorporated polymersomes is demonstrated and its 
release is characterized.  Subsequent chapters will demonstrate the significance of 
loading both an imaging agent and chemotherapeutic into one vesicles for in vivo 
applications.   
1.8.5.Chapter 5 
 Cellular studies carried out using Human Umbilical Vein Endothelial Cells 
(HUVECs) and SK-BR-3 tumorigenic cells to determine the cytotoxic potential of drug 
loaded vesicles are discussed in this chapter.  In addition, the effects of unloaded vesicles 
on cellular viability were investigated and results are presented.  Furthermore, the cellular 
uptake of vesicles was explored using porphyrin loaded polymersomes and the findings 
are noted in this chapter.   
1.8.6 Chapter 6  
 The use of porphyrin polymersome for biodistribution and diagnostic studies is 
demonstrated using biocompatible and bioresorbable polymersomes.  Initial studies over 
12 hours to 9 days utilized the biocompatible polymersome comprised of PEO-b-PBD 
due to its in vivo stability (i.e. does not degrade in vivo).  More recent work showed the 
ability to use bioresorbable polymersomes generated from PEO-b-PCL diblock 
copolymer for imaging purposes.  Furthermore, the use of drug loaded vesicles for in vivo 
applications was investigated using doxorubicin loaded PEO-b-PCL polymersomes and is 
described.  Lastly, this chapter closes by marrying the two concepts—imaging and drug 
delivery highlighting the promise for polymersomes as theranostic agents.   
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1.8.7 Chapter 7 
 This final chapter summarizes and highlights many of the findings discussed 
throughout the work presented in the previous chapters.  Preliminary and promising 
results presented are presented in further detail.  Finally, this chapter offers suggestions 
for improving and expanding upon the utility of polymersomes in vivo as drug delivery 
vehicles and imaging agents with the final goal of obtaining multi-functional vesicles for 
in vivo dual therapeutic and theranostic applications.   
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2.1 SUMMARY  
 Polymersomes (polymer vesicles) have attractive biomaterial properties compared 
to phospholipid vesicles, including prolonged circulation times, increased mechanical 
stability, and the unique ability to incorporate hydrophobic molecules within their thick 
lamellar membranes and hydrophilic molecules within their core [5-8].  The generation of 
self-assembled nano-sized vesicles from various diblock copolymers has been 
demonstrated.  The attractive biomaterial properties of these vesicles make the 
polymersome a prime vehicle for the delivery of pharmaceutical agents to tumors.   
 Currently, new thought into cancer treatment suggests the use of combination 
therapy as a method to improve the anti-tumor effects of chemotherapeutics.  Such 
combinations can include multiple chemotherapeutics, chemotherapeutics and peptides or 
antibodies, or chemotherapeutics and anti-angiogenesis agents or vascular disrupting 
agents (VDA).   
 Doxorubicin, an anthracycline antibiotic, is currently used in the treatment of a 
variety of cancers ranging from solid tumor to leukemias.  However, one of the major 
therapeutic limitations of doxorubicin is its associated cardiotoxicity at cumulative doses.  
Encapsulating doxorubicin in the aqueous core of vesicles, however, may decrease the 
toxicity.  The ability to load doxorubicin into biocompatible, bioresorbable, as well as 
stabilized vesicles is demonstrated.   
 Combretastatin A4, a VDA, has been shown to cause vascular failure in new 
vasculature around solid tumors, while not affecting healthy vasculatures.  But, this 
molecule is hydrophobic, limiting its bioavailability and creating challenges to delivery.  
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The incorporation of combretastatin in the hydrophobic vesicle bilayer, however, can 
assist with delivery.  Its incorporation into bioresorbable vesicles with and without 
doxorubicin will be explored in this chapter.  
 Here, we demonstrate the ability to encapsulate each pharmaceutical agent 
separately as well as in combination, thereby highlighting the enormous promise for 
using polymersomes as multi-drug delivery agents for the eradication of tumorigenic 
cells and endothelial cells.   
2.2 INTRODUCTION  
 Currently, many compounds with toxic side effects or low bioavailability hold 
extraordinary promise as potential therapeutic agents.  However, limited bioavailability 
of hydrophobic compounds and/or toxic side effects of these molecules can render their 
therapeutic value ineffective.  Further, the ability of the therapeutic agents to reach the 
target site can be limited by the body’s clearance.  Thus, the development of a polymeric 
delivery vehicle with specifically tuned pharmacokinetics, which can encapsulate and 
release highly toxic therapeutic agents for concentrated local delivery, should greatly 
increase therapeutic efficacy.   
 As discussed in Chapter 1, presently liposomes, vesicles derived from 
phospholipids, are used in a limited number of biotechnological and pharmaceutical 
applications to improve therapeutic indices and enhance cellular uptake [4].  However, in 
contrast to liposomes, polymersomes, polymer vesicles self-assembled from synthetic 
amphiphilies, have been shown to possess superior biomaterial properties [5, 6, 8].  Self-
assembled from amphiphilic polymers, with hydrophilic and hydrophobic blocks, 
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polymersomes can encapsulate aqueous components in their interior and hydrophobic 
molecules within their thick lamellar membranes.   
 The ability to load components into the membrane and interior of polymersomes 
shows enormous promise for dual modality polymersomes that enable delivery of two 
therapeutic agents as will be discussed in this chapter or a therapeutic agent and imaging 
agent as will be discussed in Chapter 4.  As a proof of concept, we have successfully 
loaded various hydrophobic molecules, i.e. Nile Red, into the bilayer as well as various 
hydrophilic molecules, i.e. Calcein, into the aqueous core[10].  Additionally, we have 
successfully loaded both hydrophilic and hydrophobic molecules simultaneously into the 
same polymersomes [10].   
 While the ability to load therapeutics into biocompatible polymeric vesicles, such 
as those generated from PEO-b-PBD, is crucial for understanding and comparing the 
loading and release kinetics of the drug from vesicles, the ability to load pharmaceutical 
agents into bioresorbable polymers is paramount if these vesicles are to be used for in 
vivo drug delivery.  Recently, much attention has been focused on developing 
polymersomes composed of fully-bioresorbable polymers.  The ability to generate self-
assembled, fully-bioresorbable vesicles comprised of an amphiphilic diblock copolymer 
consisting of two previously FDA-approved building blocks: poly(ethylene oxide) (PEO) 
and polycaprolatone (PCL) has been demonstrated [10].  Unlike polymersomes formed 
from the blending of “bio-inert” and hydrolysable block copolymers [26], these fully-
bioresorbable vesicles leave no potentially toxic byproducts upon degradation [29].   
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 In addition to generating vesicles that are biocompatible and biodegradable, the 
ability to stabilize the membrane and control the release of the vesicles contents, is 
imperative for the controlled release of many chemotherapeutics with a narrow 
therapeutic window.   While previous work has demonstrated the stabilization of 
polymersome membranes [61-66] we aimed to design stabilized polymersomes that are 
also biodegradable.  To that end, a functional group (i.e. acrylate) was incorporated at the 
PCL terminal end of PEO-b-PCL diblock polymers. 
 Doxorubicin (DOX) is an amphipathic anti-neoplastic agent that shows much 
promise in cancer therapy, both alone and in conjunction with antibodies and peptides 
[37].  Currently, DOX is widely administered for the treatment of various types of cancer 
ranging from solid tumors to leukemias [67-70].  One of the major limitations associated 
with administration of this chemotherapeutic agent, however, is cardiac myocyte toxicity 
[39].  However, utilizing drug carriers to deliver doxorubicin can alleviate some of the 
associated cardio-toxicity; drug carriers alter the pharmacodistribution of the drug and 
thus reduce the drug’s concentration in the heart [39].  Delivery of doxorubicin in 
liposomes has been shown to extend the circulation time and alter the pharmacodynamics 
of doxorubicin in such a way as to decrease its toxicity while still maintaining its 
anticancer activity [39].  Using active loading methods originally developed for 
liposomes, doxorubicin can be efficiently loaded into the aqueous center [10, 26, 40] of 
polymer vesicles.   
 Combination therapies, involving the combination of various chemotherapeutics 
for cancer treatment, have proven very effective and in fact many cancer therapies now 
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include a multi-drug regimen.  However, therapies that use a Maximum Tolerated Dose 
(MTD) approach, whereby the highest tolerated dose of chemotherapeutic is administered 
as a single dose or over a short period followed by drug free periods, are aimed at 
eliminating as many tumor cells as possible [71]
.
  In addition to the toxic systemic side 
effects associated with the MTD approach, during drug free cycles where the normal 
tissue is allowed to recover, non-tumorigenic endothelial cells composing the vasculature 
can continue to supply the small number of remaining tumor cells with the nutrients and 
oxygen required for survival and remove waste products.  Thus, although the initial 
administration may be efficacious, these “drug free” periods can allow tumors to relapse 
[71].  A new approach to administer chemotherapeutics over longer periods of time with 
small doses is being considered as a way to reduce systemic toxicity and possibly 
improve anti-tumor effects [71]; this slower more controlled dosing, termed ‘metronomic 
chemotherapy’  has been shown to have an anti-angiogenesis effect as well [71].  This 
bodes well for the polymersome as a potential delivery system, where the drug release 
kinetics can be specifically tuned to release drug on both short time scales (hours) to 
longer time scales (days).  The ability to vary release kinetics using different polymer 
backbones will be illustrated here; however the potential to vary the backbone and 
ultimately the release kinetics is much greater than the limited number of examples which 
are presented in this chapter.   
 In addition to administering chemotherapy in a slower more controlled manner as 
a method of creating an anti-angiogenic effect, the combination of chemotherapeutics 
with anti-angiogenic drugs has been examined.  Studies have demonstrated the potential 
of anti-angiogenic drugs to improve the cytotoxic chemotherapeutic effects which both 
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drugs are administered in combination [71].  Since tumors require a network of blood 
vessels to survive and grow, angiogenesis, the growth of new blood vessels is crucial for 
tumor survival and metastasis.  These newly formed blood vessels are required to provide 
oxygen and nutrients to the tumor cells and remove carbon dioxide and waste.  In fact, a 
crucial step in tumor growth and subsequent invasion and metastasis of tumor cells is the 
switch to the “angiogenic phenotype” [72]
.
   
 These nascent blood vessels are immature and their walls are poorly developed 
[73], distinguishing them from normal vasculature
.
  Furthermore, while angiogenesis 
occurs rapidly in tumor tissues, in normal healthy tissues the rate of angiogenesis is 
minimal [74].  For these reasons, as well as others, targeting tumor endothelium is 
advantageous in the treatment of cancer.  As a result, the combination of 
chemotherapeutics with anti-angiogenesis agents, which suppress neovascularization, or 
vascular disrupting agents (VDA), which result in rapid and selective disruption of the 
tumor vasculature has emerged as a promising therapy [71, 73].  These agents target 
genetically stable endothelial cells that constitute the blood vessels around tumors, rather 
than the transformed tumor cells themselves [75]
. 
 However, this combination therapy is not without challenges which must be 
overcome.  First, if the tumor vasculature is destroyed by the VDA prior to administering 
the chemotherapeutic, it can prevent the tumor from receiving the necessary amount of 
chemotherapeutic required to destroy the tumor cells [38].  Furthermore, inhibiting blood 
supply can lead to the upregulation of various cellular markers, for example, hypoxia 
inducible factor (HIF1-α) which has been linked to increased tumor invasiveness and 
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resistance to chemotherapy [38].  However, the use of polymer vesicles may solve some 
of the challenges associated with anti-angiogenic drug/VDA delivery by simultaneously 
delivering both chemotherapeutic and anti-angiogenic agent/VDA directly to the tumor 
site.  As discussed in Chapter 1, the polymersome architecture lends itself nicely to dual 
drug loading.   
 Thus the addition of a VDA into the hydrophobic bilayer of doxorubicin loaded 
vesicles can potentially create a multi-drug polymersome capable of destroying cancerous 
tumors cells and their vasculature.  Combretastatin A4, a hydrophobic vascular disrupting 
agent, inhibits the polymerization of tubulin and causes “irreversible vascular shutdown 
within solid tumors” while leaving the healthy vasculature intact [76].  Hence, 
combretastatin A4, is a key candidate to incorporate into the bilayer of doxorubicin 
loaded vesicles.  Thus, the combination of combretastatin A4 and doxorubicin into one 
vesicle will create a multi-modal platform for the eradication of tumor cells and the 
endothelial cells which support them. 
 This chapter explores the challenges associated with loading DOX into the 
aqueous core of polymersomes generated from biocompatible diblock copolymer, 
poly(ethylene oxide)-b-polybutatdiene (PEO-b-PBD) as well as the bioresorbable diblock 
copolymers, poly(ethylene oxide)-b-polycaprolactone (PEO-b-PCL) and poly(ethylene 
oxide)-b-poly(methyl caprolactone) (PEO-b-PmCL).  In addition, it discusses the release 
of the drug from these vesicles.  Furthermore, the ability to load doxorubicin into 
combretastatin incorporated vesicles is demonstrated, confirming the generation of a 
multi-functional multidrug vesicles for the eradication of tumor cells and the endothelial 
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cells which support them.   
2.3 EXPERIMENTAL METHODS 
2.3.1 Preparation of PEO-b-PCL Polymersomes for Doxorubicin Loading and Release 
Studies 
 Self-assembly via thin-film hydration was employed in order to form the PEO 
(2k)-b-PCL (12k) copolymers into their equilibrium morphologies.  Film hydration has 
been extensively utilized for preparing non-degradable polymersomes comprised of PEO-
b-PBD and PEO-b-PEE diblock copolymers [4, 9].  Briefly, 200 microliters of a 70 
mg/ml (or 35mg/ml for development studies) PEO-b-PCL copolymer solution in 
methylene chloride were uniformly deposited on the surface of a roughened Teflon plate 
followed by evaporation of the solvent for >12h.  Addition of aqueous solution, (~290 
milliosmolar ammonium sulfate solution, pH ~5.4) and sonication for approximately 60 
minutes at 65°C led to spontaneous budding of biodegradable polymersomes off the 
Teflon-deposited thin-film, into the aqueous solution.  The sonication procedure involved 
placing the sample vial containing the aqueous based solution and dried thin-film 
formulation (of polymer uniformly deposited on Teflon) into a sonicator bath (Branson; 
Model 3510) at 60-65°C for 30 minutes followed by constant agitation for 60 minutes at 
60-65°C.  Subsequently, five cycles of freeze-thaw extraction followed by placing the 
sample vials in liquid N2 and subsequently thawing in a water bath at ~55~65°C.  
Extrusion using a pressure driven Lipex Thermobarrel Extruder (1.5 mL capacity) at 
65°C was performed to yield small (<300-nm diameter) unilamellar polymersomes that 
possess appropriately narrow size distributions.  The size distribution of the PEO-b-PCL 
suspension was determined by dynamic light scattering (Figure 2.5).  
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 Once vesicles of the appropriate size were formed, extruded samples were 
dialyzed in iso-osmotic Sodium Acetate Solutions (50 mM Sodium Acetate, 100mM 
Sodium Chloride, pH~5.5).  Dialysis solutions were changed 3 times over approximately 
30 hours.  Post-dialysis, doxorubicin was actively loaded into the polymersomes through 
an ammonium sulfate gradient.  The polymersomes were incubated with doxorubicin in a 
ratio of 1:0.2 polymer:drug (w/w) for 7 hours at a temperature above their main gel to 
liquid-crystalline phase transition temperature [77-79].  Aggregation of DOX within the 
polymersome core led to quenching of its fluorescence emission.  For loading studies, to 
demonstrate loading, fluorescence data was obtained at various time points over the 
seven hour incubation (using a SPEX Fluorolog-3 fluorimeter; λex = 480nm, λem = 
590nm).  This incubation time was later extended to 9 hours.   
 Non-entrapped DOX was removed from the solution (using an Acta Basic 10 
HPLC with Frac 950; the solution was passed through a C-1640 column with Sephacryl 
S500-HR media.  Subsequent studies employed a HiTrap desalting column instead of the 
C-1640 column.  The collected DOX-loaded polymersome suspension was centrifuged 
and concentrated into an approximately 1 mL volume.  The vesicles were then aliquoted 
into various (290 mOsM) solutions buffered at pH ~5 (50 mM sodium acetate and 100 
mM sodium chloride) and pH ~ 7.4 (PBS), with N = 4 samples for each buffer.  Release 
studies of DOX from the loaded polymersomes were initiated immediately following 
aliquoting; DOX fluorescence was measured fluorometrically (using a SPEX Fluorolog-3 
fluorimeter; λex = 480nm, λem = 590nm) at various intervals up to fourteen days.  As 
DOX was released from the polymersome core, and diluted into the surrounding solution, 
its fluorescence emission increased over time.  At the culmination of the study, the 
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samples were solubilized using Triton X-100.  The percent release over time was 
calculated by comparing the measured fluorescence at each time point to final DOX 
fluorescence, as determined upon solubilization of remaining intact polymersomes with 
Triton X-100, at the completion of the study, as per Equation 2.1.  Release rates were 
calculated by comparing the fluorescence at two time points over the time period between 
the time points as per Equation 2.2.   
Equation 2.1: 
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2.3.2 Preparation of PEO-b-PmCL Polymersomes for Doxorubicin Loading and 
Release Studies 
 Similar to PEO-b-PCL and PEO-b-PCL-Ac doxorubicin loaded vesicles, PEO-b-
PmCL vesicles were prepared via thin film hydration.  Briefly, a thin film of polymer was 
deposited on a Teflon film, and the organic was allowed to dry.  Following this step, the 
film was hydrated with ammonium sulfate solution and sonicated at 65C.  Vesicles 
spontaneously self-assembled and budded off the Teflon as a result of the energy 
provided via sonication.  Subsequent to sonication, vesicles were further processed as 
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noted in Section 2.3.1and dialysis was performed.  Samples were dialyzed however, into 
iso-osmotic Sodium Chloride (NaCl) solution acidified with 12.1N HCl to yield a 
solution with pH~5.5, osmolarity~290mOsM.  Dialysis into sodium acetate buffer at pH 
5.5, as performed with PEO-b-PCL vesicles, discussed in Section 2.3.1did not yield 
stable loading as determined via fluorescence measurements; hence dialysis in various 
buffers was attempted, as will be discussed in Section 2.4.2, and it was determined that 
stable fluorescence counts were obtained for loading when acidified NaCl was used as 
the dialysis media.  Three exchanges were made over approximately 30 hours.  Post DOX 
loading, DOX was removed on two HiTrap desalting columns in series (GE Healthcare) 
 The vesicles were then aliquoted into various (290 mOsM) solutions buffered at 
pH ~5 (50 mM sodium acetate and 100 mM sodium chloride) and pH ~ 7.4 (PBS), with 
N = 4 samples for each buffer.  Release studies of DOX from the loaded polymersomes 
were initiated immediately following aliquoting; DOX fluorescence was measured 
fluorometrically (using a SPEX Fluorolog-3 fluorimeter; λex = 480nm, λem = 590nm) at 
various intervals up to fourteen days.  As DOX was released from the polymersome core, 
and diluted into the surrounding solution, its fluorescence emission increased over time.  
At the culmination of the study, the samples were solubilized using Triton X-100.  The 
percent release and release rate over time was calculated by comparing the measured 
fluorescence at each time point to final DOX fluorescence, as determined upon 
solubilization of remaining intact polymersomes with Triton X-100, at the completion of 
the study (Equation 2.1and Equation 2.2). 
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2.3.3 Preparation of PEO-b-PBD Polymersomes for Doxorubicin Loading and Release 
Studies 
Doxorubicin loaded PEO-b-PBD vesicles were prepared via thin film hydration as 
described above.  Briefly, a thin film of polymer (35-70mg/ml in organic) was deposited 
on a Teflon film, and the organic was allowed to dry.  Following this step, the film was 
hydrated with ammonium sulfate solution (pH ~5.3~5.5, ~290mOsM) and sonicated at 
65C.  Vesicles spontaneously self-assembled and budded off the Teflon as a result of 
the energy provided via sonication.  Subsequent to sonication, vesicles were further 
processed as noted in Section 2.3.1and dialysis was performed.   
 In order to determine the loading buffer which yields the most stable loading, for 
development, samples were initially dialyzed, into either iso-osmotic Sodium Chloride 
(NaCl) solution acidified with 12.1N HCl to yield a solution with pH~5.5 or iso-osmotic 
Sodium Acetate/Sodium Chloride Buffer at a pH of 5.5.  (Following this, studies were 
carried out using Acidified NaCl Solution for the dialysis exchange.)  Three exchanges 
were made over approximately 30 hours.   
 The vesicles were then aliquoted into various (290 mOsM) solutions buffered at 
pH ~5 (50 mM sodium acetate and 100 mM sodium chloride) and pH ~ 7.4 (PBS), with 
N = 4 samples for each buffer.  Release studies of DOX from the loaded polymersomes 
were initiated immediately following aliquoting; DOX fluorescence was measured 
fluorometrically (using a SPEX Fluorolog-3 fluorimeter; λex = 480nm, λem = 590nm) at 
various intervals up to fourteen days.  As DOX was released from the polymersome core, 
and diluted into the surrounding solution, its fluorescence emission increased over time.  
At the culmination of the study, the samples were solubilized using Triton X-100.  The 
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percent release over time was calculated by comparing the measured fluorescence at each 
time point to final DOX fluorescence, as determined upon solubilization of remaining 
intact polymersomes with Triton X-100, at the completion of the study. 
2.3.4 Doxorubicin Release from Doxil (lipid vesicles)  
Doxil®, the commercially available liposomal formulation of doxorubicin, was 
obtained from the Hospital of the University of Pennsylvania Pharmacy for research 
purposes only.  Similar to the release studies performed on PEO-b-PCL and PEO-b-
PmCL vesicles, the 10ul of the concentrated Doxil (20mg/10ml) solution was placed in 
2.95 mL of either phosphate buffered saline (PBS) (pH 7.4, 290mOsM), or sodium 
acetate buffered solution (pH 5, 290mOsM) at a concentration below the quenching 
concentration of the encapsulated doxorubicin as determined by absorbance 
measurement.  The final concentration of doxorubicin was .0068mg/ml in buffer.  
Release studies of DOX from the loaded liposomes were initiated immediately following 
aliquoting; fluorescent measurements (using a SPEX Fluorolog-3 fluorimeter; λex = 
480nm, λem = 590nm) were made at various intervals up to fourteen days post aliquoting.  
As noted, as DOX was released from the polymersome core, and diluted into the 
surrounding solution, its fluorescence emission increased over time.  At the culmination 
of the study, the samples were solubilized using Triton X-100 and heat.  The percent 
release over time was calculated by comparing the measured fluorescence at each time 
point to final DOX fluorescence, as determined upon solubilization of remaining intact 
polymersomes with Triton X-100, at the completion of the study. 
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2.3.5 Preparation of PEO-b-PCL-Ac Polymersomes  for Doxorubicin Loading and 
Release Studies 
 Prior to polymersome formation, the functionalize block copolymer was 
synthesized by Joshua S. Katz via a two step process, as shown in Figure 2.1.  Briefly, the 
diblock copolymer was synthesized via a ring opening polymerization of the ε-
caprolactone using monomethoxy PEG as a macroinitiator and stannous octoate as the 
catalyst.  Once the block copolymer was synthesized, the terminal hydroxyl group on the 
caprolactone block was acrylated using acryloyl chloride and dichloromethane. 
 
Figure 2.1- Synthesis of Acrylate-Terminated PEO-b-PCL Copolymer 
 Polymersomes were generated by the self-assembly of polymer thin films on 
roughened Teflon into aqueous medium (70-100 mg/mL solution of polymer in 
methylene chloride, drying, immersion in aqueous solution), followed by sonication at 
65C, freeze-thaw cycling (five cycles liquid nitrogen to 65C), and heated, automated 
extrusion (400 and 200 nm membranes) [4, 9].  The photoinitiator DMPA (18 µg/mg 
polymer for 1:1 mol polymer: mol photoinitiator, as determined by J.S. Katz) was co-cast 
with the polymer on the Teflon for inclusion into the membrane prior to hydration.  DOX 
was encapsulated utilizing an ammonium sulfate gradient [77-79] (a 10 mg/mL DOX in 
49 
water was added to the polymersome suspension at a ratio of 1:0.2 polymer: drug and 
incubated at 65C for 7-9 hours) [77], and free DOX was removed on two HiTrap 
desalting columns in series (GE Healthcare).  Post DOX loading and removal of free 
DOX, UV light exposure was completed with an OmniCure Series 1000 spot-curing lamp 
with a collimating lens (Exfo, Ontario, Canada; 365 nm, 55 mW/cm2).  Release into 
phosphate-buffered saline (PBS) was monitored by recording the fluorescence of 
polymersome suspensions over time (SPEX Fluorolog-3 fluorimeter, λex = 480 nm, λem = 
590 nm).  The amount of DOX encapsulated was determined by polymersome 
dissociation with addition of 100 µL of 30% TritonX-100 and incubation for 60 min at 
37C. 
2.3.6 Preparation of PEO-b-PCL Polymersomes for Combretastatin Incorporation 
Studies 
 Self-assembly via thin-film hydration was used to assemble the PEO-b-PCL 
copolymers into their equilibrium morphologies.  Film hydration has been extensively 
utilized for preparing non-degradable polymersomes comprised of PEO-b-PBD and PEO-
b-PEE diblock copolymers [4, 9].  Briefly, a 70mg/mL PEO-b-PCL copolymer solution 
in methylene chloride was prepared and added to combretastatin at a 0.9:1 drug:polymer 
molar ratio.  Two hundred microliters of the polymer-drug solution were uniformly 
deposited on the surface of a roughened Teflon plate followed by evaporation of the 
solvent for >12h.  Addition of aqueous solution, (~290mOsM Phosphate Buffered Saline, 
PBS) and sonication at 65°C led to spontaneous budding of biodegradable 
polymersomes, off the Teflon-deposited thin-film, into the aqueous solution.  The 
sonication procedure involved placing the sample vial containing the aqueous based 
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solution and dried thin-film formulation (of polymer-drug uniformly deposited on Teflon) 
into a sonicator bath (Branson; Model 3510) @ 60-65°C for 30 minutes followed by 
constant agitation for 60 minutes at 60-65°C.  Subsequently, five cycles of freeze-thaw 
extraction followed by placing the sample vials in liquid N2 and then thawing in a water 
bath at 50-60°C.  Extrusion using a pressure driven Lipex Thermobarrel Extruder (1.5 
mL capacity) at 65°C was performed to yield small (<300-nm diameter) unilamellar 
polymersomes that possess appropriately narrow size distributions.  The size distribution 
of the PEO-b-PCL suspension was determined by dynamic light scattering.  Post 
extrusion, non-entrapped combretastatin was removed from the sample by concentrating 
using a Centricon centrifugal device.  The sample was centrifuged, filtrate removed, and 
additional PBS buffer was added to the concentrated sample for a total of nine times.  
The collected polymersome solution was centrifuged to concentrate the sample.   
 To determine the concentration, one hundred microliter sample aliquots were 
removed and the combretastatin was extracted from the vesicles by adding the aliquot to 
400 microliters of PBS and 500 microliters of methylene chloride, and subsequently 
vortexing and centrifuging the sample.  The resulting aqueous layer was carefully 
removed, and the remaining organic layer with drug was placed in a vacuum.  The dried 
powder resulting from evaporation of the methylene chloride was reconstituted in 1 
milliliter of acetonitrile.  The concentration of combretastatin was determined by 
measuring the absorbance (molar extinction coefficient 12,579M-1cm-1 in acetonitrile at 
300nm).  Polymer concentration was determined by a mathematical calculation. 
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2.3.7 Preparation of Dual Drug PEO-b-PCL Polymersomes for Combretastatin 
Incorporation and Doxorubicin Loading 
 Self-assembly via thin-film hydration was used to assemble the PEO-b-PCL 
copolymers into their equilibrium morphologies.  Film hydration has been extensively 
utilized for preparing non-degradable polymersomes comprised of PEO-b-PBD and PEO-
b-PEE diblock copolymers [4, 9].  As described in section 2.3.670 mg/ml (or 35mg/ml or 
for development studies) PEO-b-PCL copolymer solution in methylene chloride was 
prepared and added to combretastatin at a 0.9:1 drug:polymer molar ratio and a thin film 
of the polymer-drug solution was uniformly deposited on the surface of a roughened 
Teflon plate.  The addition of aqueous solution, (~290mOsM Ammonium Sulfate 
Solution, pH~5.4) and sonication for approximately 60 minutes at 65°C led to 
spontaneous budding of biodegradable polymersomes, off the Teflon-deposited thin-film, 
into the aqueous solution.  As described, the sonication procedure involved placing the 
sample vial into a sonicator bath (Branson; Model 3510) @ 60-65°C for 30 minutes to 
equilibrate the sampled followed by constant agitation for 60 minutes at 60-65°C.  Post 
sonication, five cycles of freeze-thaw extraction followed by placing the sample vials in 
liquid N2 and subsequently thawing in a water bath at 50-60°C.  Extrusion using a 
pressure driven Lipex Thermobarrel Extruder (1.5 mL capacity) at 65°C was performed 
to yield small (<300-nm diameter) unilamellar polymersomes that possess appropriately 
narrow size distributions.  The size distribution of the combretastatin PEO-b-PCL 
suspension was determined by dynamic light scattering.   
Once vesicles of the appropriate size were formed, samples were dialyzed in iso-
osmotic Sodium Acetate Solutions (50 mM Sodium Acetate, 100mM Sodium Chloride, 
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and pH ~ 5.5).  Dialysis solutions were changed 3 times over approximately 30 hours.  
Post-dialysis, doxorubicin was actively loaded into the combretastatin incorporated 
polymersomes through an ammonium sulfate gradient.  The polymersomes were 
incubated with doxorubicin in a ratio of 1:0.2 polymer:drug (w/w) for 9 hours at a 
temperature above their main gel to liquid-crystalline phase transition temperature [77-
79].  Aggregation of DOX within the polymersome core led to quenching of its 
fluorescence emission.  For loading studies, to demonstrate loading, fluorescence data 
was obtained at various time points over the nine hour incubation (using a SPEX 
Fluorolog-3 fluorimeter; λex = 480nm, λem = 590nm).   
 Non-entrapped DOX and combretastatin were removed from the solution (using 
an Acta Basic 10 HPLC with Frac 950; the solution was passed through a HiTrap 
desalting column.  The collected dual drug polymersome suspension was centrifuged and 
concentrated.  Samples were aliquoted and an absorbance spectrum of the resulting 
vesicles was obtained from 190nm to 700nm.  Furthermore, vesicles were solubilized 
using Triton X-100 to demonstrate doxorubicin loading into the aqueous core.  Once the 
vesicles are solubilized, if DOX is in encapsulated in the aqueous core, there should be a 
marked increase in fluorescence from the sample as DOX from aqueous core is freed into 
the external media.   
2.4 RESULTS AND DISCUSSION 
2.4.1 Loading and Release of Doxorubicin in PEO-b-PCL Polymersomes 
 To assess the mechanism by which the PEO-b-PCL vesicles load a 
physiologically relevant, the loading of Doxorubicin (DOX) was monitored 
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spectrofluorometrically (λex=480nm, λem=590nm) over the course of 7 hours; this was 
later followed through 9 hours.  Since the aggregation of doxorubicin inside the core, 
when loaded actively via ammonium sulfate gradient, results in quenching of the 
fluorophore, a decrease in fluorescence over time was generally observed as drug 
molecules load into the vesicles.  However, it should be noted, this decrease in 
fluorescence was concentration dependent, and hence if the concentration outside the 
vesicles was initially high (i.e. above the quenching concentration), loading was actually 
seen as an increase in fluorescence as the DOX concentration in the external solution 
decreased below the quenching concentration with loading.  As such, in all loading 
studies, the final determination of loading was thus made based on stabilization of the 
fluorescence output over time.   
Figure 2.2- Schematic of remote DOX loading in vesicles 
by an ammonium sulfate gradient created between the intravesicle aqueous phase 
and the external solution 
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[79]. 
 
 
 Figure 2.3- Characterizing the loading of doxorubicin into PEO
polymersomes. 
A) Doxorubicin fluorescence spectra
normalized maximum fluorescence of doxorubicin over time, where all values are 
normalized back to the 0h fluorescence maxima.  In both graphs, A) and b) 
decrease in fluorescence and the stabilization of the fluorescent signal after 3 hours 
is clearly demonstrated 
 Using Cryotransmission electron microscopy (cryo
remote loading of DOX did not adversely affect the structure of the membrane or 
vesicular structure of the polymersome.  DOX loaded polymersomes were observed via 
cryo-TEM (Figure 2.1) and demonstrate the vesicle like morphology seen with unloaded 
polymersomes.  However, in contrast to unloaded polymersomes, images of DOX loaded 
vesicles have an electron
resulting from the fibrous
encapsulated in the presence of a pH gradient
55 
 over time while loading into vesicles.  B) The 
-TEM) we confirmed that the 
-opaque band in the aqueous core [79] (Figure 
-bundle aggregates formed when doxorubicin precipitates when 
 [80].   
 
-b-PCL 
he 
2.1, A-C) 
Figure 2.4- Cryo-TEM Images of Doxorubicin loaded PEO
Note the solid like aggregates in both circular and rod like form in the vesicle 
center; this is the solgel 
 We assessed the mechanism b
2.4.1) and release a physiologically relevant encapsulant.  As a model system, 
Doxorubicin, an anti neoplastic agent which inhibits DNA replication, was actively 
encapsulated into the aqueous compartment of 200nm PEO
though an ammonium sulfate gradient 
where doxorubicin release
over 14 days.  Cumulative release and release rate were calculated according to equations 
Equation 2.1and Equation 
 While the kinetics of the release varied at the two pHs, an initial burst release 
phase (where approximately
observed for both pH’s followed by a more controlled pH dependent release
day release study (Figure 
condition (Figure 2.6B).  
entire 14 days; it appears that the dominant mechanism of release at both short and long 
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-b-PCL vesicles.  
 
y which PEO-b-PCL vesicles load (See Section 
-b-PCL vesicles (
[77, 79, 81] (See Section 2.3.1).  
 was monitored fluorometrically (λex=480nm, 
2.2, respectively.   
 20% of the initial payload within the first 8 hrs) was 
2.6A).  However, the dynamics of release varied at each 
At a pH of 5, one single release phase (β’) is observed over the 
 
 
Figure 2.5) 
 in situ release 
C) 
λem=590nm) 
 over the 14 
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times at this pH is acid catalyzed hydrolysis of the PCL membrane (Figure 2.6C).  In 
contrast, at a pH of 7.4, two distinct phases (α, β) are observed.  Kinetic release studies 
suggest that initially (days 1-5, α phase) doxorubicin release from the polymersome core 
is primarily dependent upon passive diffusion of the drug across the PCL membrane.  At 
subsequent times, (days 5-14, β phase) drug release is predominantly facilitated by 
hydrolytic matrix degradation of the caprolactone backbone Figure 2.6C).  The rate 
constants of the β (pH 7.4) and β’ (pH 5) phases are similar further suggesting a similar 
mechanism of release.  Since acid catalyzed hydrolysis of the membrane occurs at both 
short and long times at pH 5, DOX release at pH 5 is more rapid that at pH 7.4  
 
Figure 2.5- Cumulative histogram of the size distribution of PEO(2k)-b-PCL(12k)-
based polymersomes as obtained via dynamic light scattering (DLS) at 25oC.   
Vesicles were formed via thin film self- assembly upon aqueous hydration and 
heating at 65oC for 1 hr.  A mono-dispersed distribution of 200 nm diameter 
polymersomes was subsequently obtained upon 5 cycles of freeze-thaw extraction 
followed by extrusion through a thermo-barrel supported (5 passes at 65oC) 200 nm 
pore cutoff membrane. 
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Figure 2.6- in situ release of doxorubicin from PEO-b-PCL polymersomes  
(A) Cumulative in situ release of doxorubicin, loaded within 200 nm diameter 
PEO(2K)-b-PCL(12K)-based polymersomes, under various physiological conditions 
(pH 5 and 7.4; T = 37 °C) as measured fluorometrically over 14 days.  N = 4 samples 
at each data point; individual data points for each sample varied by less than 10% 
of the value displayed at each time interval.  (B) Release rates of DOX (Vdox) from 
200 nm diameter PEO(2K)-b-PCL(12K)-based polymersomes vs time.  Dotted and 
solid lines represent exponential fits obtained by regression analysis R2 = 0.99 for 
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each curve), and the displayed equations correspond to the respective release 
regimes (α, β, β’,).  (C) Schematic illustrating differing regimes of DOX release via 
(α) intrinsic drug permeation through intact vesicle membranes vs (β, β′) release 
predominantly by PCL matrix degradation. 
2.4.2 Loading and Release of Doxorubicin into PEO-b-PmCL Vesicles 
 To determine whether the addition of a methyl group on the γ-carbon of the 
caprolactone back bone alters the loading or release rate of doxorubicin from the vesicle 
interior, Doxorubicin was actively encapsulated into the aqueous compartment of 200nm 
PEO-b-PmCL vesicles (Figure 2.1) though an ammonium sulfate and pH gradient [77, 
79, 81]  (See Section 2.3.2).  Figure 2.7A demonstrates that an increase in DOX 
fluorescence occurs post vesicle destruction with Triton X-100; as explained above, 
releasing the DOX from the vesicle core results in an increase in DOX fluorescence.  
Figure 2.7B-D are cryo-TEM images of DOX loaded PEO-b-PmCL vesicles; the areas in 
the center of the vesicle are due to the DOX-SO4-2 gel-like precipitate, and further 
demonstrate encapsulation of DOX into the aqueous core; however, loading into each 
vesicle appears variable and it appears that some vesicles may have loaded more or less 
DOX than other vesicles.   
Figure 2.7- Doxorubicin loading in PEO
A) Doxorubicin Fluorescence pre (PTX) and post (TX) treatment with Triton X
The increase in fluorescence upon vesicle rupture due to Triton X
loading of doxorubicin into the aqueous core of the vesicles.  B
of DOX loaded PEO-b-PmCL vesicles where the DOX aggregates, circular and rod
like in form, appear as dark areas in the aqueous core.  
 In contrast to PEO
osmotic Sodium Chloride (NaCl) solution (pH~5.5, os
dialysis into sodium acetate buffer at pH 5.5 yielded stable DOX loading for PEO
vesicles (Figure 2.3), dialysis in this buffer did n
fluorescence measurements) for PEO
acetate buffer, when loading PEO
conditions (starting) to basic conditions after dialysis, demonstrating the efflux of 
ammonia and the establishment of an H
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-b-PmCL vesicles  
-100 confirms the 
-D) CyroTEM images 
 
-b-PCL vesicles, samples were dialyzed into unbuffered iso
molarity~290mOsM).  While 
ot yield stable loading (as determined via 
-b-PmCL vesicles (Figure 2.8).  The pH of the spent 
-b-PCL vesicles showed an increased in pH from acidic 
+
 gradient (Figure 2.2).  This was not observed for 
 
-100.  
-
-
-b-PCL 
the loading of DOX in PEO
solutions remained acidic.  It was surmised that the methyl group in the PmCL block 
have increased the hydrophobicity of the block in comparison to PCL, hindering the 
ammonia from crossing the bilayer and establishing the pH gradient.  As such, dialysis in 
various buffered and unbuffered solutions was attempted, and it was determined 
stable fluorescence counts (correlating to stable loading) were obtained for loading when 
acidified NaCl was used as the dialysis media (
examined, the pH of the spent acidified NaCl also increased from acidic to basic 
conditions, suggesting that NH
gradient across the PmCL membrane.  
Figure 2.8- Doxorubicin fluorescence over time while loading into PEO
vesicles after dialysis in various iso
-
C.   Note the fluorescence remains relatively stable after three hours of loading 
for either of the samples dialyzed in sodium chloride solution.  NaOAc 
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-b-PmCL vesicles, where the pH of the spent dialysis 
Figure 2.8).  Furthermor
3 crossed the vesicle membrane and established a pH 
 
-osmotic buffered and unbuffered solutions.  
may 
that 
e, when 
 
-b-PmCL 
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Buff.=Sodium Acetate/Sodium Chloride Buffered Solution at pH 5.5 (samples 1-3, 
not stirred while loading, samples 4- 5- stirred while loading); NaCl Sol’n=Sodium 
Chloride Solution, pH 5.5 (unbuffered); Sucr. Sol’n=Sucrose Solution, pH 5.5 
(unbuffered) 
 in situ release studies were conducted at various physiological conditions (pH 5.5 
and pH 7.4,@T=37C) where doxorubicin release was monitored fluorometrically as 
described above (λex=480nm, λem=590nm) over 14 days.  Cumulative release and release 
rate were calculated according to equations Equation 2.1and Equation 2.2, respectively.  
Similar to release from PEO-b-PCL, we observed an initial burst phase release where 
over 50% of the total amount of drug released was released during the first 12 hours.  
This correlates well with the release rate where the initial release rate during the burst 
phase is significantly higher than the release rate during the subsequent days.  The dip 
observed in the cumulative release of the drug in the pH 7.4 buffer could be the result of 
drug degradation in pH 7.4 buffer at 37C or the drug “reloading” in the vesicles post 
release to establish an equilibrium across the non-hydrolyzed vesicle membrane.  As is 
evident from the cyro-TEM images in  Figure 2.7, not all vesicles are loaded with the 
same amount of DOX and hence some of the DOX may be redistributed upon release.  In 
both the pH 5.5 and the pH 7.4 buffers, the percent cumulative release of drug from the 
vesicles is significantly less than observed for the PEO-b-PmCL vesicles (Figure 2.6).   
  
Figure 2.9- in situ  release of doxorubicin from PEO
A) Doxorubicin Cumulative Release and B) Release Rate from PEO
vesicles at physiological pH's
2.4.3 Loading and Release of Doxorubicin in PEO
 To examine the releas
biodegradable vesicles, DOX was loaded actively into PEO
gradient.  Similar to DOX loading in PEO
tested, and it was determined that the optim
fluorescence within 7-9 hours was iso
loading was confirmed by cryo
Triton X-100 and heat.   
63 
-b-PmCL polymersomes
 
-b-PBD Polymersomes
e of Doxorubicin from biocompatible but non
-b-PBD vesicles through a 
-b-PmCL vesicles, various dialysis media were 
al dialysis solution which leads to a stable 
-osmotic acidified NaCl (pH 5.5).  Successful 
-TEM microscopy and bursting of the vesicles using 
 
 
-b-PmCL 
 
-
Figure 2.10- Doxorubicin loading into PEO
A)Loading of doxorubicin in
confirmation of doxorubicin loading in PEO
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-b-PBD polymersomes 
to PEO-b-PBD vesicles over time 
-b-PBD vesicles. 
 
and B) the 
Figure 2.11- Cryo-TEM Images of DOX loaded PEO
A) Budding vesicles are observed, B) Not all vesicles are loaded with DOX, C) Fully 
loaded DOX vesicle with not much space between the DOX aggregate and the 
vesicle wall, D-E) Pearlized structures resulting from DOX loading.  
 From Figure 2.11 
it; furthermore, at times there is very little (if any) separation between the DOX aggregate 
and the bilayered membrane.  Additionally, some of the vesicles have a cause of the 
appearance of "stringed vesicles" but they are prevalent in the images. 
65 
-b-PBD vesicles 
it is evident that not every vesicle has DOX encapsulated within 
 
 
 
Figure 2.12- in situ  release of DOX from PEO
A) Cumulative DOX release 
pH 5 and pH 7.4 
 In situ DOX release
PEO-b-PBD vesicles in physiologically simulated conditions.  Vesicles in pH 7.4 
undergo a burst phase release where over 20% of the total DOX is released within the 
first 12 to 24 hours (Figure 
quick rate of DOX release over the first 24 hours (
quickly tapers off over the subsequent 13 days
that the drug released during this early time period is drug which was adhered to the PEO 
brush or localized to the membrane, but not locked into the core.  
phase release, a more controlled release is observed.  It is interesting to note that
case of DOX loaded PEO
time points; again, this may be the result of DOX degradation in the pH 7.4 solution as 
DOX is known to degrade more rapidly in non
vesicle has DOX inside (
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-b-PBD vesicles  
and B) DOX Release Rate from PEO-b
 studies were carried out fluorometrically for DOX loaded 
2.12A); this burst phase at pH 7.4 is further evidenced by the 
Figure 2.12B, closed boxes) 
 (Figure 2.12B, open boxes)
Following the burst 
-b-PmCL vesicles, the cumulate DOX release decreases at later 
-acidic solutions [82, 83].  Since not every 
Figure 2.11B-D) another possibility for the decrease in 
 
-PBD vesicles at 
which 
.  It is surmised 
, as in the 
cumulative DOX release at later times is that DOX is reentering unloaded vesicles 
(Figure 2.11) which are initially still intact at pH 7.4.  
 At a pH of 5.5, less than 10% of the drug is released from the PEO
vesicles within the first 24 hours, and it appears that the vesicles do not go through the 
burst phase release, as evidenced by the slow and controlled cumulative release and 
slower release rate, Figure 
1.5% initial load/ hr even at early time points.  Since it is unlikely that the PBD backbone 
is degraded over the 14 days, in both conditions, it is believed that the drug release at 
both pHs is due to permeation of DOX across the membrane and not vesicl
2.4.4 Release of Doxorubicin from Doxil ® (Doxorubicin liposomal formulation)
Doxorubicin loaded liposomes were obtained and diluted to yield a .0068mg/ml 
concentration of DOX in iso
Acetate Buffer.   
 
Figure 2.13-Release of Doxorubicin from the clinically administered liposomal 
formulation of doxorubicin
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2.12A and B, respectively.  Release rates do not reach ove
-osmotic pH 7.4 PBS buffer or iso-osmotic pH 5.5 Sodium 
 
-b-PBD 
r 
es destruction.   
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A)Cumulative doxorubicin release from liposomes (Doxil ®) and (B) Doxorubicin 
release rate from liposomes  
 Similar to the above release experiments, the release of DOX from lipid vesicles, 
(DOXIL ®) was measured fluorometrically.  Cumulative release and release rate were 
calculated according to equations Equation 2.1and Equation 2.2, respectively.  Release at 
both pH’s demonstrates a characteristic burst phase over the first 12 hours followed by a 
more controlled release over the subsequent days.  However, the burst release is more 
pronounced in the acid buffer as over 20% of the drug is released in the first 12 hours at a 
pH of 5.5, whereas in PBS buffer (pH 7.4) only 10% of the total is released over the first 
12 hours (Figure 2.13A).  The burst phase is further demonstrated by examining the 
release rate of the drug (%initial load/hr) which is greater than 1.0% initial load/hr for the 
first 12 hour for the pH 5.5 condition, but quickly decreases post burst phase release to 
less than 0.5% initial load/hr after the first day (B).  At a pH of 7.4, it appears the DOX 
fluorescence decreases over days 1-3; this may be due to a redistribution of drug back 
into the vesicles, or the result of DOX degradation at pH 7.4 as discussed above; during 
these days, the rate of degradation or re distribution is greater than the rate of release.  
However, as the vesicles begin to breakdown due to hydrolysis of the lipid, the rate of 
release surpasses the rate of degradation and/or drug redistribution, and the cumulative 
release of drug slowly increases over the next 11 days (Figure 2.13A).  The release rate 
correlates with this observed cumulative release, as initially the %initial load/hr is 0.5-
1.0, but decreases after the burst phase to approximately 0.1% (Figure 2.13B).   
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2.4.5 Loading and Release of Doxorubicin into PEO-b-PCL-Ac Membrane Stabilized 
Vesicles 
 As mentioned, one of the benefits of polymersomes over liposomes is the unique 
ability to tune to degradation and release kinetics of the polymer backbone for enhanced 
control of drug delivery rates.  To that end, we sought to stabilize the membrane structure 
and decrease the permeation of drug across the membrane prior to membrane hydrolysis 
by forming biodegradable membrane stabilized vesicles through the use of a acryl group 
on the terminal hydroxyl end of the PCL block, a photoiniator, and a light source.  Once 
assembled into polymersomes and in the presence of a photoinitiator, UV light exposure 
induces a radical polymerization through the functional groups (Figure 2.14).  This 
approach does not hinder hydrolysis of the PCL chain and yields oligo-caprolactone 
units, PEG, and kinetic chains of poly(acrylic acid) as the degradation products [84]. 
 
Figure 2.14- Schematic of Hydrophobic End Group Polymerization for Stabilization 
of Polymersome Membranes 
 Joshua S. Katz determined that only in the case where DMPA, the photoinitiator 
was loaded into the bilayer and the polymersomes were exposed to UV irradiation was 
polymerization of the acrylate groups observed (i.e., disappearance of acrylate peaks in 
NMR spectra, Figure 2.15
the NMR spectrum of the UV exposed polymersomes containing DMPA, indicative of an 
increase in molecular weight that would be expected to accompany acrylate 
polymerization.  UV light alone or simply the presence of DMPA were both insufficient 
to induce polymerization
conversion of the acrylate groups was also investigated (
1:1 mol/mol ratio of DMPA to polymer was necessary for complete conversion of 
acrylates.   
Figure 2.15- (A) NMR spectra of dehydrated polymersomes of AcPCL
or without DMPA loaded into the membrane before and after UV light exposure as 
indicated. The -DMPA+UV sample received a 30min dose of UVlight, while the 
+DMPA+UV sample received a 5 min dose
polymersomes with varying amounts of DMPA loaded into the membrane (reported 
as molar ratio of polymer:DMPA).  All samples received a 10 min dose of UV light.  
Lowercase letters indicate assignment of peaks to the chemical
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A).  Additionally, significant peak broadening can be seen in 
.  Furthermore, the amount of DMPA necessary for complete 
Figure 2.14, Figure 
.  (B) NMR spectra of AcPCL
 structure shown.
2.15B).  A 
 
-b-PEG with 
-b-PEG 
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 To demonstrate membrane stabilization as a method of controlling the release of 
drug from the polymersome, doxorubicin was encapsulated in PEO-b-PCL-Ac 
polymersomes loaded with DMPA in the membrane and the release was monitored via 
fluorescence dequenching of the drug as discussed in Section 2.3 EXPERIMENTAL 
METHODS.  We compared formulations with and without 15 min exposure to UV light 
(Figure 2.16A).  As mentioned, as DOX releases from the polymersome and is diluted 
into the surrounding solution, its fluorescence increases over a baseline level [85], 
enabling tracking of the release from the polymersomes.  Results are normalized to the 
initial amount of DOX encapsulated (determined by membrane disruption through Triton 
exposure to an additional sample for each group) less the baseline fluorescence.  
Formulations were also highly stable, exhibiting negligible release (<1%) when stored at 
4C over the same period of time.  The characteristic initial burst phase release, seen 
with PEO-b-PCL vesicles, was seen for both stabilized and non-stabilized polymersomes; 
however, the amount of drug released was slightly more when encapsulated in the non-
stabilized polymersomes.  The drug molecules released during this burst phase are likely 
from the DOX that partitioned into the membrane prior to stabilization (DOX is 
amphiphilic).  However, following the burst phase release, the rate of release was much 
slower for stabilized polymersomes compared to the non-stabilized polymersomes 
(Figure 2.16B).  By 7 days, only an additional ∼5% more of the drug from that released 
during the burst phase was observed to be released for the stabilized vesicles, compared 
to the additional ∼25% more being released for the non-stabilized samples, similar to 
what was observed with PEO-b-PCL vesicles in Section 2.4.1.  Due to degradation of 
DOX in aqueous solutions
method.  However, from the two observed profiles (
release is significantly retarded by stabilization of the membrane.
Figure 2.16- Doxorubicin Release from PEO
(a) Percent cumulative released and (b) release rates of DOX encapsulated in PEO
b-PCL-Ac polymersomes with 1:1 DMPA either without exposure (circles) or with 
exposure to 15 min UV light (squares).  The amount released was normalized to the 
initial amount encapsulated and is reported as means (
deviations. 
2.4.6 Incorporation of Combretastatin into PEO
 Combretastatin, an anti
membrane of the PEO-
methylene chloride prior to thin
monodispersed vesicle population of approximately 200nm drug incorporated vesicles 
was obtained post vesicle formation and extrusion as determined by DLS.  Incorporation 
of combretastatin was determined by spectroscopy; absorban
compared for vesicles with and without drug as well as free drug 
spectra demonstrate that the combretastatin was inc
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 [82, 83], exact release profiles cannot be determined by this 
Figure 2.16), it is evident that drug 
 
-b-PCL-Ac vesicles  
n=3) and standard 
-b-PCL Vesicles 
-angiogenesis drug, was incorporated into the hydrophobic 
b-PCL vesicles by dissolving it as well as the polymer in 
-film hydration and vesicle formation.  A relatively 
ce spectra were obtained and 
Figure 
orporated into the vesicles as a peak 
 
-
2.17.  These 
at approximately 345nm was observed for vesicles containing combretastatin, but not for 
drug free vesicles.  The red shift in the combretastatin spectra for combretastatin vesicles 
in comparison to spectra of free comb
environment inside the vesicle membrane.  
Figure 2.17- Absorbance spectra of 
vesicles (closed triangle, closed squ
combretastatin in ACN (plus sign).
2.4.7 Dual Drug Vesicles:  The Incorporation of Combretastatin and Loading of 
Doxorubicin in PEO-b-PCL Vesicles 
 As described, dual drug loaded polymersomes were generated by 
film of combretastatin and PEO
formation, vesicles were dialyzed to establish an ammonium sulfate gradient and 
subsequently loaded with doxorubicin.  Doxorubicin loading was tracked 
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retastatin in ACN is probably due to the altered 
 
1) combretastatin incorporated PEO
are), 2)PEO-b-PCL vesicles (circles), and 3) free 
 
 
-b-PCL and hydrating to form vesicles.  Post vesicle 
 
-b-PCL 
forming a thin 
fluorometrically as described in sections 
fluorescence changes over time while loading DOX into combretastatin incorporated 
vesicles.  Again, fluorescence intensity stabilizes after the first three hours and remains 
constant over the entire loading study.  In order to demonstrate both the incorporation of 
combretastatin and the encapsulation of doxorubicin, absorbance spectra of the vesicles 
were obtained.  In Figure 
(~280nm) are clearly visible demonstrating the incorporation of both drugs into one 
vesicle.  Figure 2.18B clears
X-100 and heat demonstrating release of doxorubicin
initially quenched state inside vesicle aqueous core.
Figure 2.18- Doxorubicin loading in Combretastatin vesicles 
A) Fluorescence intensity while loading over time B) Bursting of Sample 1 of DOX 
loaded combretastatin vesicles; S1= Sample 1, etc.; PTX
Triton X; TX- after treatment with Triton X
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2.3.1and 2.4.1.  Figure 
2.19, the peaks for both DOX (~480nm) and combretastatin 
 shows an increase in fluorescence post treatment of T
 into the external solution from its 
   
 
- prior to treatment with 
 
2.18A shows 
riton 
 
Figure 2.19- Absorbance Spectra of DOX loaded combretastatin incorporated 
polymeric vesicles.   
The top image shows the entire spectra with peaks for both DOX 
combretastatin, while the bottom image shows the spectra for combretastatin alone.  
S1= sample 1, etc.; -1 is the first part of the sample, etc.
2.5 CONCLUSIONS
 This study highlights the enormous potential of polymersomes as vehicles for 
both single drug and combination drug cancer therapy.  Doxorubicin, an amphipathic 
anti-neoplastic agent, was loaded into the aqueous core of both biocompatible (PEO
PBD) and bioresorbable (PEO
release was characterized i
was loaded into the aqueous core of fully biodegradable stabilized polymersomes, and a 
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-b-PCL and PEO-b-PmCL) nano-polymersomes and the 
n physiologically relevant buffers.  Furthermore, doxorubicin 
 
and 
-b-
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decreased release rate was observed in comparison to non-stabilized vesicles.  This 
reduced release rate is beneficial for high local delivery of chemotherapeutics over an 
extended period.   
 Combretastatin, a VDA which binds tubulin and leads to vascular disruption in 
tumors, was incorporated into the hydrophobic bilayer of PEO-b-PCL vesicles with and 
without doxorubicin.  Because of the enhanced permeation and retention (EPR) effect, 
discussed in Chapter 1, vesicles naturally accumulate at the tumor site to do the leaky and 
abnormal vasculature.  Hence, vesicles loaded with combretastatin traffic to the tumor 
site, even without targeting moieties, thereby further assisting with the elimination of 
endothelial cells lining the tumor vasculature.   
 The ability to load both chemotherapeutics and vascular disrupting agents from 
bioresorbable vesicles in a controlled fashion suggests that these vesicles may be useful 
for clinical applications.    
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3.1 SUMMARY  
 Biological membranes are complex molecular assemblies of phospholipids and 
stabilized by cholesterol, proteins and carbohydrates [86].  Liposomes, vesicles self-
assembled from natural or synthetic phospholipid amphiphiles [87], can mimic biological 
membranes [88, 89], probe cell machinery[90], and be used to develop bio-inspired 
materials for medical applications [91, 92].  The design of synthetic lipid amphiphiles for 
vesicle self-assembly represents a formidable challenge since both natural and synthetic 
amphiphiles generated by traditional methods can produce unstable liposomes that 
require tedious separation and stabilization [91, 93-97].   
 Here we show that libraries of amphiphilic Janus-dendrimers self-assemble, by 
simple injection of their ethanol solution into water, into monodisperse and stable 
vesicles with excellent mechanical properties; these dendrimeric vesicles have been 
termed dendrosomes. In contrast to polymersomes, polymeric vesicles self-assembled 
from polydisperse block co-polymer amphiphiles[3, 4, 98, 99] with limited 
bioresorbability, stable and monodisperse dendrosomes exhibit, in addition to the classic 
spherical shape, the less encountered tubular[100], multilamellar vesicles[101], 
polygonal[102], cubosome[103] and other complex architectures such as disc-like, 
torroidal, rod-like, polygonal, spherical, ribbon-like and helical ribbon-like micelles[104].   
 Preliminary experiments demonstrate that dendrosomes are non-toxic to cells at 
short times, and many produce pH-sensitive membranes that deliver cancer drugs, such as 
doxorubicin, and incorporate pore forming proteins. Therefore, dendrosomes expand the 
precise and monodisperse primary structure of dendritic building blocks into new 
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functions[105-108]. Amphiphilic Janus-dendrimers self-assemble also in bulk and can be 
used to elucidate the mechanism of self-assembly of amhiphiles in the absence and 
presence of water[12]. We anticipate that dendrosomes will extend the capabilities of 
synthetic amphiphiles, generating responsive membranes with permeability controllable 
for desirable technological applications including novel pathways for targeted drug and 
gene delivery, in vivo imaging, and mediation of the efficiency of enzymes[109] and 
nucleic acids. 
3.2 INTRODUCTION  
 The Perec Laboratory has designed twelve libraries containing 107 uncharged and 
positively charged amphiphilic Janus-dendrimers (Figure 3.1).  These Janus-dendrimers 
were designed from natural AB3 and constitutional isomeric AB2 building blocks 
containing both hydrophilic and hydrophobic segments that can be rapidly combined to 
produce a large array of exact and monodispersed primary structures (Figure 3.1).  These 
dendrimeric structures were synthesized by a combination of convergent, for the 
hydrophobic portion, and divergent or convergent methods for the hydrophilic portion.  
Two hydrophobic segments (one aliphatic and one mixed aliphatic-aromatic) and six 
hydrophilic segments (derived from oligoethylene oxide, dimethylolpropionic acid, 
glycerol, thioglycerol, tert-butylcarbamate and quaternary ammonium salts) were 
synthesized to generate the libraries of dendrimeric structures (Figure 3.1).  This modular 
concept allowed the weight fraction of hydrophilic to hydrophobic blocks to be 
systematically varied.  
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 The monodispersity of the dendrimers sets them apart from polymers and block 
copolymers which are polydisperse [3, 4, 98, 99].  Furthermore, while polymer chains 
have only limited scope for additional functionalization since they contain only two chain 
ends, the design of amphiphilic Janus-dendrimers, with their branched ends, allows a 
higher concentration and larger diversity of functionalities to be incorporated at both the 
hydrophilic and hydrophobic fragments of the molecule.   
 
Figure 3.1- Library of Janus Dendrimers synthesized by the Perec Laboratory at 
the University of Pennsylvania 
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 All amphiphilic Janus-dendrimers from Figure 3.1 self-assemble in both bulk  and 
in aqueous based solutions to form regular structures (Figure 3.2 and Figure 3.3).  Vesicle 
formation via injection of ethanol solutions of Janus-dendrimers into water (solvent 
injection method) was monitored by dynamic light scattering (DLS) as a function of 
concentration, temperature, and time. Formation of vesicles by injection of dendrimer in 
ethanol and in a variety of other protic and polar aprotic solutions into water was 
investigated as a function of temperature at a concentration of 0.5 mg/mL.  Assemblies 
with sizes from 55 nm to 732 nm with polydispersity ranging from 0.021 to 0.530 were 
observed for the various concentrations, temperature, and time.  These assemblies were 
stable in aqueous solutions up to at least 300 days from 25C-80C. Surprisingly most 
of the assemblies have low polydispersities of 0.021 to 0.200 via the solvent injection 
method alone (i.e. no further processing); in the field of self-assembled vesicles, these 
low values are considered monodisperse. For dendrimers from library 1, the size and 
polydispersity depend on concentration. For example, the dendrimer (3,5)12G1-PE-
BMPA-G2(OH)8 exhibited polydispersities ranging from 0.106 to 0.44 and Z-average 
sizes ranging from 84nm to 206 nm for concentrations ranging from 0.5 mg/mL to 4 
mg/mL. In contrast, for dendrimers containing oligoethyleneoxide in the hydrophlic 
portion, polydispersity and size are minimally dependent on concentration. 
 Small assemblies fabricated by injection of ethanol solutions of the amphiphilic 
Janus-dendrimers into water were analyzed by cryo-TEM. 80 of these assemblies are 
unilamelar spherical dendrosomes and 55 have a polydispersity lower than 0.2 (Figure 
3a). In addition, dendrosomes within dendrosomes [101, 110], polygonal [102] and 
tubular [100] dendrosomes, bicontinuous cubic particles (cubosomes [103]) and other 
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complex architectures such as disc-like, toroidal, rod-like, polygonal, spherical, ribbon-
like and helical ribbon-like micelles[104] were also observed by the analysis of the 3-D 
intensity profiles of the optical micrographs and cryo-TEM images (Figures 2, 3). To our 
knowledge this is the first example of dendrocubosome obtained in a two-phase non-ionic 
surfactant system. The bilayer thickness of the dendrosomes was measured from cryo-
TEM and found to range from 5 to 8 nm. Liposomes from phospholipids exhibit 
membrane thicknesses of 3 to 5 nm while the membrane thickness of polymersomes can 
be varied between 8 to 20 nm or even greater. The mechanical properties in combination 
with the measured thicknesses suggest that dendrosomes are excellent candidates for 
models of biological membranes.   
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Figure 3.2- CryoTEM of dendritic assmeblies in aqueous solutions  
(a) Monodisperse dendrosomes from (3,4)12G1-PE-(3,5)-3EO-G1-(OCH3)4 in 
ultrapure water (b) Dendrosomes contained inside a dendrosome bag from 
(3,4,5)12G1-PE- (3,4,5)-3EO-G-(OH)6 in PBS (c) Polygonal dendrosomes from 
(3,4)12G1-PE-(3,4)-3EO-G1-(OMe)4 (d) Bicontinuous cubic particles co-existing 
with low concentration of spherical dendrosomes from (3,5)12G1-PE-(3,4,5)-2EO-
(OMe)6 (e) Disc-like micelles and toroids from (3,4,5)12G1-PE-(3,5)-3EO-(OMe)4 
(f) Micelles from (3,4,5)12G1-PE-BMPA-G2-(OH)8 (g) Dendrosomes from 
(3,5)12G1-PE-(3,4,5)-3EO-(OMe)6 (h) Rod-like, ribbon and helical micelles from 
tris12-PE-BMPA-G2-(OH)8. 
 In addition to solvent injection method which yielded vesicles with little 
polydispersity, dendrosomes were also prepared by thin film hydration.  In brief, 
hydration experiments were performed on films drop cast onto a roughened Teflon 
surface at a concentration of 2 mg dendrimer (in 200 µL solvent) per ~1 cm2. Samples 
were dried under vacuum prior to hydration with 2 mL of ultra pure water or phosphate 
buffered saline at 50°C. This method was used to generate giant dendrosomes ranging in 
size from 2 to 50 µm in diameter, which were analyzed by either phase contrast or bright 
field microscopy. Visualization of both vesicle wall and cavity was carried out using 
fluorescence microscopy and a combination of hydrophobic (Nile Red) and hydrophilic 
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(Calcein) dyes. The hydrophobic dye was mixed with the Janus-dendrimer by adding 10 
µM Nile Red to a solution of amphiphile in dichloromethane or diethyl ether. Films were 
prepared as described above and hydrated with 10 µM Calcein solution in saturated 
sucrose. Following hydration, Calcein containing dendrosomes were isolated from the 
free dye by repeated centrifugation washing cycles. Giant unilamellar dendrosomes were 
visualized by fluorescence microscopy where the hydrophobic dye was observed to 
concentrate exclusively in the wall whereas the hydrophilic dye was observed only in the 
aqueous interior (Figure 3.3).  
 
Figure 3.3- Optical Microscopy of giant dendrosomes  
(a) Fluorescence microscopy image of dendrosome from (3,5)12G1-PE-(3,4)3EO-
(OH)4 encapsulating both hydrophobic Nile Red and hydrophilic Calcein dyes 
(b)Dendrosome from (3,4)12G1-PE-BMPA-G2-(OH)8 visualized with Nile Red. (c) 
Worm-like micelle from (3,4,5)12G1-PE-BMPA-G2-(OH)8 encapsulating Nile Red 
(d) Spherical micelle from (3,4)12G1-PE-(3,4,5)3EO-(OH)6 encapsulating Nile Red. 
(e), Dendrosome from (3,4,5)12G1-PE-(3,4,5)3EO-G1-(OH)6 visualized with Nile 
Red and Calcein. Copyright (2009) Nature. 
 Micromanipulation experiments revealed that dendrosomes are more 
mechanically stable than liposomes, possessing higher areal expansion moduli, Ka than 
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phospholipids, yet displaying lipid-like critical areal strains (Figure 3.4). For example, 
dendrosomal materials 35-12-8 and 34-12-8 have area expansion moduli of 
approximately 950 mN/m, well in excess of the 781 mN/m measured for a 50% 
SOPC/50% cholesterol mixture [111].   
 
Figure 3.4-Micropipette aspiration experiments on dendrosomes  
(a) Micropipette aspiration assessment of mechanical strength by micro 
deformation undernegative pressure of (3,5)12G1-PE-BMPA-G2(OH)8. f, The same 
dendrosome under negative pressures howing small deformation of membrane. k, 
Areal strain (〈c) determined from micropipette aspiration upon rupture. Copyright 
(2009) Nature. 
 The stability of dendrosomes was investigated in biologically relevant media by 
formation of membranes via ethanol injection into both phosphate buffered saline and 
citrate buffer.  Dendrosomes formed from compounds in library 1 showed poor stability 
in phosphate buffered saline. However, stability in citrate buffer was maintained over a 
period of two weeks.  Dendrosomes formed from compounds from library 2 exhibited 
excellent stability in ultrapure water as well as in phosphate and citrate buffers. Selected 
dendrosomes were loaded with the anthracyclin drug, Doxorubicin, [92] used extensively 
in the treatment of Hodgkins lymphoma, stomach, lung and breast cancers.  This drug 
shows activity as a DNA intercalator.  As mentioned, one major limitation of 
Doxorubicin is cardiotoxicity at the therapeutic dosage.  However, it is believed that 
cardiotoxicity is mitigated though encapsulation of the drug in nanoparticles; 
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encapsulated doxorubicin is commercially available in the liposomal preparation as Doxil 
[92, 96].  However, synthetic liposomal drug formulations suffer from higher leakage and 
reduced in vivo stability when compared to their natural counterparts.  
 Rapid growth and higher metabolic turnover exhibited by neoplastic cells result in 
both leaky vasculature and a lower than physiological pH (~5.2). As a consequence of the 
leaky vasculature and poor lymphatic drainage, nanoparticles, such as dendrosomes, tend 
to aggregate at tumor sites rather than healthy tissue; this is know as the EPR effect [24, 
25].  As a consequence, dendrosomes tend to passively target tumor cells rather than 
healthy tissue. Janus-amphiphiles contain cleavable bonds which breakdown under acidic 
conditions and destabilize the vesicle structure. Without special design, NMR analysis 
showed that the cleavable bond in the Janus-dendrimer structure under identical pH 
conditions is the aromatic-aliphatic ester bond. Engineering the dendrosome with 
alternative pH-sensitive groups [92] is in progress in the Perec Laboratory. Selected 
Janus-dendrimers tagged with Texas Red dye were shown to co-assemble into fluorescent 
giant unilamelar liposomes with unlabelled Janus-dendrimers, block-copolymers and 
phospholipids which demonstrate the potential utility of tagged Janus-dendrimers, 
suggesting their use in theranotics (for detection and treatment of disease). 
 In order to determine their biocompatibility, unloaded dendrosomes were 
incubated with HUVECs for a predetermined period and then subsequently Cell Titer 
Blue assay was performed to determine the toxicity of the material on endothelial cells.  
It was determined that the dendrosomes are relatively nontoxic to endothelial cells and 
thus provide great promise as drug carriers. 
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 Several examples of liposomes assembled from positively charged polymer-
dendrimer block copolymers[112] and from charged amphiphilic dendrimers[108, 113] 
are available. Nevertheless, the results demonstrate a simple and general strategy to the 
design and synthesis of amphiphilic Janus-dendrimers that self-assemble into stable and 
monodisperse dendrosomes and other complex architectures. Dendrosomes expand the 
field of supramolecular dendrimer chemistry into new functions with possible 
technological applications. 
3.3 EXPERIMENTAL METHODS 
3.3.1 Preparation of Doxorubicin Loaded Dendrisomes (dendrimeric vesicles) for 
Loading and Release Studies 
 Self-assembly via thin-film hydration was used to assemble the dendrimers into 
their equilibrium morphologies.  Film hydration has been extensively utilized for 
preparing non-degradable polymer vesicles comprised of PEO-b-PBD and PEO-b-PEE 
diblock copolymers [4, 9].
  
Briefly, 200 microliters of a 10mg/mL dendrimer solution in 
methylene chloride were uniformly deposited on the surface of a roughened Teflon plate 
followed by evaporation of the solvent for >12h under vacuum.  Addition of aqueous 
hydration solution, (~290 milliosmolar ammonium sulfate solution and doxorubicin 
(DOX) (.2mg/ml), pH 7.3) followed by sonication led to spontaneous budding of drug 
encapsulated nanosized dendrosomes dendrosomes, off the teflon-deposited thin-film, 
into the aqueous solution.  The sonication procedure involved placing the sample vial 
containing the aqueous based solution and dried thin-film formulation (of dendrimer 
uniformly deposited on Teflon) into a sonicator bath (Branson; Model 3510) @ 60-65°C 
for 30min followed by constant agitation for 60 minutes at 60-65°C.  Subsequently, five 
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cycles of freeze-thaw extraction followed; freeze-thaw extraction was carried out by 
placing the sample vials in liquid N2 and subsequently thawing in a water bath at 50-
60°C.    
 After hydration and sonication, samples were placed into dialysis cassettes and 
dialyzed at 4°C in iso-osmotic citrate phosphate buffer (pH~7.4)  to remove non-
entrapped DOX.  Dialysis solutions were changed 4 times over approximately 48 hours.  
After the dialysis, the samples were removed from the dialysis cassette, and diluted in the 
citrate phosphate buffer.  Release studies of DOX from the loaded dendrosomes were 
initiated immediately following dilution in buffer.    
3.3.2 Doxorubicin Release from Dendrisomes Studies 
 Doxorubicin release from the dendrisome core was was measured 
fluorometrically (using a SPEX Fluorolog-3 fluorimeter;λex = 480nm,λem = 590nm) at 
various intervals up to fourteen days. The fluorescence was obtained at time zero for all 
samples.  Subsequently, a portion of the samples were acidified with 12.1N HCl to 
reduce the pH down to approximately 5.2 and the fluorescence was remeasured, with this 
new fluorescence being time zero for the acidified samples.  Inside the aqueous core, the 
DOX is aggregated and its fluorescence is quenched.  As the drug is released from the 
dendrosome core and diluted into the external solution its fluoreswcence  is no longer 
quenched and thus increases.  Thus, an increase in fluorescence over time can be 
correlated to doxorubicin release.   
 At the culmination of the study, the samples were solubilized using Triton X-100 
and heat.  The percent of Dox release over time was calculated as the ratio between the 
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fluorescence measured at each time point to the maximum final fluorescence obtained upon lysis 
of the vesicles with TritonX-100 at the culmination of the study according to the equation: 
P% = (It-It0)/(Imax(Tx)-It0)x100  Equation 3.1 
where It = fluorescence at each time point t 
It0 = fluorescence at time point 0 
Imax(Tx) = maximum fluorescence upon lysis with Triton X 
3.3.3 Cytotoxicity Studies of Various Dendrimers 
 Since endothelial cells are the first point of contact for intravenous drug formulations, the 
toxicity of the dendrosomes was evaluated in vitro on human umbilical vein endothelial cells 
(HUVECs). In order to estimate the toxicity of these dendrosomes, cell viability 
experiments were carried out on human umbilical vein endothelial cells (HUVECs).  
Dendrosomes from library 2 were incubated with HUVECs at varying concentrations for 
a period of four hours. Cell viability assays with Cell Titer-BlueTM, a dye that becomes 
fluorescent in the presence of living cells, were carried out at 1, 2 and 4 h intervals 
Library 2 showed no discernable toxicity when compared to the control experiments 
(Figure 5) indicating an excellent biocompatibility for dendrosomes.. 
 HUVECs were cultured in EGM Endothelial Growth Media (LONZA) supplemented 
with bovine brain extract (BBE) with heparin, h-EGF, hydrocortisone, gentamicin, amphotericin 
B (GA-1000), and fetal bovine serum (FBS).  Cells were maintained in plastic culture flasks at 
37C in a humidified atmosphere containing 5% CO2 and were further subcultured when the 
flasks were 70% to 90% confluent.  The passage number of the cells for the HUVECs in vitro 
studies ranged from 5-8.  
 HUVECs were plated at a density of 3,200 cells per well (10,000cells/cm2) in 96 
well tissue culture plates and allowed to adhere overnight.  Culture media was removed 
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from the wells and replaced with 250µL of either:  100% media, 94% media/6% PBS 
buffer, 87.5% media/12.5% PBS buffer, 75% media/25% PBS buffer, 100% PBS buffer, 
and various concentrations of sterile dendrosomes and PEO-b-PCL and PEO-b-PBD 
polymersomes ranging from 0.0625mg to 0.25mg in the three concentrations of 
media/PBS, and maintained at 37◦C in a humidified atmosphere of 5% CO2. The 
dendrosomes and polymersomes were prepared by film the hydration method as 
described in and manually extruded 25 times through 100 nm polycarbonate membrane. 
Dendrosomes and polymersomes were sterilized by exposing them for 30min to UV 
radiation. 
 The investigation of dendrosome toxicity and cell viability was assessed 
fluorometrically using the indicator dye resazurin (CellTiter-Blue Cell Viability Assay, 
Promega) which is reduced by viable cells from a non fluorescent form to a highly 
fluorescent form, resorufin, according to Equation 3.2. The viable cells retain the 
metabolic capacity to convert resazurin to resorufin while nonviable cells rapidly lose 
metabolic capacity and are not able to reduce the indicator dye hence no fluorescent 
signal is generated.  As such, cell viability can be monitored by fluorescent changes. 
Equation 3.2- Reduction of resazurin to resorufin in the presence of live cells. 
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 At various defined time points (1h, 2h, and 4h post vesicle administration), wells 
were washed three times with 250µL of PBS and 100µL of fresh media was added.  To 
the fresh media, 20µL of Cell-Titer Blue (Promega) was added and cells were incubated 
at 37◦C in a humidified atmosphere containing 5% CO2 for 2 hours.  Subsequently, 
100µL of media containing Cell-Titer Blue was removed from the cells and placed in the 
wells of a 96 well black bottom plate.  The fluorescence intensity at 590nm emanating 
from the wells when excited at 560nm was then determined using a TECAN 
Inifinite2000 plate reader. 
3.4 RESULTS AND DISCUSSION 
3.4.1 Doxorubicin Release from Dendrosomes 
 Selected dendrosomes from libraries 1 and 2 were loaded with the anthracyclin 
drug, Doxorubicin, and its release was monitored fluorometrically at 37C at 
physiological pH (~7.2~7.4) and acidic pH (~5.2~5.4).  Figure 3.1 shows selected 
experiments that illustrate a significantly higher release of drug at acidic pH than at 
physiological pH.  As mentioned, Janus-amphiphiles contain cleavable bonds which 
breakdown under acidic conditions leading to destabilization of the vesicle structure; 
hence more drug is released at low pH.  Since the vasculature surround the tumor has a 
lower than physiological pH (~5.2), hence, this increased release at low pH is quite 
beneficial for delivering drug to the tumor.  For both conditions, the characteristic burst 
phase release is seen where approximately 20% of the drug is released within the first 
twelve hours.  Subsequent release of the drug from dendrosomes at both pHs is slower.   
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Figure 3.5- Characterization of the release of doxorubicin from dendrosomes 
(a) Release of Doxorubicin from dendrosomes assembled from (3,5)12G1-PE-
BMPA-G2-(OH)8 showing excellent stability at physiological temperature and pH 
7.4 and rapid release of the drug at physiological temperature and pH 5.2 (b) 
Comparative of release of doxorubicin dendrosomes from different libraries. 
3.4.2 Dendrosome Cytotoxicity Studies 
 Since endothelial cells are the first point of contact for intravenous drug formulations, the 
toxicity of the unloaded dendrosomes was evaluated in vitro on human umbilical vein endothelial 
cells (HUVECs) over the course of four hours.  Dendrosomes from library 2 were incubated 
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with HUVECs at varying concentrations for a period of four hours. Cell viability assays 
with Cell Titer-BlueTM, a fluorometric agent that reports metabolic activity of cells, were 
carried out at 1h, 2h and 4h intervals.  Live cells undergo metabolism causing a change in 
the fluorescence of the molecule, while dead cells do not undergo metabolism and hence 
do not change the fluorescence of the molecule; this can be quantified via the 
fluorescence of the CellTiter Blue substrate.  Library 2 showed only slight toxicity when 
compared to the polymersome control experiments (Figure 3.6) after one and four hours.  
At 2 hours, the dendrosomes showed no discernable toxicity when compared to the 
control experiments (Figure 3.6); these results indicated an excellent biocompatibility for 
dendrosomes.  Hence, the viability results demonstrate that the uptake of dendrosomes is 
well tolerated by the HUVECs.   
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Figure 3.6- Cell viability studies conducted using various dendrosomes from library 
2  
with human umbilical vein endothelial cells (HUVEC) and CellTiter-BlueTM cell 
viability assay after 1h (top), 2h (middle) and 4h (bottom) from the moment the cell 
were fed with dendrosomes. Control: EGM Endothelial Growth Media (LONZA) 
Polymersome 1: hydrogenated polybutadiene-b-polyethyleneoxide; Polymersome 2: 
polycaprolactone-b-polyethyleneoxide; Dendrosome 1: (3,4)12G1-PE-(3,4,5)3EO-
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G1-(OMe)6; Dendrosome 2: (3,5)12G1-PE-(3,4,5)3EO-G1-(OMe)6; Dendrosome 3: 
(3,4,5)12G1-PE-(3,4,5)3EO-G1-(OH)6 
3.5 CONCLUSIONS  
 The results of studies described in this chapter demonstrate the potential use of 
self-assembled dendrimeric vesicles for drug delivery purposes.  Here we show that 
libraries of amphiphilic Janus-dendrimers self-assemble into monodisperse and stable 
vesicles, termed dendrosomes.  In addition to the classical spherical shape, these 
dendrimers self-assemble into a variety of less encountered shapes.   
 Doxorubicin, a chemotherapeutic, was successfully loaded into the aqueous core 
of vesicles self assembled from a variety of the amphiphilic Janus-dendrimers.  In 
contrast to DOX loading in polymersomes (Chapter 2), DOX was not loaded actively 
across the membrane with a gradient, but rather passively in the hydration solution.  The 
release of the drug from the vesicles was investigated at two physiologically relevant 
pH’s and characterized.  Furthermore, toxicity studies with these vesicles confirmed that 
these vesicles are non-toxic to Human Umbilical Vein Endothelial Cells (HUVECs) at 
short times.  Based on the performance of the dendrimeric vesicles in laboratory 
experiments, it is expected that dendrosomes will extend the capabilities of synthetic 
amphiphiles, generating responsive membranes with permeability controllable for 
desirable drug delivery. 
3.6 ACKNOWLEDGEMENTS 
 Financial support by the National Science Foundation and P. Roy Vagelos Chair 
at Penn is gratefully acknowledged. 
99 
3.7 REFERENCES 
1. Singer, S.J. and G.L. Nicolson, FLUID MOSAIC MODEL OF STRUCTURE OF 
CELL-MEMBRANES. Science, 1972. 175(4023): p. 720-&. 
2. Bangham, A.D., M.M. Standish, and J.C. Watkins, DIFFUSION OF UNIVALENT 
IONS ACROSS LAMELLAE OF SWOLLEN PHOSPHOLIPIDS. Journal of 
Molecular Biology, 1965. 13(1): p. 238-&. 
3. Ghadiri, M.R., J.R. Granja, and L.K. Buehler, ARTIFICIAL TRANSMEMBRANE 
ION CHANNELS FROM SELF-ASSEMBLING PEPTIDE NANOTUBES. Nature, 
1994. 369(6478): p. 301-304. 
4. Percec, V., et al., Self-assembly of amphiphilic dendritic dipeptides into helical 
pores. Nature, 2004. 430(7001): p. 764-768. 
5. Haluska, C.K., et al., Time scales of membrane fusion revealed by direct imaging 
of vesicle fusion with high temporal resolution. Proceedings of the National 
Academy of Sciences of the United States of America, 2006. 103(43): p. 15841-
15846. 
6. Barenholz, Y., Liposome application: problems and prospects. Current Opinion 
in Colloid & Interface Science, 2001. 6(1): p. 66-77. 
7. Guo, X. and F.C. Szoka, Chemical approaches to triggerable lipid vesicles for 
drug and gene delivery. Accounts of Chemical Research, 2003. 36(5): p. 335-341. 
8. Ringsdorf, H., B. Schlarb, and J. Venzmer, MOLECULAR ARCHITECTURE 
AND FUNCTION OF POLYMERIC ORIENTED SYSTEMS - MODELS FOR 
THE STUDY OF ORGANIZATION, SURFACE RECOGNITION, AND 
DYNAMICS OF BIOMEMBRANES. Angewandte Chemie-International Edition in 
English, 1988. 27(1): p. 113-158. 
9. Thomas, J.L. and D.A. Tirrell, POLYELECTROLYTE-SENSITIZED 
PHOSPHOLIPID-VESICLES. Accounts of Chemical Research, 1992. 25(8): p. 
336-342. 
10. Lasic, D.D. and D. Papahadjopoulos, LIPOSOMES REVISITED. Science, 1995. 
267(5202): p. 1275-1276. 
11. Krafft, M.P., Fluorocarbons and fluorinated amphiphiles in drug delivery and 
biomedical research. Advanced Drug Delivery Reviews, 2001. 47(2-3): p. 209-
228. 
12. Papahadjopoulos, D., et al., STERICALLY STABILIZED LIPOSOMES - 
IMPROVEMENTS IN PHARMACOKINETICS AND ANTITUMOR 
THERAPEUTIC EFFICACY. Proceedings of the National Academy of Sciences 
of the United States of America, 1991. 88(24): p. 11460-11464. 
13. Discher, B.M., et al., Polymersomes: Tough vesicles made from diblock 
copolymers. Science, 1999. 284(5417): p. 1143-1146. 
14. Discher, D.E. and A. Eisenberg, Polymer vesicles. Science, 2002. 297(5583): p. 
967-973. 
15. Cornelissen, J., et al., Helical superstructures from charged poly(styrene)-
poly(isocyanodipeptide) block copolymers. Science, 1998. 280(5368): p. 1427-
1430. 
16. Kita-Tokarczyk, K. and W. Meier, Biomimetic Block Copolymer Membranes. 
Chimia, 2008. 62(10): p. 820-825. 
100 
17. Chiruvolu, S., et al., A PHASE OF LIPOSOMES WITH ENTANGLED TUBULAR 
VESICLES. Science, 1994. 266(5188): p. 1222-1225. 
18. Walker, S.A., M.T. Kennedy, and J.A. Zasadzinski, Encapsulation of bilayer 
vesicles by self-assembly. Nature, 1997. 387(6628): p. 61-64. 
19. Dubois, M., et al., Self-assembly of regular hollow icosahedra in salt-free 
catanionic solutions. Nature, 2001. 411(6838): p. 672-675. 
20. Almgren, M., K. Edwards, and G. Karlsson, Cryo transmission electron 
microscopy of liposomes and related structures. Colloids and Surfaces a-
Physicochemical and Engineering Aspects, 2000. 174(1-2): p. 3-21. 
21. Walter, A., et al., INTERMEDIATE STRUCTURES IN THE CHOLATE-
PHOSPHATIDYLCHOLINE VESICLE MICELLE TRANSITION. Biophysical 
Journal, 1991. 60(6): p. 1315-1325. 
22. Percec, V., et al., Controlling polymer shape through the self-assembly of 
dendritic side-groups. Nature, 1998. 391(6663): p. 161-164. 
23. Percec, V., et al., Self-organization of supramolecular helical dendrimers into 
complex electronic materials (vol 419, pg 384, 2002). Nature, 2002. 419(6909): p. 
862-862. 
24. Lee, C.C., et al., Designing dendrimers for biological applications. Nature 
Biotechnology, 2005. 23(12): p. 1517-1526. 
25. Esfand, R. and D.A. Tomalia, Poly(amidoamine) (PAMAM) dendrimers: from 
biomimicry to drug delivery and biomedical applications. Drug Discovery Today, 
2001. 6(8): p. 427-436. 
26. Hillmyer, M.A., et al., Complex phase behavior in solvent-free nonionic 
surfactants. Science, 1996. 271(5251): p. 976-978. 
27. Walde, P. and S. Ichikawa, Enzymes inside lipid vesicles: Preparation, reactivity 
and applications. Biomolecular Engineering, 2001. 18(4): p. 143-177. 
28. Lasic, D.D., Colloid chemistry - Liposomes within liposomes. Nature, 1997. 
387(6628): p. 26-27. 
29. Needham, D. and R.S. Nunn, ELASTIC-DEFORMATION AND FAILURE OF 
LIPID BILAYER-MEMBRANES CONTAINING CHOLESTEROL. Biophysical 
Journal, 1990. 58(4): p. 997-1009. 
30. Iyer, A.K., et al., Exploiting the enhanced permeability and retention effect for 
tumor targeting. Drug Discovery Today, 2006. 11(17-18): p. 812-818. 
31. Duncan, R., Polymer-Drug Conjugates: Targeting Cancer, in Biomedical Aspects 
of Drug Targeting, V.R. Muzykantov and V.P. Torchlin, Editors. 2002, Kluwer 
Academic Publishers: Boston. p. 197-199. 
32. Vanhest, J.C.M., et al., POLYSTYRENE-DENDRIMER AMPHIPHILIC BLOCK-
COPOLYMERS WITH A GENERATION-DEPENDENT AGGREGATION. 
Science, 1995. 268(5217): p. 1592-1595. 
33. Al-Jamal, K.T., T. Sakthivel, and A.T. Florence, Dendrisomes: Vesicular 
structures derived from a cationic lipidic dendron. Journal of Pharmaceutical 
Sciences, 2005. 94(1): p. 102-113. 
34. Ghoroghchian, P.P., et al., Near-infrared-emissive polymersomes: Self-assembled 
soft matter for in vivo optical imaging. Proceedings of the National Academy of 
Sciences of the United States of America, 2005. 102(8): p. 2922-2927. 
101 
 
 
  
102 
Chapter 4  
POLYMERSOMES:  SELF-ASSEMBLED VESICLES FOR IMAGING 
AND DRUG DELIVERY 
ADAPTED FROM 
Dalia Hope Levine, Nimil Sood, Julie Czupryna, Lanlan Zhou, Ramacharan Murali, 
Daniel A. Hammer, Manuscript in Preparation 
 
  
103 
4.1 SUMMARY  
 The bioresorbable poly(ethylene oxide)-b-poly(ε-caprolactone) polymersome, 
with its thick lamellar hydrophobic membrane, of approximately 22nm, and large 
aqueous core, holds great clinical promise for use in theranostic biomedical applications, 
where both drug and imaging agent are simultaneously loaded into the same vesicle for 
drug delivery and imaging purposes.  This chapter discusses the generation of a near 
infrared (NIR) emissive polymersome, a self-assembled polymer vesicle, loaded with the 
NIR dye porphyrin in its hydrophobic compartment.  Much of the seminal research 
regarding NIR-emissive polymersomes was carried out by Ghoroghchian et al.  Yet, the 
ability to combine an imaging capability with drug delivery remained to be created and 
characterized.  The following chapter illustrates the design of a polymersome with the 
capability to load both an imaging agent as well as a chemotherapeutic into one vesicle, 
creating an optimal platform for both drug delivery and imaging.  
 This chapter demonstrates the ability to encapsulate doxorubicin, a 
chemotherapeutic, into poly(ethylene oxide)-b-poly(ε-caprolactone) NIR-emissive 
polymersomes.  In addition to loading studies, the release of doxorubicin from the 
vesicles was investigated.  The increase in fluorescence from doxorubicin, as it is 
released from the vesicle, and the decrease in fluorescence from the porphyrin 
chromophore, as the polymersome membrane degrades, were examined and will be 
discussed in this chapter.  Subsequent chapters will elaborate on the use of the NIR-
emissive polymeric vesicles for in vitro cellular uptake studies (Chapter 5) and in vivo 
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imaging (Chapter 6).  Furthermore, the use of the porphyrin-doxorubicin multi-modal 
polymersome for imaging drug delivery will be explored in Chapter 6.   
4.2 INTRODUCTION  
 The attractive biomaterial properties of polymersomes such as prolonged 
circulation times [8], increased mechanical stability [7],and the ability to incorporate 
numerous large hydrophobic molecules within their thick lamellar membranes and 
hydrophilic molecules within their lumen [5, 6] render these vesicles useful in a variety 
of clinical applications.  One such application is in vivo deep tissue fluorescence based 
optical imaging.   
 Currently, intravital microscopy (IVM), through the use of visible probes, has 
enabled anatomical, functional and molecular imaging of live animals [114]; however, 
due to light scattering and optical absorption by living tissue, the in vivo imaging 
potential of these visible probes decreases substantially at tissue depths great than 500 
µM to 1 mm [115].  Since light scattering decreases with increasing wavelength and the 
absorbance spectra for hemoglobin and water reach their lowest values in the Near 
Infrared (NIR) region of the spectra (Figure 4.1) [115], research efforts have been 
focused on developing optical imaging probes in the NIR window for in vivo 
applications.   
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Figure 4.1- The absorbance spectra for water, hemoglobin, and water clearly 
showing a nadir in their optical absorption over the NIR window.   
Adapted from Weissleder [115].  
 A family of molecules which emit in the NIR has been developed by the Therien 
Laboratory.  The chemical structure and absorption spectra of these porphyrin based 
fluorophores (PBF) is shown in Figure 4.2 and Figure 4.3A.  These porphyrin molecules 
are derived from the linkage of (porphinato) zinc (II) (PZn) macrocycles by meso-to-
meso, beta-to-meso, and beta-to-beta ethynyl- and butadiynyl-bridges [116-118].  The 
optical properties of these biologically inspired porphyrin molecules can be tuned over a 
large window of the visible and NIR spectra by varying the number of macrocycles per 
molecule, the bond type and location of the linkages between the macrocycles, and lastly 
by changing the side groups [117].  These subtle changes in porphyrin chemical structure 
can predictably change the optical properties of the fluorophores.  The porphyrin trimer, 
(PZn3), denoted as DDD in Figure 4.2, with its absorption maxima at 790nm and 
106 
emission maxima at 809nm, is optimal for biologically based imaging applications for 
reasons enumerated above.  All NIR-emissive polymersome in situ, in vitro, and in vivo 
work to be discussed therein utilized this particular porphyrin molecule.   
 These porphyrin molecules, however, are very large, ranging from 2.1nm 
(monomer) to 5.3nm (pentamer) in length, and are highly hydrophobic, thus underscoring 
the need for an appropriate amphipathic delivery system with a large hydrophobic region 
[9].  Due to its large hydrophobic bilayer, the polymersome makes for a great delivery 
vehicle for the porphyrin molecules.  Recall the polymersome hydrophobic membrane 
(~9nm-22nm), tuned by the length of the hydrophobic block of the copolymer, is at least 
double the  thickness of the  liposome membrane (~3nm-4nm) [9].  As such, only the 
monomeric or dimeric porphyrin molecules can be incorporated into liposomes, and only 
at loading levels of ~1 mol%.  In contrast, the incorporation of larger porphyrin structures 
into the polymersome bilayer is easily obtained even at loading levels greater than 5 
mol% (Figure 4.3B) with little effect on the spectral properties of the chromophore or the 
structural properties of the polymersome membrane [51].  In addition to the large 
hydrophobic membrane, which renders the polymersome ideal for the incorporation of 
porphyrin fluorophores, the optimal biological properties of polymersomes previously 
discussed, such as increased circulation due to the fully PEG-ylated brush [8] and 
increased mechanical and thermodynamic stability [3], make the porphyrin loaded 
polymersome quite useful for biological imaging applications.   
Figure 4.2-Some of the porphyrin molecules (
 whose macrocycles are 
and in vivo studies use the porphyrin trimer, DDD.  Image adapted from Duncan 
[118].  
Figure 4.3- A) A subset of the family of porphyrin molecules
and non-covalently incorporated into
oxide)-b-polybutadiene polymersomes.  Adapted from Ghoroghchian (2005) [10].
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 The NIR emissive polymersome soft matter complex, developed and extensively 
characterized by Ghoroghchian et al [9, 51, 52, 119], is formed through the cooperative 
self assembly of the diblock copolymer with the porphyrin molecules [9].  Following self 
assembly, the vesicles maintain an aqueous core free of dye and there is no need for 
further processing to remove unincorporated dye.  Furthermore, no release of dye to the 
internal or external aqueous solution is observed [51].   Figure 4.3B depicts the 
stable, non-covalent, and uniform incorporation of multiple porphyrin molecules copies 
into the polymersome bilayer.  Incorporating the family of porphyrin molecules into 
polymeric vesicles leads to a family of soft matter optical imaging agents with emission 
maxima that span the window from approximately 575nm to 1000nm [51].   
 The incorporation of therapeutics into the aqueous core of the porphyrin 
polymersome leads to the generation of multi-modal vesicles, with the capability to both 
track vesicle location in vivo and locally deliver therapeutics.   
 The ability to incorporate numerous porphyrin molecules into one polymersome 
creates an intensely bright fluorescent contrast agent with great promise for in vivo 
imaging applications.  The additional encapsulation of therapeutics into these contrast 
agents lead to the creation of a multi-functional polymer vesicle with great theranostic 
utility.   
4.3 EXPERIMENTAL METHODS 
4.3.1 Preparation of Porphyrin Loaded PEO-b-PBD and PEO-b-PCL Vesicles  
Self-assembly via thin-film hydration was used to assemble the PEO-b-PCL and 
PEO- b-PBD copolymers into their equilibrium morphologies.  Film hydration has been 
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extensively utilized for preparing non-degradable polymersomes comprised of PEO-b-
PBD and PEO-b-PEE diblock copolymers [4, 9].  Furthermore, Ghoroghchian, et al. 
demonstrated the ability to load porphyrin molecules of various sizes into polymer 
vesicles [9, 51, 52, 119].   
Briefly, a PEO-b-PCL copolymer or PEO-b-PBD copolymer solution in 
methylene chloride was prepared (35mg/ml-100mg/ml polymer) and added to porphyrin 
at a 1:40 porphyrin:polymer molar ratio.  Two hundred microliters of the polymer-
porphyrin solution were uniformly deposited on the surface of a roughened Teflon plate 
followed by evaporation of the solvent for >12h.  Addition of aqueous solution, 
(~290mOsM Phosphate Buffered Saline, PBS) and sonication at 65°C led to spontaneous 
budding of polymersomes, off the Teflon-deposited thin-film, into the aqueous solution.  
The sonication procedure involved placing the sample vial containing the aqueous based 
solution and dried thin-film formulation (of polymer-drug uniformly deposited on Teflon) 
into a sonicator bath (Branson; Model 3510) @ 60-65°C for 30min followed by constant 
agitation for 60 minutes at 60-65°C.  Subsequently, five cycles of freeze-thaw extraction, 
which involved placing the sample vials in liquid N2 followed by thawing in a water bath 
at 50-60°C.  Extrusion using a pressure driven Lipex Thermobarrel Extruder (1.5 mL 
capacity) at 65°C was performed to yield small (<300-nm diameter) unilamellar 
polymersomes that possess appropriately narrow size distributions.  The size distribution 
of the vesicle suspensions was determined by dynamic light scattering. The sample was 
centrifuged, filtrate removed, and additional PBS buffer was added to the concentrated 
sample for a total of nine times.  The collected polymersome solution was centrifuged to 
concentrate the sample.   
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Absorbance spectra of the NIR-emissive polymersomes were obtained using an 
Ultrospec 2100pro Amersham Biosciences UV/Visible Spectrophotometer.  Fluorescence 
spectra of NIR-emissive polymersomes were obtained with a Spex Fluorolog-3 
spectrophotometer (Jobin Yvon, Edison, NJ)  The concentration of porphyrin in the 
vesicles was determined by measuring the absorbance (molar extinction coefficient 
1.29*105 cm-1M-1 in polymersomes at 794nm [9]).   
4.3.2 Preparation of Porphyrin and Doxorubicin Loaded PEO-b-PCL Vesicles and the 
Release of Doxorubicin and Porphyrin from PEO-b-PCL Vesicles 
Similar to previous procedures, a PEO-b-PCL copolymer solution in methylene 
chloride was prepared (35mg/ml-100mg/ml polymer) and added to porphyrin at a 1:40 
porphyrin:polymer molar ratio.  The solution was deposited on the surface of a roughened 
Teflon plate followed by evaporation of the solvent for >12h.  Hydration of the samples 
in Ammonium Sulfate Solution (~290mOsM, pH~5.4), equilibration at 60-65C for 30 
minutes, and finally sonication at 60-65°C using a sonicator bath (Branson; Model 3510) 
led to spontaneous budding of polymersomes, off the Teflon-deposited thin-film, into the 
aqueous solution.  Five cycles of freeze-thaw extraction as described in Section 4.3.1 
followed the sonication.  Extrusion using a pressure driven Lipex Thermobarrel Extruder 
(1.5 mL capacity) at 65°C was performed to yield small (<300-nm diameter) unilamellar 
polymersomes that possess appropriately narrow size distributions.  The size distribution 
of the vesicle suspensions was determined by dynamic light scattering.   
Vesicles of the appropriate size were dialyzed against iso-osmotic acidified 
sodium chloride solution (pH~5.5—acidified with 12.N HCl, ~290mOsM) to establish a 
gradient across the vesicle membrane; three buffer exchanges were made in 
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approximately 30 hours.  Similar to the loading in PEO-b-PmCL, dialysis into sodium 
acetate buffer at pH 5.5, as performed with PEO-b-PCL vesicles discussed in Chapter 2, 
did not yield stable loading as determined via fluorescence measurements.  Hence, 
dialysis in various buffers was attempted, as will be elaborated upon in Section 4.4.2, and 
it was determined that stable fluorescence counts were obtained for loading when iso-
osmotic acidified NaCl (pH~5.5) was used as the dialysis media. 
 Post dialysis, vesicles were incubated with doxorubicin at a ratio of .2:1 
(drug:polymer) at 65C for greater than 7 hours [77-79].  Non-entrapped DOX was 
removed from the multi-functional polymersome suspension using an HPLC (Acta Basic 
10 HPLC with Frac 950) and the solution was passed through a HiTrap desalting column.  
The fractions containing only multi-functional polymersomes were collected, centrifuged 
and concentrated.  Incorporation of porphyrin and encapsulation of DOX was confirmed 
spectrophotometrically using an Ultrospec 2100pro Amersham Biosciences UV/Visible 
Spectrophotometer.   
 The release of doxorubicin from the vesicles and the decrease in porphyrin 
fluorescence over time was determined fluorometrically.  Aliquots of the samples were 
placed into either PBS buffer (290 mOsM at pH ~7.4) or sodium acetate buffer (50 mM 
sodium acetate and 100 mM sodium chloride, at pH ~ 5, 290mOsM) with N = 4 samples 
for each buffer.  Release studies of DOX from the loaded polymersomes were initiated 
immediately following aliquoting; DOX and Porphyrin fluorescence were measured 
fluorometrically using a SPEX Fluorolog-3 fluorimeter (DOX:  λex = 480nm, λem = 
590nm; Porphyrin:  λex = 480nm, λem = 800nm) at various intervals up to fourteen days.  
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As DOX is released from the polymersome core and diluted into the surrounding 
solution, its fluorescence emission increases over time.  In contrast, as the vesicle 
membrane is hydrolyzed, the porphyrin fluorescence decreases upon membrane 
degradation.  At the culmination of the study, the samples were solubilized using Triton 
X-100, which disrupts the vesicle membrane and releases the encapsulated DOX into the 
external solution.  The percent release over time and release rate were calculated by 
comparing the measured DOX fluorescence at each time point to final DOX 
fluorescence, as determined upon solubilization of remaining intact polymersomes with 
TritonX-100, at the completion of the study. 
4.4 RESULTS AND DISCUSSION 
4.4.1 The Loading of Porphyrin into PEO-b-PCL and PEO-b-PBD Vesicles 
Porphyrin trimer was successfully loaded into PEO-b-PCL and PEO-b-PBD 
vesicles at a molar ratio of 1:40 (Porphyrin to polymer) as previously described by P. 
Peter Ghoroghchian [9, 51].  In both cases, the incorporation of porphyrin was confirmed 
using absorbance spectroscopy, where the spectra clearly demonstrate both scatter due to 
the vesicles as well as the characteristic absorbance peaks of porphyrin (Figure 4.4).  
Porphyrin PEO-b-PBD vesicles were used in the initial vesicle biodistribution studies 
discussed in subsequent chapters.  Once the biodistrbution was determined, 
biodegradable porphyrin PEO-b-PCL vesicles were used to further elucidate the 
biodistribution and degradation of the vesicles in vivo.   
Figure 4.4- Absorbance spectra of 
showing the incorporation of porph
PBD Vesicles.  The characteristic absorbance peaks as well as the scatter from the 
vesicles is clearly visible.
4.4.2 Loading and Release of Doxorubicin and Porphyrin in PEO
Polymersomes 
 Doxorubicin and porphy
the method described in section 
was determined by obtaining fluorescence spectra of the dual loaded vesicles and 
confirming the existence of the characteristic emission peaks (
encapsulation of doxorub
and post incubation with the nonionic surfactant, Triton X
 Doxorubicin was actively
porphyrin PEO-b-PCL vesicles (~200nm) though a gradient established by dialyzing 
samples in acidified NaCl solution 
vesicles are dialyzed against sodium acetate buffer.  
attempted, however, similar to the case for PEO
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icin was further confirmed by comparing fluorescence data pre 
-100 (Figure 4.
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[77, 79, 81] (See Section 4.3.2).  Recall, PEO
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fluorescence during loading did not stabilize.  Hence, acidified sodium chloride solution 
was tested as dialysis exchange media and deemed acceptable.   
 In situ release studies were conducted at various physiological conditions (pH 5 
and pH 7.4,@T=37C) where changes in doxorubicin and porphyrin were monitored 
fluorometrically (λex=480nm, λem-DOX=590nm, λem-porphyrin=794nm) over 14 days.  At both 
pH’s, the characteristic initial burst phase release (where approximately 20% of the initial 
payload within the first 12 hours) was observed followed by a more controlled pH 
dependent release over the 14 day release study (Figure 4.4 B,C).  At a pH of 5, the initial 
release rate is significantly faster than the rate observed over the entire 14 days; 
furthermore, similar to the findings for PEO-b-PCL vesicles alone, it appears that the 
dominant mechanism of release at both short and long times at this pH is acid catalyzed 
hydrolysis of the PCL membrane.  At a pH of 7.4, two distinct phases (α, β) were 
observed for DOX release from PEO-b-PCL vesicles.  In contrast, when porphyrin is 
incorporated into the hydrophobic membrane, it appears that the large porphyrin 
molecules hinder extensive initial passive diffusion of the drug across the PCL 
membrane, and thus significant doxorubicin release from the polymersome core at pH 7.4 
occurs at later times.  This suggests that DOX release from the porphyrin vesicles is 
predominantly facilitated by hydrolytic matrix degradation of the caprolactone backbone 
(Figure 4.6 B, C), even in non-acidic environments.  Since acid catalyzed hydrolysis of 
the membrane occurs at both short and long times at pH 5, DOX release at pH 5 is more 
rapid and more drug is released than that at pH 7.4  
 Figure 4.6A depicts the decrease in porphyrin fluorescence over the 14 day time 
period.  Porphyrin fluorescence is highly environmentally dependent and changes in the 
environment are reflected as changes in the florescence.  Thus, as the membrane breaks 
down and porphyrin is no longer in the hydrophobic environment of the PCL membrane, 
its fluorescence decreases.  As expected, the porphyrin fluorescence decrease
days, as the membrane degrades, correlates nicely with the increase in DOX fluoresce
(drug release).   
Figure 4.5- Fluorescence spectra of DOX/porphyrin PEO
The doxorubicin and porphyrin peaks are clearly visible.  The inlay is a zoomed in 
version of the curve from 70
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-b-PCL vesicles.  
0nm to 900nm to show the porphyrin peak.  
 over the 14 
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Figure 4.6- (A) Porphyrin decrease in fluorescence corresponds with (B) 
doxorubicin cumulative release as determined by doxorubicin increase in 
fluorescence and (C) rate of doxorubicin release from PEO
vesicles. 
4.5 CONCLUSIONS
 The findings discussed in this chapter highlight the potential of polymersomes to 
be used simultaneously as contrast agents for imaging applications as well as drug 
delivery vehicles for therapeutic applications.  The results demonstrated the method used 
to generate NIR-emissive polymersomes for imaging applications can be expanded upon 
to encapsulate a chemotherapeutic, doxorubicin, into the aqueous core, creating a 
functional polymersome.  Extensive doxorubicin loading studies established the use of 
both an ammonium sulfate and a pH gradient across the porphyrin incorporated 
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hydrophobic bilayer of the polymersome as the optimal loading environment.  Once the 
loading parameters were determined, release studies were conducted and the release of 
DOX from the vesicle and vesicle breakdown was characterized.   
 The theranostic applications of these polymer vesicles loaded with therapeutics 
and imaging agents will be elaborated upon further in Chapter 7.   
4.6 ACKNOWLEDGEMENTS 
 This work was supported by grants from the National Institutes of Health 
(EB003457-01 and CA115229), the National Cancer Institute (R33-NO1-CO-29008), 
Commonwealth Funds, Pennsylvania and Abramson Cancer Center, University of 
Pennsylvania, and infrastructural support was provided by a grant from the MRSEC 
Program of the National Science Foundation (DMR05-20020 and DMR-00-79909).  A 
portion of the work discussed in this chapter was performed in the University of 
Minnesota I.T. Characterization Facility, which receives partial support from the NSF 
through the NNIN program. 
4.7 REFERENCES 
1. Photos, P.J., et al., Polymer vesicles in vivo: correlations with PEG molecular 
weight. Journal of Controlled Release, 2003. 90(3): p. 323-334. 
2. Bermudez, H., et al., Molecular weight dependence of polymersome membrane 
structure, elasticity, and stability. Macromolecules, 2002. 35(21): p. 8203-8208. 
3. Lee, J.C.M., et al., Preparation, stability, and in vitro performance of vesicles 
made with diblock copolymers. Biotechnology and Bioengineering, 2001. 73(2): 
p. 135-145. 
4. Meng, F., G.H.M. Engbers, and J. Feijen, Biodegradable polymersomes as a basis 
for artificial cells: encapsulation, release and targeting. Journal of Controlled 
Release, 2005. 101(1-3): p. 187-198. 
5. Jain, R.K., L.L. Munn, and D. Fukumura, Dissecting tumour pathophysiology 
using intravital microscopy. Nature Reviews Cancer, 2002. 2(4): p. 266-276. 
6. Weissleder, R., A clearer vision for in vivo imaging. Nature Biotechnology, 2001. 
19(4): p. 316-317. 
118 
7. Lin, V.S.Y. and M.J. Therien, The role of porphyrin-to-porphyrin linkage 
topology in the extensive modulation of the absorptive and emissive properties of 
a series of ethynyl- and butadiynyl-bridged bis- and tris(porphinato)zinc 
chromophores. Chemistry-a European Journal, 1995. 1(9): p. 645-651. 
8. Lin, V.S.Y., S.G. Dimagno, and M.J. Therien, HIGHLY CONJUGATED, 
ACETYLENYL BRIDGED PORPHYRINS - NEW MODELS FOR LIGHT-
HARVESTING ANTENNA SYSTEMS. Science, 1994. 264(5162): p. 1105-1111. 
9. Duncan, T.V., et al., Exceptional near-infrared fluorescence quantum yields and 
excited-state absorptivity of highly conjugated porphyrin arrays. Journal of the 
American Chemical Society, 2006. 128(28): p. 9000-9001. 
10. Ghoroghchian, P.P., et al., Near-infrared-emissive polymersomes: Self-assembled 
soft matter for in vivo optical imaging. Proceedings of the National Academy of 
Sciences of the United States of America, 2005. 102(8): p. 2922-2927. 
11. Ghoroghchian, P.P., et al., Broad spectral domain fluorescence wavelength 
modulation of visible and near-infrared emissive polymersomes. Journal of the 
American Chemical Society, 2005. 127(44): p. 15388-15390. 
12. Discher, B.M., et al., Polymersomes: Tough vesicles made from diblock 
copolymers. Science, 1999. 284(5417): p. 1143-1146. 
13. Ghoroghchian, P.P., et al., Controlling bulk optical properties of emissive 
polymersomes through intramembranous polymer-fluorophore interactions. 
Chemistry of Materials, 2007. 19(6): p. 1309-1318. 
14. Ghoroghchian, P.P., et al., Quantitative membrane loading of polymer vesicles. 
Soft Matter, 2006. 2(11): p. 973-980. 
15. Discher, D.E. and A. Eisenberg, Polymer vesicles. Science, 2002. 297(5583): p. 
967-973. 
16. Haran, G., et al., Transmembrane Ammonium-Sulfate Gradients in Liposomes 
Produce Efficient and Stable Entrapment of Amphipathic Weak Bases. 
Biochimica Et Biophysica Acta, 1993. 1151(2): p. 201-215. 
17. Lopes de Menezes, D.E., Pilarski, L.M., Allen, T.M., , Cancer Research, 1998. 
58: p. 3320-3330. 
18. Bolotin, E.M., et al., Ammonium Sulfate Gradients for Efficient and Stable 
Remote Loading of Amphiphathic Weak Bases into Liposomes and 
Ligandoliposomes. Journal of Liposome Research, 1994. 4(1): p. 455-479. 
19. de Menezes, D.E.L., L.M. Pilarski, and T.M. Allen, In vitro and in vivo targeting 
of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Research, 
1998. 58(15): p. 3320-3330. 
  
119 
Chapter 5  
POLYMERSOMES:  DISCOVERING THEIR IMAGING AND DRUG 
DELIVERY POTENTIAL IN VITRO 
 ADAPTED FROM 
D. H Levine, J. S. Katz, N. Dang, J. A. Burdick, J. Hadfield, and D. A. Hammer, 
Manuscript in Preparation 
 
 
  
120 
5.1 SUMMARY  
 Polymersomes (polymer vesicles) have been shown to possess a number of 
attractive biomaterial properties compared to liposomes (phospholipid vesicles), 
including prolonged circulation times, increased mechanical stability, as well as the 
unique ability to incorporate numerous large hydrophobic molecules within their thick 
lamellar membranes and hydrophilic molecules within their lumen.  We have shown the 
ability to generate fully-bioresorbable self-assembled nanovesicles, from two FDA-
approved building blocks, poly(ethylene oxide) (PEO) and polycaprolactone (PCL). We 
have successfully loaded imaging agents, such as porphyrin-based near infrared (NIR) 
fluorophores, and therapeutics such as doxorubicin and combretastatin A-4 into these 
polymersomes and tracked their release (See Chapters 2 and 4). 
 Tumors require a network of blood vessels to survive and grow; these blood 
vessels are required to provide oxygen and nutrients to the tumor cells and remove carbon 
dioxide and waste.  However, these tumor blood vessels are immature and poorly 
developed.  As a result, the combination of chemotherapeutics with anti-angiogenesis 
drugs/vascular disrupting agents (VDA) has emerged as a promising therapy for 
eradicating tumors.  These agents target genetically stable endothelial cells that constitute 
the blood vessels around tumors rather than the transformed tumor cells themselves. 
Combretastatin A-4, a hydrophobic cytotoxic agent, inhibits the polymerization of tubulin 
and is highly toxic to tumor vasculature, but is believed not to affect healthy vasculature.  
Hence, in addition to delivering drug to tumorigenic cells, the ability to deliver 
121 
therapeutics to the endothelial cells lining the newly formed vasculature would be 
advantageous in cancer therapy. 
 Here, we determined the cytotoxic potential of combretastatin A-4 loaded 
polymeric vesicles and doxorubicin loaded polymeric vesicles on human umbilical vein 
endothelial cells (HUVECs) and SK-BR-3 tumorigenic cells both separately cultured, as 
well as in co-cultured.  For both cell lines and both therapeutic agents, toxicity was both 
concentration and time dependent.  Furthermore, we utilized NIR-emissive 
polymersomes formulated from PEO-b-PCL diblock copolymer and loaded with 
porphyrin (a NIR emissive fluorophore) to assess cellular uptake of polymersomes.  
Vesicle uptake by HUVECs was dependent on both concentration and incubation time.  
A viability assay using CellTiter-Blue™  (Promega) demonstrated biocompatibility of the 
unloaded polymersomes at short time for the SK-BR-3 cells and at extended time for the 
HUVECs. Thus, this study highlights the feasibility of using polymersomes to deliver 
vascular disrupting agents to endothelial cells simultaneously with treating tumors 
directly.  
5.2 INTRODUCTION  
 Polymersomes (polymer vesicles) have been shown to possess a number of 
attractive biomaterial properties compared to liposomes (phospholipid vesicles), 
including prolonged circulation times [8], increased mechanical stability [7], as well as 
the unique ability to incorporate numerous large hydrophobic molecules within their 
thick lamellar membranes and hydrophilic molecules within their lumen [5, 6].  We have 
shown the ability to generate fully-bioresorbable self-assembled nanovesicles, from two 
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FDA-approved building blocks, poly(ethylene oxide) (PEO) and polycaprolactone (PCL) 
[10]. We have successfully loaded imaging agents, such as porphyrin-based near infrared 
(NIR) fluorophores, and therapeutics such as doxorubicin and combretastatin A-4 into 
these polymersomes and tracked their release (See Chapters 2 and 4). 
 Doxorubicin (DOX), an amphipathic antibiotic used to treat a wide array of 
malignancies, from solid tumors to leukemias [67-70], has been known to cause 
cardiotoxicity at cumulative doses [69, 120]. This has created a major therapeutic 
limitation. However, as discussed, encapsulating the drug into a vesicle has been shown 
to decrease cardiac toxicity thereby reducing the levels of DOX in heart muscle with 
minimal effects on the therapeutic efficacy of the drug [69, 120].   
 As discussed in Chapter 2, tumors require a network of blood vessels to survive 
and grow; these blood vessels are required to provide oxygen and nutrients to the tumor 
cells and remove carbon dioxide and waste.  However, these tumor blood vessels are 
immature and poorly developed [73].  As a result, the combination of chemotherapeutics 
with anti-angiogenesis drugs/vascular disrupting agents (VDA) has emerged as a 
promising therapy for eradicating tumors [71, 73].  These agents target genetically stable 
endothelial cells that constitute the blood vessels around tumors, rather than the 
transformed tumor cells themselves [75]. Combretastatin A-4, a hydrophobic cytotoxic 
agent, inhibits the polymerization of tubulin and is highly toxic to tumor vasculature, but 
is believed not to affect healthy vasculature [76].   
 Hence, in addition to delivering drug to tumorigenic cells, the ability to deliver 
therapeutics to the endothelial cells lining the newly formed vasculature is highly 
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advantageous in cancer therapy.  The therapeutic potential of the DOX/Combretastatin A-
4 co-drug combination vesicles, as well as the single drug -vesicle, on Human Umbilical 
Vein Endothelial Cells (HUVECs) and the human breast cancer cells, SK-BR-3 cells, 
cultured separately and in co-culture was investigated.   
 It should be noted that the HUVECs are a good "surrogate" for the new 
endothelial cells making up the tumor vasculature since they are a well established cell 
line that mimics the endothelial cells partially because the HUVECs express some of the 
proteins upregulated on new endothelial near tumors [121].   
 The findings of the enumerated toxicity studies will be explored in this chapter.  
First, however, the biocompatibility of non-drug loaded vesicles, as well as cellular 
uptake of vesicles by HUVECs and SK-BR-3 cells, were examined and will be discussed.   
5.3 EXPERIMENTAL METHODS 
5.3.1 Preparation of Drug and Imaging Agent Loaded PEO-b-PCL Vesicles 
 Drug loaded vesicles were prepared as described in Chapter 2.  Porphyrin loaded 
PEO-b-PCL and Porphyrin/DOX Vesicles were prepared as described in Chapter 3.  
Vesicles were concentrated post formation using Millipore Centricon Tubes.   
To determine the concentration of combretastatin in the PEO-b-PCL vesicles, one 
hundred microliter sample aliquots were removed and the combretastatin was extracted 
from the vesicles by adding the aliquot to 400 microliters of PBS and 500 microliters of 
methylene chloride, and subsequently vortexing and centrifuging the sample.  The 
resulting aqueous layer was carefully removed, and the remaining organic layer with drug 
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was placed in a vacuum.  The dried powder resulting from evaporation of the methylene 
chloride was reconstituted in 1 milliliter of acetonitrile.  The concentration of 
combretastatin was determined by measuring the absorbance (molar extinction 
coefficient 12, 579M-1cm-1 in acetonitrile at 300nm). Polymer concentration was 
determined by a mathematical calculation, as the molar ratio of combretastatin to 
polymer is known to be 0.9:1.   
 To determine the concentration of Doxorubicin in the PEO-b-PCL polymersomes, 
sample aliquots were removed from the concentrated stock solution, and lyophilized to 
destroy the vesicle structure and release the encapsulated DOX from the core of the 
polymersome.  The freeze-dried powder was reconstituted in tertiary butanol:water 9:1, 
v/v containing 0.075N HCl or 90% isopropyl alcohol containing 0.075 M HCl.  The 
concentration of DOX was determined using Beer’s Law by measuring the absorbance at 
480nm using a molar extinction coefficient of 12,500cm-1M-1 in either solvent [70, 122].   
The concentration of the porphyrin vesicles in solution was determined by 
measuring the absorbance at 794nm using a molar extinction coefficient of 1.29*105M-
1cm-1 in THF[9].  Polymer concentration was determined by a mathematical calculation, 
since the ratio of porphyrin to polymer was set at 1:40 (molar ratio).   
 For cell studies, 10x concentrations of the drug-polymer vesicles and 
imaging agent-polymer vesicles were made by diluting the resulting concentrated sample 
in PBS.  The 10x samples were further diluted in sterile culture media to yield final 
desired drug concentrations in a 90% media-10% PBS aqueous solution.  The PBS-
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Media-vesicle suspension was sterilized under UV light in a cell culture hood for 30 
minutes, yielding sterile drug loaded vesicles in media-PBS.   
5.3.2 Cell Culture 
 Human umbilical vein endothelial cells (HUVECs) were cultured in EGM 
Endothelia Growth Media (LONZA) supplemented with bovine brain extract (BBE) with 
heparin, h-EGF, hydrocortisone, GA-1000 (gentamicin, amphotericin B), and fetal bovine 
serum (FBS).  Cells were maintained in plastic culture flasks at 37◦C in a humidified 
atmosphere containing 5% CO2 in air and subcultured when the flasks were 70% to 90% 
confluent.  To subculture cells, growth media was removed from the HUVEC culture 
flask via aspiration and the flask was washed with Hepes Buffered Saline Solution 
(HBSS).  The HBSS was removed and 0.025mg/ml trypsin-EDTA was added and the 
flask was returned to the incubator for 5min at 37C and 5% CO2 in air.  Post trypsin 
incubation, trypsin neutralizing solution (TNS, LONZA) was added to the flask and the 
wall was washed in order to remove all cells.  The cell suspension was then transferred to 
a conical tube and centrifuged at 1000rpm for 5 minutes to pellet the cells.  The 
supernatant was aspirated and the cells were resuspended in fresh growth media and a 
cell count was performed with a hemocytometer for future culturing and well-plating.  
HUVECs in vitro studies were conducted with cells between passages 4-8.   
The human breast cancer cells, SK-BR-3 cells, were cultured in McCoy's 5a 
Medium Modified (base media), 10% fetal bovine serum (FBS), and 1% Pen/Strep 100X 
(10000u/ml P - 10mg/ml S).  Cells were maintained in plastic culture flasks at 37◦C in a 
humidified atmosphere containing 5% CO2 in air and subcultured at subcultivation ratio 
of 1:3 when the flasks were 70% to 90% confluent.  When cells were deemed 70%-90% 
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confluent, growth media was removed from the culture flask via aspiration and the flask 
was washed with Phosphate Buffered Saline (PBS).  The PBS was removed and trypsin-
EDTA (0.25%)was added and the flask was returned to the incubator for 5min at 37C 
and 5% CO2 in air.  Post trypsin incubation, media was added to the flask and the wall 
was washed in order to remove all cells.  The cell suspension was then transferred to a 
conical tube and centrifuged at 1000rpm for 5 minutes to pellet the cells.  The supernatant 
was aspirated and the cells were resuspended in fresh growth media and a cell count was 
performed with a hemocytometer for future culturing and well-plating.  For in vitro 
experiments, SK-BR-3 cells between passages 15 to 30 were used.   
5.3.3 Determining Cellular Uptake of PEO-b-PCL Vesicles by HUVECs and SK-BR-3 
Cells 
 In order to investigate the cellular uptake of PEO-b-PCL vesicles as a function of 
cell number, vesicle concentration, and incubation time, HUVECs and SK-BR-3 cells 
were plated at varying densities ranging from 3.0*104 cells/well to 0.7*104 cells/well in 
96 well (black frame, clear well) cell culture plates (Isoplate-96 TC, Perkin Elmer) in 
complete growth media and allowed to adhere overnight (~20-24hours).  Culture media 
was removed from the wells, wells were washed once with 250uL of PBS and replaced 
with 250uL of either:  90% media/10% PBS without polymersomes, or 90% media/10% 
PBS with various concentrations of porphyrin polymersomes and maintained at 37◦C in a 
humidified atmosphere containing 5% CO2 in air.  The suspensions were sterilized with 
30 min exposure to a UV lamp in the culture hood prior to addition to cells.  At various 
defined time points (.75H, 1.5H, 3H, and 5H post vesicle administration), plates were 
removed from the incubator, wells were washed three times with 250uL of PBS to 
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remove free vesicles and 100uL of fresh media was added.  The fluorescence intensity 
emanating from the wells as a result of vesicles that had been taken up was then 
determined using a LICOR Odyssey, an Infrared (IR) Imaging System. 
5.3.4 Investigating the Biocompatibility and Viability of Unloaded PEO-b-PCL on 
HUVECs and SK-BR-3 Cells 
 In addition to determining vesicle uptake, viability studies were carried out to 
determine the biocompatibility of unloaded PEO-b-PCL polymersomes on HUVECs and 
SK-BR-3 cells in vitro.  HUVECs and SK-BR-3 cells were plated in 96 well plates in 
complete growth media and allowed to adhere overnight (~20~24hours).  Cells were 
removed from the flasks as per the procedure described in Section 5.3.2.  When 
examining the effects on HUVECs, HUVECs were plated at a density of 3,200 cells per 
well; in separate plates, SK-BR-3 cells were plated at a density of 5,000 cells per well to 
examine the effect on SK-BR-3 cells.  In each case, cells were allowed to adhere for 20 to 
24 hours.  Culture media was removed from the wells, wells were washed once with 
250uL of PBS and replaced with 250uL of either:  90% media/10% PBS without 
polymersomes, or 90% media/10% PBS with various concentrations of unloaded 
polymersomes and maintained at 37◦C in a humidified atmosphere containing 5% CO2 in 
air.  The suspensions were sterilized with 30 min exposure to a UV lamp in the culture 
hood prior to addition to cells.  At various defined time points (.12H, 24H, 48H, and 72H 
post vesicle administration), plates were removed from the incubator, wells were washed 
three times with 250uL of PBS to remove free vesicles, and 100uL of fresh media was 
added.  20ul of CellTiter-Blue® (Promega) was added to each well and the plate was 
returned to the incubator.  After two hours of incubation, 20ul of the CellTiter-Blue™ 
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/Media from the wells was added to 80ul of PBS in a 96-well black bottom assay plate, 
and the fluorescence emanating from the wells, which is a measure of cell viability, was 
determined using a TECAN Infinite® 2000 Multimode microplate reader.   
5.3.5 Investigating the Anti-vasculature Potential of Combretastatin PEO-b-PCL 
Polymersomes on HUVECs and SK-BR-3 Cells Cultured Separately 
 In order to investigate the anti-vasculature potential of combretastatin loaded 
PEO-b-PCL vesicles, HUVECs were plated at a density of 3,200 cells per well 
(10,000cells/cm2) in 96 well cell culture plates and SK-BR-3 cells were plated in separate 
96 well cell cultures plates at a density of 5,000 cells per well; in each instance, cells 
were allowed to adhere overnight (~20-24hours).  Culture media was removed from the 
wells, wells were washed with 250uL of PBS, and replaced with 250uL of either:  100% 
media, 90% media/10% PBS, 100% PBS, and various concentrations of drug in 90% 
media/10% PBS, and maintained at 37◦C in a humidified atmosphere containing 5% CO2 
in air.  The suspensions were sterilized with 30 min exposure to a UV lamp in the culture 
hood prior to addition to cells.  At various defined time points (12H, 24H, 48H, and 72H 
post drug administration), wells were washed with 250uL of PBS and 100uL of fresh 
media was added.  To the fresh media, 20uL of CellTiter-Blue® (Promega) was added to 
each well and the cells and Titer Blue were incubated at 37◦C in a humidified atmosphere 
containing 5% CO2 in air for 2 hours.  Subsequently, 20uL of media containing CellTiter-
Blue™ was removed from the wells and diluted into 80uL of PBS in the wells of a 96-
well black bottom assay plate.  The fluorescence intensity emanating from the wells, 
which is a measure of cell viability, was then determined using a TECAN Infinite® 2000 
Multimode microplate reader. 
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5.3.6 Investigating the Cytotoxic Effects of Doxorubicin Loaded PEO-b-PCL Vesicles 
on HUVECs and SK-BR-3 Cells Cultured Separately 
Doxorubicin single culture cytotoxicity studies were carried out in a manner 
similar to the previously discussed studies.  HUVECs were plated at a density of 3,200 
cells per well (10,000cells/cm2) in 96 well cell culture plates and SK-BR-3 cells were 
plated in separate 96 well cell cultures plates at a density of 5,000 cells per well; in each 
instance, cells were allowed to adhere overnight (~20-24hours).  Culture media was 
removed from the wells, wells were washed with 250uL of PBS, and replaced with 
250uL of either:  100% media, 90% media/10% PBS, 100% PBS, and various 
concentrations of drug in 90% media/10% PBS, and maintained at 37◦C in a humidified 
atmosphere containing 5% CO2 in air.  The suspensions were sterilized with 30 min 
exposure to a UV lamp in the culture hood prior to addition to cells.  At various defined 
time points (12H, 24H, 48H, and 72H post drug administration), wells were washed with 
250uL of PBS and 100uL of fresh media was added.  To the fresh media, 20uL of 
CellTiter-Blue® (Promega) was added to each well and the cells and Titer Blue were 
incubated at 37◦C in a humidified atmosphere containing 5% CO2 in air for 2 hours.  
Subsequently, 20uL of media containing CellTiter-Blue™ was removed from the wells 
and diluted into 80uL of PBS in the wells of a 96-well black bottom assay plate.  The 
fluorescence intensity emanating from the wells, which is a measure of cell viability, was 
then determined using a TECAN Infinite® 2000 Multimode microplate reader. 
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5.3.7 Investigating the Anti-vasculature and Anti-tumor Potential of Combretastatin 
and Doxorubicin Loaded PEO-b-PCL Polymersomes on HUVECs and SK-BR-3 Cells 
in Co-Culture 
In order to determine the cytotoxic effects of drug loaded vesicles in co-culture, 
HUVECs and SK-BR-3 cells were stained using Cellvue ® NIR815(λEx max =786nm, λEm 
max =814nm) and Cellvue ® Burgundy (λEx max =683nm and λEm max =707nm) from 
Molecular Targeting Technologies Inc.(MTTI), respectively.  These dyes provide stable 
labeling of the lipid regions of the cell membrane.  Labeling was carried out as per 
protocol obtained from MTTI, but scaled down for 2 million cells.  Stained cells were 
plated at a density of 3,200 cells per well (10,000cells/cm2) in 96 well (black frame, clear 
well) cell culture plates (Isoplate-96 TC, Perkin Elmer) and were allowed to adhere 
overnight (~20~24hours).  Culture media was removed from the wells, wells were 
washed with 250uL of PBS, and replaced with 250uL of either:  100% media, 90% 
media/10% PBS, 100% PBS, and various concentrations of drug loaded vesicles in 90% 
media/10% PBS, and maintained at 37◦C in a humidified atmosphere containing 5% CO2 
in air.  The suspensions were sterilized with 30 minute exposure to a UV lamp in the 
culture hood prior to incubation with cells.  Immediately following addition of drug 
loaded polymersomes, the fluorescence intensity was measured using a LICOR Odyssey, 
an Infrared (IR) Imaging System and this fluorescence was deemed to be the initial 
fluorescence per well.  At various defined time points (12H, 24H, 48H, and 72H) post 
drug administration, wells were washed with 250uL of PBS to removed dead cells and 
250uL of fresh media was added to the wells.  The fluorescence intensity emanating from 
the washed wells, as a result of live stained cells in the wells, was then determined using 
a LICOR Odyssey.   
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5.4 RESULTS AND DISCUSSION 
5.4.1 Cellular Uptake of Porphyrin Loaded PEO-b-PCL Vesicles by HUVECs and SK-
BR-3 Cells 
 To determine the cellular uptake of polymer vesicles by HUVECs and SK-BR-3 
cells, we utilized ~200nm NIR-emissive polymersomes formulated from PEO-b-PCL 
diblock copolymer and loaded with porphyrin (a NIR emissive fluorophore) and the 
LICOR Odyssey, an Infrared (IR) Imaging System.  Figure 5.1 shows the raw data 
obtained for the uptake of ~200nm porphyrin polymersomes by HUVECs after 5 hours of 
incubation; similar images were obtained for the other time points as well as for SK-BR-3 
cells.   
 
Figure 5.1- Raw HUVEC uptake data from the Odyssey.   
Row A: 3*104 Cells/Well; Row B:  2.25*104 Cells/Well; Row C: 1.5*104 Cells/Well; 
Row D: 0.75*104 Cells/Well Column 1-3: Media Only; Column 4-6: 9uM PEO-b-
PCL; Column 7-9: 4.5uM PEO-b-PCL; Column 10-12: 1.125uM PEO-b-PCL; 
Porphyrin Vesicles=Green (800 channel) 
The vesicle uptake by HUVECs was both concentration and incubation time 
dependent.  In general, as vesicle concentration in the media increased, cellular uptake 
also increased, until the saturation capacity of the cell was reached, especially at low cell 
numbers (Figure 5.2).  Furthermore, increased incubation time or higher concentration of 
vesicles generally resulted in increas
cell densities, uptake was seen as early as 45 minutes and increased with extended 
incubation times.  At lower v
significant vesicle uptake.    
  
Figure 5.2- The effect of concentration and cell numb
HUVECs  
(A) and SK-BR-3 cells
polymersomes. (n=3; error bars ± S.E.)
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Figure 5.3- The effect of concentration and incubation time on polymersome uptake 
by HUVECs (A-B) and 
5.4.2 Determination of the Viability and Biocompatibility of Unloaded PEO
Vesicles on HUVECs and SK
 A viability assay using 
biocompatibility of the PEO
in culture.  HUVECs and SK
PCL polymer vesicles at varying concentrations for up to 72 hours.  A moderate drop in 
viability (∼55-75%) was observed wi
concentration or time dependent (
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Figure 5.4- The viability of HUVECs (A
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with combretastatin vesicles, viability decreased over the 72 hours in both a time and 
dose dependent manner (Figure 5.5). 
 For HUVECs cultured with combretastatin vesicles for 12 hours, viability appears 
to be highly concentration dependent and ranged from ~40% viable at 9uM concentration 
of combretastatin to ~100% viable for the 0.25uM combretastatin condition.  At later 
times however, while viability still appears to be concentration dependent, the viability 
has significantly decreased and by 72 h, viability dropped to less than ~35% for all 
doses of combretastatin (Figure 5.5A).  
 For SK-BR-3 cells, cell growth for drug treated cells was arrested, and at 
extended times cells appeared to be dying.  After the first 24 hours, the cellular viability 
decreased to 50% or less for all concentrations, and by 72 hours, viability was less than 
~25% for all concentrations of combretastatin in polymersomes (Figure 5.5B).  Recall 
however, that a portion of the toxic effects are due to the vesicles themselves as 
evidenced in Figure 5.4B and thus some of the toxic effects seen may be due to the 
vesicles and not only the drug.   
Figure 5.5- The effect of varying concentration
polymersomes on HUVECs
Each bar represents the mean of four samples and error bars are standard 
deviation.  All conditions are normalized to cultures grown in 
Media(90%)/PBS(10%) without vesicles
5.4.4 Determination of the Cytotoxic Potential of Doxorubicin Loaded PEO
Polymersomes on HUVECs and SK
 The cytotoxic potential of doxorubicin loaded PEO
HUVECs and SK-BR-3 tu
incubation time dependence.  Both cell lines were separately cultured in the presence of 
~200nm doxorubicin loaded PEO
for up to 72 hours.  For both ce
decreased over the 72 hours in both a time and concentration dependent manner (
5.6). 
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Figure 5.6- The effect of varying concentrations of 
polymersomes on HUVECs
Each bar represents the mean of four samples and error bars are standard 
deviation.  All conditions are normalized
Media(90%)/PBS(10%) without vesicles
 After 24 hours of incubation, HUVEC viability does not appear to be effected by 
doxorubicin vesicles, even at high concentration.  However, the cellular
decreased sharply after the first 48 hours, where the viability is less than ~10% for cells 
incubated with doxorubicin at concentrations greater than 2.5uM.  After 72 hours, 
cellular viability is less than ~25% for all concentrations of DOX grea
(Figure 5.6A).  While one might expect to observe a less dramatic effect on HUVEC 
viability after incubation with the chemotherapeutic, one must cons
chemotherapeutics have anti
both in vitro and in vivo [71]
 For SK-BR-3 tumorigenic cells, the cytotoxic effect of doxorubicin was more 
prevalent after 24hours.  In fact, viability is less than ~75% in for all concentration, and 
less than ~50% for most concentrations of DOX.  Similar to the HUVEC response, by 48 
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hours, the cellular viability dropped to less than ~25% for DOX concentrations greater 
than 2.5uM and after 72 hours, only cells incubated with concentrations less than 0.25uM 
were greater than ~25% viable (Figure 5.6B).   
5.4.5 Investigating the Anti-vasculature and Anti-tumor Potential of Combretastatin 
and Doxorubicin Loaded PEO-b-PCL Polymersomes on HUVECs and SK-BR-3 Cells 
in Co-culture 
 HUVECs and SK-BR-3 cells were each stained using MTTI’s Cellvue ® 
Burgundy and Cellvue ® NIR815, respectively.  Post staining, cells were plated in 96 
well (black frame, clear well) cell culture plates (Isoplate-96 TC, Perkin Elmer) for 
further examination of the effects of drug loaded vesicles on HUVECs and SK-BR-3 
cells in co-culture.  Figure 5.7 shows the initial fluorescence emanating from the wells of 
the 96 well plates, post plating with stained HUVECs and SK-BR-3 cells.  In order to 
determine cell viability, cells incubated with drug loaded vesicles were washed to remove 
non-adherent cells and then assayed for fluorescence.  Specifically, the fluorescence 
emanating from each well post incubation with drug vesicles was normalized against its 
original fluorescence intensity, post initial wash and prior to incubation with drug.  
Subsequent to that normalization step, intensity per well was normalized against the 
normalized value for wells without drug.  This double normalization accounted for the 
fact that the washing step can remove some viable loosely adherent cells.   
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Figure 5.7- Image of stained co-cultured HUVECs and SK-BR-3 cells using the 
LICOR Odyssey prior to incubation with drug loaded vesicles. 
Green=HUVECs (700 Channel); Red= SK-BR-3 (800 Channel) 
 When combretastatin loaded PEO-b-PCL polymersomes are administered to 
HUVECs and SK-BR-3 cells in co-culture, the anti-vasculature effect of the drug on 
HUVECs appears to be less pronounced than when the drug is administered to cells in 
single culture; however, viability of cells cultured with drug loaded polymersomes is 
compared to the viability of cells cultured in PBS only (negative control as all cells will 
be dead), there is a noticeable effect after 12 hours (Figure 5.8A).  Noting that the 
viability of the PBS only cells is quite high, a CellTiter-Blue™ Cell Viability Assay 
(Promega) was carried out to determine if the PBS only wells still contained viable cells.  
Though this assay, it was confirmed that these wells were devoid of living cells.  From 
this, it is believed that the non-viable stained HUVECs stick to the wells even post 
washing and this sticking increases with increased incubation time in the wells.  Hence, 
the fluorescence from the PBS only wells increases over time, even though it was 
confirmed that the cells were dead after culturing in PBS for 72 hours.  Data not shown.   
 Post 12 hour incubation with combretastatin polymersomes, SK-BR-3 cell 
viability appeared to be adversely effected by the administration of combretastatin loaded 
polymersomes as well (Figure 5.8B).  After 24 hours, the viability drops to ~75% or less, 
and 48 hours post administra
~50%.  For the SK-BR-3 cells, the toxicity in co
cells are cultured separately; this may be the result of having the same concentration of 
polymer and drug, but 1.25 times more cells.  
Figure 5.8- The effect of combretastatin loaded polym
BR-3 cells (B) in co-culture. Each bar represents the mean of four samples and 
error bars are standard deviation. All conditions are normalized to the initial 
fluorescence and then to cultures grown in Media(90%)/PBS(10%) without vesicles. 
 Twenty four hours post i
of HUVECs appears to decrease to about 60% (when the viability is compared against 
that of the cells cultured in PBS only).  When comparing against the fluorescence 
emanating from PBS cultured cel
loaded vesicles, it appears that the viability drops greatly after a 72 hour incubation with 
drug loaded vesicles.  Again however, it must be noted, that sticking of the non
cells cultured in PBS only was observed and from this we can surmise that cells cultured 
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 The effect of doxorubicin loade
with HUVECs is apparent after 24 hours, when cellular viability decreased to less than 
~80% after administration of drug loaded polymersomes.  For concentrations of drug 
2.5uM and greater, the decrease in SK
concentration is demonstrated
less than 20% after 72 hours at the higher concentrations.  At 48 and 72 hours post 
incubation with drug loaded polymersomes, t
becomes apparent as decreasing concentration of drug at a particular time point leads to 
an increase in viability.  In contrast to the combretastatin co
that although there are more cells in
the SK-BR-3 cells are still adversely affected by incubation with doxorubicin.
Figure 5.9- The effect of doxorubicin l
HUVECs (A) SK-BR-3 cells
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Each bar represents the mean of four samples and error bars are standard 
deviation.  All conditions are normalized to the initial fluorescence and then to 
cultures grown in Media(90%)/PBS(10%) without vesicles.   
 As a final proof of concept, the following preliminary studies were carried out to 
investigate the effect of dual drug (DOX and combretastatin) loaded polymersomes on 
co-cultures of SK-BR-3 cells and HUVECs.  Similar to the single drug loaded vesicles, 
we see a strong dependence on both concentration and time for the SK-BR-3 cells, 
especially at the higher drug concentrations where viability decreases with each time 
point after the first 24 hours.  In addition, at the 72 hour time point, a clear drug 
concentration dependence is exhibited where the viability ranges from ~100% at the 
lowest concentration to ~20% at the highest concentration of drug (Figure 5.10B).  The 
HUVEC response to the dual drug loaded vesicles is not nearly as strong as what is 
observed for the SK-BR-3 cells.  A loose dependence on concentration and time is 
observed (Figure 5.10A), however, additional studies are required to precisely determine 
the effect of the dual drug vesicles on HUVECs in co-culture.  Follow up studies will be 
described in Chapter 7.   
Figure 5.10- The effect of doxorubicin
polymersomes on HUVECs (A) and SK
Each bar represents the mean of four samples and error bars are standard 
deviation.  All conditio
cultures grown in Media(90%)/PBS(10%) without vesicles.  
5.5 CONCLUSIONS
 We successfully utilized nano
diblock copolymer for in vitro
NIR-emissive polymersomes were used to determine uptake of polymersomes in human 
umbilical vein endothelial cells (HUVECs) and SK
uptake for both cell lines was dependent on concentration and 
vesicle concentration in the media increased, cellular uptake also increased.  Furthermore, 
increased incubation time generally resulted in increased uptake.  At higher HUVEC 
densities and/or high vesicle concentration
increased with extended incubation times.  At lower concentration
necessary for significant vesicle uptake. 
 Toxicity studies on drug loaded as well as empty vesicles were carried out using 
CellTiter-Blue™ Cell Viability Assay 
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biocompatibility of the nanoparticles without drug or imaging agent at all concentrations 
with HUVECs.  The SK-BR-3 cells demonstrate a 50% loss in viability after 12 hour 
incubation with empty vesicles at high and intermediate concentrations of polymer.  At 
low concentration of polymer, SK-BR-3 viability does not appear to be effected. The 
cytotoxic potential of combretastatin A-4 loaded polymeric vesicles and doxorubicin 
loaded polymeric vesicles on HUVECs and SK-BR3 tumorigenic cells were determined. 
For both cell lines, toxicity was generally both concentration and time dependent. For 
HUVECs, a 50% reduction in viability is seen within 12 hours at high concentrations of 
combretastatin A-4; at longer times, cellular viability is decreased to approximately 25% 
viable even at low concentrations of combretastatin A-4.  For SK-BR3 cells, cell growth 
for drug treated cells was arrested, and at extended times cells appeared to be dying.  
Similar results were observed for HUVECs and SK-BR-3 cells treated with doxorubicin 
loaded vesicles. When co-cultured, the effect of the drug is less pronounced then when 
the cells are treated separately, but at high concentrations of drug and/or extended 
incubation times, the cytotoxic effect of the drug loaded vesicles is observed.  
 Thus, this study highlights the feasibility of using polymersomes to deliver 
vascular disrupting agents to endothelial cells simultaneously with treating tumors. 
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6.1 SUMMARY  
 Polymersomes (polymer vesicles) have been shown to possess a number of 
attractive biomaterial properties compared to liposomes (phospholipid vesicles), 
including prolonged circulation times, increased mechanical stability, as well as the 
unique ability to incorporate numerous large hydrophobic molecules within their thick 
lamellar membranes and hydrophilic molecules within their core.  We have previously 
shown the ability to generate two types of self-assembled nano-sized vesicles ranging in 
size from 100’s of nanometers to 10’s of microns; one type comprised of a biocompatible 
diblock copolymer consisting of polyethyleneoxide (PEO) and polybutadine (PBD) and a 
second fully-bioresorbable vesicle consisting of two FDA-approved building blocks: 
polyethyleneoxide (PEO) and polycaprolactone (PCL).  In addition, we have successfully 
loaded imaging agents, such as porphyrin-based near infrared (NIR) fluorophores, and 
therapeutics such as doxorubicin, an anti-neoplastic agent, into these polymersomes and 
tracked their release in situ and in vivo.   
 NIR-emissive polymersomes, loaded with porphyrin, can be used for 
biodistribution studies, to track the location of the polymersomes, and potentially for 
diagnostic studies.  Here, we utilize NIR-emissive polymersomes to determine 
polymersome biodistribution in tumor bearing mice using a noninvasive small animal 
optical imaging instrument which detects the NIR fluorescence signal.   Passive 
accumulation of NIR-emissive polymersomes in tumor tissues of mice, as well as other 
organs, is evidenced.  Using porphyrin polymersomes for biodistribution studies will 
greatly decrease the number of animals required for such studies since the location of the 
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polymersomes can be determined without sacrificing animals at multiple time points to 
perform histology on the excised organs.   
 Doxorubicin, an anti-neoplastic agent, was encapsulated to serve as a model 
system for the release of a physiologically relevant compound from the PEO-b-PCL 
polymersomes.  The therapeutic potential of doxorubicin loaded polymersomes is shown; 
drug loaded bioresorbable polymersomes were administered in vivo and their capability 
to retard tumor growth was assessed using such metrics as tumor size and body weight.  
Doxorubicin loaded polymersomes were able to retard tumor growth in a live animal on a 
par with the commercially available DOXIL, liposomal doxorubicin.  Furthermore, 
mouse weights remained within +/-1.5g, for all treatment groups throughout the study.   
 Lastly, the marriage of the porphyrin polymersome with the doxorubicin 
polymersome was attempted in vivo.  Results are promising suggesting with further work 
that the multi-functional polymersome for theranostic applications could be a reality.   
6.2 INTRODUCTION  
 The fully PEG-ylated polymersome, with its thick hydrophobic membrane and 
large aqueous core, posses a number of superior biomaterial properties [4-6, 8] which 
make it ideally suited to facilitate biomedical applications such as deep tissue optical 
imaging and drug delivery.   
 Chapter 4 discusses the basis and rationale for using near infrared imaging (NIR) 
agents in contrast to visible probes for in vivo imaging applications and the tunable 
spectral properties of the porphyrin fluorophores used in the in vivo imaging studies 
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discussed in this chapter.  This chapter will build upon those concepts highlight in the 
previous chapters and discuss some of the principles of in vivo fluorescence based 
imaging.   
 In vivo deep tissue fluorescence based imaging characterizes the interaction of 
photons with tissue through three basic parameters, namely absorption, light scattering, 
and emission.  As discussed in Chapter 4, light absorption by the oxy and 
deoxyhemoglobin, water, and other molecules found in tissues [123, 124] is greatest 
below 700nm, causing significant auto-fluorescence in the visible spectra [125] and 
limiting the penetration depth to less than a few millimeters [126].  However, owing to 
the small tissue absorption coefficient in the NIR window (700nm-900nm) of the 
spectrum, light can penetrate much deeper into the tissues, enabling imaging deeper 
imaging into the tissues in contrast to imaging with probes in the visible region of the 
spectra [115].   
 In addition to the tissue properties which complicate in vivo imaging, the contrast 
agent itself must be nontoxic and overcome certain challenges in vivo such as absorption, 
distribution, metabolism, and excretion [127].  Furthermore, the contrast agent must be 
able localize and remain at the site with enough fluorescent intensity to be imaged [127, 
128].   
 Hence, the development of NIR contrast agents with appropriate biological 
parameters is crucial for in depth optical imaging of living tissues.  We have investigated 
the performance of NIR-emissive porphyrin polymersomes, polymeric vesicles loaded 
with porphyrin contrast agents, in both a biocompatible and bioresorbable formulation 
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and demonstrated their ability to assist in diagnostic applications as well as drug 
biodistribution studies.   
 Chapter 2 and Chapter 4 discuss the fabrication of the drug loaded polymersomes 
and the drug loaded polymersome for imaging purposes, while Chapter 5 demonstrates 
the potential of these vesicles in vitro.  In addition to the use of polymersomes for in vivo 
optical imaging in the NIR, this chapter will investigate use of drug loaded vesicles for in 
vivo applications.   
 Currently many pharmaceutical agents exist whose systemic toxicity is too great 
to be administered clinically.  Other compounds, would be clinically beneficial, however 
their hydrophobicity precludes them from being administered by conventional methods.  
Hence, a delivery vehicle with the ability to deliver such toxic and hydrophobic 
molecules at a high payload to the site of interest is imperative for advancing therapies.  
 Previously, researchers have demonstrated the therapeutic benefits of 
encapsulating pharmaceutical agents with low bioavailabilty or high systemic toxicity in 
PEG-ylated lipid vesicles, termed liposomes [120, 129, 130].  As described throughout 
this thesis, polymersomes, polymeric vesicles, have unique biological properties [4-6, 8] 
to render them superior to liposomes for drug delivery applications.  Hence considerable 
effort has been made in developing polymeric vesicles for drug delivery tools [27, 43, 
131, 132].  The in vivo performance of the fully bioresorbable PEO-b-PCL polymersome 
for the delivery of doxorubicin, a chemotherapeutic agent known to causes cardiotoxicty 
will be examined in this chapter.  Lastly, the chapter will close by demonstrating the 
potential for using polymersomes as both drug and imaging delivery agents.   
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6.3EXPERIMENTAL METHODS 
 Nude athymic mice used in the studies discussed below were housed under 
USDA- and AAALAC-approved conditions with free access to food and water. The 
University of Pennsylvania Institutional Animal Care and Use Committee and Small 
Animal Imaging Facility (SAIF) Animal Oversight Committee approved all experimental 
procedures. All in vivo imaging was conducted at the SAIF in the Department of 
Radiology at the University of Pennsylvania. 
6.3.1 Preparation of Drug and Imaging Agent Loaded Polymersomes 
 Drug loaded vesicles, porphyrin loaded vesicles, as well as drug-porphyrin 
vesicles were prepared as described in Chapter 2 and Chapter 4.  Briefly, thin-film 
hydration was used to assemble the ~200nm PEO-b-PCL copolymers into equilibrium 
morphologies [10]. Polymersomes were incubated with doxorubicin in a ratio of 1:.4 
polymer:drug (w/w) for ~9h at a temperature above their main gel to liquid-crystalline 
phase transition temperature, trapping the drug in the aqueous core.  Nonentraped DOX 
was removed using HPLC; the solution was passed through two HiTrap desalting 
columns and further removed using a Centricon tube to ensure the absorbance of drug in 
the subnatant was undetectable at 480nm. The collected DOX polymersome suspension 
was concentrated and passed through a 1um membrane prior to injection.   
 To determine the concentration of doxorubicin in the PEO-b-PCL polymersomes, 
sample aliquots were removed from the concentrated stock solution, and lyophilized to 
destroy the vesicle structure and release the encapsulated DOX from the core of the 
polymersome.  The freeze-dried powder was reconstituted in tertiary butanol:water 9:1, 
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v/v containing 0.075N HCl or 90% isopropyl alcohol containing 0.075 M HCl.  The 
concentration of DOX was determined using Beer’s Law by measuring the absorbance at 
480nm using a molar extinction coefficient of 12,5000cm-1M-1 in either solvent [70, 122].   
6.3.2Preparation of Porphyrin Imaging Agent Loaded PEO-b-PBD and PEO-b-PCL 
Polymersomes 
 Porphyrin loaded PEO-b-PCL and PEO-b-PBD polymersomes were prepared as 
described in Chapter 4.  Briefly, self-assembly via thin-film hydration followed by freeze 
thawing and extrusion were used to yield small porphyrin PEO-b-PBD polymer vesicles 
or porphyrin PEO-b-PCL polymersomes (~200nm diameter)[9].  The porphyrin dye is 
localized to the vesicle membrane.  The suspension was centrifuged using Millipore 
Centricon Tubes to obtain a porphyrin concentration of 15uM as determined by 
absorbance spectroscopy.  Prior to injection, vesicles were passed through a sterile 
200nm membrane.   
The concentration of the porphyrin vesicles in solution was determined by 
measuring the absorbance at 794nm using a molar extinction coefficient of 1.29*105M-
1cm-1 [9].  Polymer concentration was determined by a mathematical calculation, since 
the ratio of porphyrin to polymer was set at 1:40 (molar ratio).   
6.3.3 Cell Culture and Establishment of Tumors in Nude Mice 
 The T6-17 cell line which is derived from NIH-3T3 cells by over-expressing the 
human erbB2 receptor was used for all in vivo studies; these cells are HER2-expressing 
transformed tumor cells with the ability to develop tumors in nude mice [133].   
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 The T6-17 cells, were cultured in DMEM - high glucose 4.5 gm/L (base media), 
10% fetal bovine serum (FBS), 1% Pen/Strep 100X (10000u/ml P - 10mg/ml S), and 1% 
glutamine.  Cells were maintained in plastic culture flasks at 37◦C in a humidified 
atmosphere containing 5% CO2 in air and subcultured at subcultivation ratio of 1:10 
when the flasks were 70% to 90% confluent.  When cells were deemed 70%-90% 
confluent, growth media was removed from the culture flask via aspiration and the flask 
was washed with Phosphate Buffered Saline (PBS).  The PBS was removed and 
0.25%trypsin-EDTA was added and the flask was returned to the incubator for 5min at 
37C and 5% CO2 in air.  Post trypsin incubation, media was added to the flask and the 
wall was washed in order to remove all cells.  The cell suspension was then transferred to 
a conical tube and centrifuged at 1000rpm for 5 minutes to pellet the cells.  The 
supernatant was aspirated and the cells were resuspended in fresh growth media.  When 
cells were to be used for tumor studies, a cell count was performed.   
6.3.4 In vivo Biodistribution and Diagnostic Studies Using Porphyrin loaded PEO-b-
PBD Polymersomes  
 To establish the tumor in vivo, T6-17 tumor cells (1x106) were injected s.c. into 
the flank of athymic nude female mice.  At least ten days after inoculation of tumor cells, 
when tumors were visible and palpable, treatment with polymersomes commenced as 
described.   
 In order to reduce background fluorescence for extended imaging studies, lasting 
more than 12 hours, mice were switched from a fenbendazole-impregnated diet for 
prophylaxis purposes to AIN-76A, a low-autofluorescence rodent diet (Research Diets, 
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Inc.; New Brunswick, NJ). 5 to 7 days prior to imaging and remained on the low-
fluorescence feed until the culmination of the study.   
 Once the tumors were visible and palpable, 100ul of the porphryin polymersome 
solution (15uM porphyrin) was injected intravenously into the tail vein of a tumor 
bearing (T6-17 cells) nude mouse.  Fluorescent signal was measured prior to injection, as 
well as at specific time points ranging from hours to days, post injection, using one of the 
following small animal imagers:  a) the GEART eXplore Optics, 2) the LICOR Pearl 
Imager.  At the culmination of the study, the mice were sacrificed according to protocol.  
At the culmination of the extended study, sacrificed mice were carefully dissected and 
their organs were excised for further analysis.   
6.3.5 In vivo Intratumor Studies Using Porphyrin loaded PEO-b-PBD Polymersomes  
 To establish the tumor in vivo, T6-17 tumor cells (1x106) were injected s.c. into 
the flank of athymic nude female mice.  At least ten days after inoculation of tumor cells, 
when tumors were at least visible and palpable, 100uL of a 15uM solution of porphyrin 
PEO-b-PBD polymersomes was injected intravenously into the tail vein of the tumor 
bearing nude mouse.  Approximately eight hours post injection of vesicles, 100ul of 
AngioSense-IVM 680 (VisEn Medical), a large fluorescence agent (250k MW) that 
remains localized in the vasculature for extended periods of time (λex=680±10nm, 
λex=700±10nm), was intravenously injected into the retro-orbital vein of the mouse.   
 Immediately following the injection of AngioSense-IVM 680, a full body scan of 
the mouse in the prone position was taken using the GEArt.  Subsequently, a small 
portion the skin was removed from the tumor and the tumor was imagined using the 
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Olympus IV-100.  At the culmination of the study, the mice were euthanized as per 
protocol.  . 
6.3.6 In vivo Therapeutic Study Using Doxorubicin Loaded PEO-b-PCL Polymersomes 
 To establish the tumor in vivo, T6-17 tumor cells (1x106) were injected s.c. into 
the flank of athymic nude female mice.  One week after inoculation of tumor cells, when 
tumors were visible and palpable, treatment with polymersomes commenced as 
described.   
Once the tumors were visible and palpable, the mice were injected through the tail 
vein with 200uL of (1) polymersomes loaded with DOX at a concentration of 1mg/ml, 
(2) DOXIL (liposomal formulation of DOX) at a DOX concentration of 1mg/ml, (3) free 
DOX (unencapsulated drug) at a DOX concentration of 1mg/ml, and (4) PBS. Each 
group consisted of five mice.  The concentration of DOX in all administrations was 
1mg/ml and 200ul of solution was administered to each mouse, to yield a dose of 10mg 
of drug/kg.   
 After the administration of treatment (i.e. post i.v. injection), tumors were 
measured daily and mice were weighed every other day.  Tumor volume was determined 
by the equation, l*w*h.  Nine days after the start of treatment, the mice were sacrificed, 
bled from the retrooribital sinuses, and organs were harvested.  Using a HEMAVET, 
blood work was performed to be used as a metric for systemic toxicity resulting from 
each of the treatment groups.  Physical appearance and behavior were recorded as well.   
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6.3.7 In vivo Theranostic Study Using Doxorubicin and Porphyrin Loaded PEO-b-PCL 
Polymersome  
 To establish the tumor in vivo, T6-17 tumor cells (1x106) were injected s.c. into 
the right flank of athymic nude female mice.  Nine days after inoculation of tumor cells, 
when tumors were visible and palpable, treatment with polymersomes commenced as 
described in the following sections.   
 In order to reduce background fluorescence for extended imaging studies, lasting 
more than 12 hours, mice were switched from a fenbendazole-impregnated diet for 
prophylaxis purposes to AIN-76A, a low-autofluorescence rodent diet (Research Diets, 
Inc.; New Brunswick, NJ). 5 to 7 days prior to imaging and remained on the low-
fluorescence feed until the culmination of the study.   
Once the tumors were visible and palpable, the mice were injected through the tail 
vein with 250uL of:   
(1) Doxorubicin-Porphyrin PEO-b-PCL polymersomes at a concentration of 
0.122mgDOX/ml (4.65uM porphyrin and 2.6 mgPEO-b-PCL/ml as determined by 
the porphyrin absorbance),  
(2) Porphyrin PEO-b-PCL polymersome at a concentration of 2.6mgPEO-b-
PCL/ml (4.65uM porphyrin) 
(3) PEO-b-PCL polymersomes without DOX or porphyrin at a concentration of 
2.6mgPEO-b-PCL/ml  
(4) free DOX drug at a DOX concentration of 0.122mg/ml.   
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 Each group consisted of four mice.  The concentration of DOX delivered to the 
mice in this study was approximately 10% of the concentration delivered in the 
Therapeutic Study described above.  Furthermore the porphyrin concentration was 
approximately 1/3 the concentration delivered in the Diagnostic Studies described above, 
however, twice the volume of porphyrin vesicle suspension was delivered, making the 
total porphyrin injected approximately 2/3 of the amount injected in previous studies.  
Recall from Chapter 4, the loading of DOX into porphyrin vesicles is difficult and 
inefficient; this is most likely the result of the large hydrophobic porphyrin molecules 
hampering the diffusion of the DOX molecules across the hydrophobic bilayer.   
 Post treatment, tumors were measured daily and mice were weighed every day.  
Tumor volume was determined by the equation, l*w*h.   
 Prior to treatment, mice that were to be administered porphyrin vesicles and 
porphyrin-DOX vesicles were pre-scanned using the Licor Odyssey Infrared Imaging 
System equipped with the Odyssey MousePOD In vivo Imaging Accessory.  Mice were 
then scanned at regular intervals using the Odyssey and MousePOD Accessory.  Five 
days after the start of treatment, the mice were sacrificed and carefully dissected.  Organs 
were imaged post excision using the LICOR Odyssey.   
6.4 RESULTS AND DISCUSSION 
6.4.1 In vivo Biodistribution Studies Using Porphyrin Polymersomes 
 When Porphyrin loaded NIR-emissive nanopolymersomes are injected into the 
tail-vein of mice, the biodistribution of the nanoparticles can be tracked in vivo via non-
invasive NIR fluorescence-based optical imaging.  Figure 6.1 demonstrates the ability to 
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track PEO-b-PBD polymer vesicles in tumor bearing mice over 12 h.  Additional 
extended studies using porphyrin loaded PEO-b-PBD (Figure 6.2) and PEO-b-PCL 
polymersomes demonstrated the ability to track vesicles in vivo for up to 9 days and will 
be discussed in this section and in Section6.4.4.  It is important to note that initial studies 
were carried out using the biocompatible vesicle since it was known not to degrade in 
vivo.  Nonetheless, it is envisioned that the bioresorbable vesicles generated from PEO-b-
PCL diblock, might be able to link changes in fluorescence not only to the clearance of 
the vesicle but also to degradation of the vesicle.   
 Porphyrin NIR- emissive polymersomes injected into the tail vein of a tumor 
bearing mouse accumulated at the tumor site of non-necrotic tumors within four hours 
and remain at the tumor site for at least 72hours.  Furthermore, these vesicles are 
observed in vivo for at least 9 days and are cleared by organs of the reticuloendothelial 
system (RES) as determined by imaging of fluorescence signals.  Upon culmination of 
the extended studies and excision of the organs, it was determined, though fluorescence 
imaging of the organs, that there was significant vesicles accumulation in the spleen, and 
liver.  Furthermore, even 7 days post treatment, a significant fluorescent signal is 
observed from the tail.   
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Figure 6.1- Tumor imaging by NIR-emmisive PEO-b-PBD polymersome.  
Fluorescence images obtained using eXplore Optix instrument of the same  mouse 
taken prior to administration of NIR-emissive polymersomes, and at 4, 8, and 12 h 
post tail-vein injection. (A) Prone position, (B) supine position (kex = 785  nm, kem = 
830–900 nm). The arrows in the prone and supine positions suggest location of 
organs. In the supine position, the arrow suggests the fluorescence emanating from 
the lower portion of the mouse body is from the tumor; it may also be emanating 
from the gut of the mouse due to break down of food.
Figure 6.2- Fluorescence images of the same mouse taken right after administration 
of NIR-emissive PEO-b-
216 hours post tail-vein injection.  
Images were acquired using the Licor Pearl Imager.  (A) Prone Position (B) Supine 
Position (λex =785nm, λem=830
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PBD polymersomes, and at 4, 8,12, 48, 72, 144, 168, 192, and
 
-900nm)  
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6.4.2 In vivo Intratumor Studies Using Porphyrin loaded PEO-b-PBD Polymersomes  
 The Olympus IV-100, intravital laser scanning microscope for small animal 
imaging, was used to examine the location of polymersome in relation to the tumor 
vasculature.  Prior imaging with the Olympus IV-100, the mouse was imaged using the 
GEArt to confirm the distribution of porphyrin vesicles and AngioSense-IVM 680 in the 
mouse’s body; furthermore the localization of porphyrin vesicles at the tumor site was 
verified using the GEArt.   
 Once the distribution of dye and vesicles was confirmed using the GEArt, the 
tissue on the tumor just below skin was imaged using the Olympus IV-100.  Figure 6.3 
clearly shows the co-localization of AngioSense IVM-680 in the vasculature and the 
porphyrin PEO-b-PBD vesicles, confirming their location in the tumor vasculature.  The 
left hand panel of Figure 6.3 used the signal from AngioSense IVM-680 to show the 
tumor vasculature (700 channel), while the middle panel shows the fluorescent signal 
from the polymersomes in the same area (800channel); the right hand panel is an overlay 
of the left and middle panels and clearly shows the localization of porphyrin vesicles 
within the tumor vasculature.  
  
  
Figure 6.3- Intravital microscopy of the tumor tissue using the Olympus IV
Left hand pannel shows the tumor vasculature (using AngioSense IVM 680, 700 
channel); Middle pannel shows the localization of porphyrin polymersomes (800 
channel); Right pannel is the overly of the images from each channel clearly 
showing the co-localizati
6.4.3 In vivo Therapeutic Study Using Doxorubicin loaded PEO
 Doxorubicin loaded bioresorbable PEO
in vivo to xenotransplanted
capability to retard tumor growth was assessed 
weight.   
As demonstrated 
loaded PEO-b- PCL polymersomes
with the commercially available
formulation of doxorubicin
weights remained within ±1.5 g of the initial
the study.  
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on of porphyrin vesicles in the blood vessels.  
-b-PCL Polymersomes
-b-PCL polymersomes were administered 
 (T6-17 cells) tumor-bearing mice and their therapeutic 
using such metrics as tumor size and body 
in Figure 6.4Error! Reference source not found.
 were able to retard tumor growth in 
 agent DOXIL ® (a clinically administered
), and better than free drug and PBS alone.  
 weight, for all treatment groups throughout
 
-100.   
 
 
, doxorubicin 
mice on a par 
 liposomal 
Further, mouse 
 
Figure 6.4- Anti-tumor effects of doxorubicin loaded 
mice.  
Mice were inoculated with tumor cells on day 0, were administered drug (free dox, 
dox loaded polymersome, or DOXIL) or PBS on day 7, and sacrificed on day
Images of tumor bearing mice 
culmination of the study, day 16. (B); (C
Tumor volumes of the 5 mice per group averaged. Error bars are reported as 
standard error. 
A blood sampled was drawn from each mouse and analyzed using a HEMAVET 
(Figure 6.5).  White blood cell (
elevated in control mice 
in any form.  Since WBC is a measure of the body’s response to cytotoxic agents, the 
results demonstrate that all DOX treatments have the same level of systemic toxicity.  
RBC counts, HB, HCT and PLT values are similar for the various treatment groups
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PEO-b-PCL polymersome in 
administered PBS (A) and DOX polymersomes at the 
–E) Average tumor Volume vs. Time, 
WBC) count and neutrophil (NE) count are slightly 
receiving PBS only, but similar for the mice administered DOX 
 
 16. 
.    
Figure 6.5- The effect of different treatments on the red blood cell (RBC) count (A), 
platelet (PLT) count (B), white blood cell (
(D), hemoglobin (HB) count (E), and hematocrit (HCT) (F).  
n=5. Error bars= ±S.E. 
The tails and bodies of mice administered Doxil (cage 1) turned pink one day 
after drug was administered
(cage 4)  (Figure 6.6C) and PBS or free DOX were no
mouse bodies and tails were 
and/or scabbing tails were observed on 3/5 of the mice receiving
(Figure 6.6A,B) while the tails of mice receiving DOX 
(cage 4) showed only slight
the culmination of the study.  It should be noted that mice some of the mice that received 
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WBC) count (C), neutrophil (NE) count 
 
 (Figure 6.6A,B) while those administered polymerso
t nearly as pink.  Pictures 
taken two days after drug administration. 
 free 
polymersome
 signs of irritation (Figure 6.7C,D).  Images were obtained at 
 
mes 
of the 
Infected, oozing 
DOX (cage 3) 
s as a treatment 
Doxil treated mice exhibited aggressive behavior and were difficult to handle in 
comparison to the mice re
better tolerated than DOXIL.  
Figure 6.6- Images of mouse bodies and tails two days after administration of (A, B) 
Doxil and (C) DOX polymersome
Images were taken two days after treatment.  
166 
ceiving other treatments suggesting that DOX polymersome is 
 
s.   
 
 
Figure 6.7- Images of mouse tails post free DOX treatment (A,B) and 
DOXpolymersomes (C,D).  
Images were taken at the culmination of the study.  
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6.4.4 In vivo Theranostic Study Using Doxorubicin and Porphyrin Loaded PEO-b-PCL 
Polymersome  
 This study married the two main goals of this thesis linking drug delivery with 
imaging.  As described, mice were administered one of the following treatments:  
doxorubicin-porphyrin polymersomes, porphyrin polymersomes, unloaded polymersomes 
or free doxorubicin in PBS, all at the same concentration of drug (doxorubicin), imaging 
agent (porphyrin), and polymer where applicable.   
 Figure 6.8 demonstrates the ability to track bioresorbable PEO-b-PCL vesicles 
loaded with porphyrin in vivo using an Odyssey Imager with MousePOD Accessory.  It 
should be noted that there was considerable background on many of the images due to 
residual dye on the skin or skin distress; when the skin is distressed, the laser light gets 
trapped in the nicks of the roughened skin, and is detected erroneously as fluorescent 
signal.   
 Similar to the imaging study described in Section 6.4.1 using biocompatible PEO-
b-PBD vesicles, fully bioresorbable PEO-b-PBD vesicles localize to the tumor within 12 
hours, and clear over the course of 120 hours, with the greatest accumulation occurring 
24-48 hours post administration.  At 24 hours post vesicle administration, signal was 
observed in vivo from 100% of the mice administered porphyrin vesicles and 75% of the 
mice administered doxorubicin-porphyrin vesicles.  At 120 hours post vesicle 
administration, signal is observed ex vivo from 100% of the tumors of mice administered 
porphyrin vesicles and porphyrin-doxorubicin vesicles (Figure 6.10).  As expected, 
excised tumors of mice administered PEO-b-PCL polymersomes without porphyrin only 
showed fluorescent signal in the 700 channel (red) due to auto fluorescence, but did not 
show any fluorescent signal in the 800 channel (green) (
Figure 6.8- Representative fluorescent images of a mouse administered porphyrin 
PEO-b-PCL vesicles.   
Left hand panel:  two color images showing 700 channel (red, auto fluorescence) and 
800 channel (green, porphyrin po
rendering of the 800 channel showing the intensity of the signal from various 
organs.  Top (890 to 5000), Bottom (370
position.  Pink arrow- liver; Cyan arrow:  sple
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Figure 6.10).   
lymersomes).  Right hand panel:  Pseudo
-472).  Top- supine position; Bottom
en; Yellow arrow:  tumor.  
 
-colored 
- prone 
 
Figure 6.9- White light image of mouse shown in 
Figure 6.10- Ex vivo imaging of tumors excised 120 hours post administration of 
vesicles.   
A) Two color images showing 700 channel (red,
(green, porphyrin polymersomes); B) Pseudo
showing the intensity of the signal from various tumors (Range 300
Tumors excised from mice administered porphyrin PEO
Tumors excised from mice administered porphyrin
vesicles; Row C- Tumors excised from mice administered PEO
without porphyrin.   
 Vesicle accumulation in the spleen and liver is apparent in the images in
6.8 and Figure 6.11A.  Vesicles are cleared by the kidneys as evide
well as the fluorescence emanating from the mouse paws and underbelly (observed in 
Figure 6.8); this results from residual fluorophore on the skin from the urine.  
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Figure 6.8.   
 auto fluorescence) and 800 channel 
-colored rendering of the 800 channel 
-b-PCL vesicles; Row B
-doxorubicin PEO
-
nced 
 
-140).   Row A- 
- 
-b-PCL 
b-PCL vesicles 
 Figure 
Figure 6.11A as 
Figure 6.11 
B and C demonstrate that the accumulation of vesicles in the tumor is heterogeneous and 
most likely dictated by the blood vesicles or lack thereof in portions of the tumor.  Note 
that after 120 hours, a majority of the vesicles have been cleared from the tumor and have 
localized to the organs of the RES.  Note that there is minimal accumulation of the 
vesicles in the heart (Figure 
the site of injection, while 
this difference is probably caused by variability in the tail vein injections.  It appears that 
sequestering of vesicles in the tail is predominan
evidenced by multiple fluorescent sites) are required to deliver the volume of vesicles.  
Figure 6.11- Pseudo colored images from fluorescence in the 800 channel 
from A) excised organs (clockwise:  liver, lungs, spleen, kidneys, and tumor.  Center 
position:  heart) B) sliced tumor and C) whole tumor.  
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6.11).  Figure 6.12B shows vesicles sequestered in the tail at 
Figure 6.12A shows the tail almost entirely cleared of vesicles; 
tly observed when multiple injections (as 
 
 
 
emanating 
Figure 6.12- Excised tails from two different mice 
clearance of the vesicles, while the bottom tail shows considerable accumulation of 
the vesicles in the tumor at the sites of injection.
 Figure 6.13 shows the tumor volumes in millimeters cubed for the mice 
administered the different treatments.  It is clear that mice administered porphyrin only 
vesicles had larger tumors than mice administered doxorubicin
four days after treatment.  The tumors of the mice administered porphyrin
vesicles were on par with mice 
mice administered free DOX after four days of treatment.  This most likely results fro
the fact that at the start of the administration of treatment two populations of tumor sizes 
were present—large and small.  We used mice with tumors in the “large population” for 
the imaging-drug studies and mice with tumors in the “small population” for
studies (free DOX and vesicles only).  As such, the growth potential for tumors in the 
“small population” was much less than that of the tumors in the “large population.  
Hence, although mice administered doxorubicin
on par or greater than mice administered vesicles only or free DOX, respectively, this is 
probably the result of different tumor sizes at the 
the amount of drug administered was approximately 10% of that
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imaged ex vivo.  Top tail shows 
 
-porphyrin vesicles up to 
administered vesicles only and larger than the tumors of 
-porphyrin vesicles had tum
beginning of the study.  Additionally, 
 administered in the 
 
-doxorubicin 
m 
 the control 
ors that were 
therapeutic study.  At such a low concentration of drug, variability in the success of the 
t.v. injection can also lead to a significant variation in the amount of drug delivered.  
 After five days, there is a great increase in the si
administered free DOX, while the size of those administered DOX in vesicles does not 
increase nearly as much even though they were larger.  This is possibly due to the fact 
that the free drug is cleared much more rapidly from t
 4
Figure 6.13- Tumor Volume (mm3) for mice administered porphyrin PEO
Vesicles (blue diamonds), Doxorubicin
squares), PEO-b-PCL 
circles). 
Four mice per group, error bars are reported as 
 Results from this study demonstrate the possibility that with an increased 
dosage and tumors of the same size at the start of the study
tumor size between mice administered porphyin
treatments could be observed.  
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ze of the tumors of the mice 
he tumor site than the vesicles.  
-Porphyrin PEO-b-PCL Vesicles (red 
Vesicles (green triangles), and Free Doxorubicin (yellow 
±SEM 
, a dramatic difference in
-DOX vesicles and all other 
 
 
 
 
-b-PCL 
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6.5 CONCLUSIONS  
 We have shown that porphyrin PEO-b-PBD and PEO-b-PCL polymersomes can 
be used to non-invasively track the location of polymersomes, and may potentially be 
applied for diagnostic studies.  Porphyrin polymersomes will greatly decrease the number 
of animals required for biodistribution since the location of the polymersomes can be 
determined without sacrificing animals at multiple time points to perform histology on 
the excised organs.  Furthermore, the localization of the vesicles in the tumor vasculature 
was confirmed using intravital microscopy.   
 The ability of doxorubicin loaded PEO-b-PCL polymersomes to retard tumor 
growth on par with DOXIL® (the clinically administered liposomal formulation of 
doxorubicin) and better than free DOX was confirmed.  Multi-functional polymersomes 
loaded with doxorubicin and porphyrin were tracked in vivo for 120 hours and were able 
to retard tumor growth in comparison to porphyrin polymersomes.  Due to tumor size 
variation at the start of the study, the porphyrin-doxorubicin PEO-b-PCL polymersomes 
did not did not perform as expected.  However, based on overall polymersome 
performance, it is believed that with minor modifications which will be discussed in 
Chapter 7, multimodal polymersomes hold promised for theranostic applications.    
 The ability to load components into the polymersome membrane and core shows 
enormous promise for dual modality polymersomes which will allow for the continuous 
noninvasive monitoring of drug-loaded nanopolymersomes in vivo, obviating the need to 
sacrifice animals at each time point to determine basic pharmacokinetic and 
biodistribution profiles, thereby greatly reducing animal load.  Hence, polymersomes 
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hold enormous potential to be nanostructured biomaterials for future drug delivery and 
imaging applications. 
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Chapter 7  
SUMMARY, MAJOR FINDINGS, AND SUGGESTED FUTURE 
RESEARCH FOR THE DEVELOPMENT OF FULLY BIORESORBABLE 
MULTI-FUNCTIONAL POLYMERSOMES  
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7.1 SUMMARY  
 The ability to deliver systemically toxic pharmaceutical agents or hydrophobic 
therapuetics with low bioavailability is a major challenge in treating malignancies.  
Combination therapies, consisting of either two different small molecules or a 
combination of small molecules and biologically active ligands, are currently used for the 
treatment of various cancers;  thus, the capability co-administer and simultaneously 
deliver them is of great importance.  In addition to treatment challenges, noninvasive 
diagnostic tools for the screening, diagnosis, and post treatment monitoring, are of 
particular clinical interest.  The ability to coencapsulate drug and imaging agent, enabling 
the “imaging of drug delivery”, can greatly enhance exploration into various treatment 
options and elucidate the efficacy of these treatments.  Liposomes are presently used in 
various biotechnological and pharmaceutical applications to improve therapeutic indices 
and enhance cellular uptake [4], but it appears that polymersomes can offer superior 
advantages for future clinical therapeutic and diagnostic applications.   
 In this thesis, I develop, characterize, and evaluate in situ, in vitro, and in vivo, 
polymersomes (polymeric vesicles):  
a)  with the ability to co-encapsulate doxorubicin, a chemotherapeutic, and 
combretastatin, a vascaular disrupting agent, for the co-administration of two 
different therapeutics, creating a tool for the eradication of both tumorigenic 
cells and vascular cells.   
b)  and with the ability to co-incorporate doxorubicin and porphyrin, a highly 
hydrophobic near infrared fluorophore, for the capability to simultaneously 
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image and deliver pharamacetuical agents, essentially creating a tool for 
therapy and diagnosis.   
7.2 MAJOR RESULTS WITH RESPECT TO THE AIMS DELINEATED IN 
CHAPTER 1  
7.2.1 Aim 1:  To load physiologically relevant molecules and imaging agents into the 
polymersome and characterize release kinetics 
 Doxorubicin was successfully loaded into the PEO-b-PCL polymersome, as well 
as polymeric vesicles compromised of other diblock copolymers.  The different loading 
parameters were explored and it was determined that loading DOX into PEO-b-PCL 
vesicles could be accomplished using only an ammonium sulfate gradient, but the loading 
of DOX into PEO-b-PBD and PEO-b-PmCL required the generation of a pH gradient as 
well as an ammonium sulfate gradient.  This difference in loading environment was 
attributed to the differences in hydrophobicity between the different hydrophobic 
backbones.  Combretastatin incorporation into PEO-b-PCL vesicles was also established.   
 The insight gained from loading doxorubicin into these polymeric vesicles, 
enabled the successful encapsulation of doxorubicin into combretatstatin incorporated 
vesicles and into porophyrin encapusulated vesicles.  Similar to the encapsulation of 
DOX into PEO-b-PBD and PEO-b-PmCL vesicles, these encapsulations required the use 
of both a pH and ammonium sulfate gradient.   
 Doxorubicin release kinetics from the various vesicles and co-encapsulations was 
characterized.  The cumulative release of drug from the vesicles interior occur though the 
diffusion of the amphiphilic molecule across the vesicle membrane and by degradation of 
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the hydrophobic backbone of the vesicle.  These release mechanisms depend upon both 
the pH of the external solution and the polymer and hydrophobic encapsulant 
composition of the vesicles.   The successful co-encapsulation of DOX and 
combretastatin lead to the generation of a polymersome with the potential to treat tumors 
by affecting both the vasculature and tumor cells.  The encapsulation of DOX into 
porphyrin incorporated vesicles lead to the creation of vesicles with therapeutic and 
diagnostic capabilities.   
7.2.2 Aim2 Load Doxorubicin into the Aqueous Core of Dendrosomes 
 Doxorubicin was successfully encapsulated into the aqueous core of 
dendrosomes, vesicles self-assembled from various amphiphilic Janus-dendrimers.  Due 
to stability issues of the dendrosomes at low pH, doxorubicin was not actively loaded 
across a gradient as it was for the case of polymersomes, but rather it was loaded 
passively by incorporation in the hydration solution.  Release studies were performed and 
show a significantly higher release of drug at acidic pH than at physiological pH.  Drug 
release was observed to vary depending on both pH of the external solution and 
dendrosome library.   
 The toxicity of the dendrosomes was evaluated in vitro on human umbilical vein 
endothelial cells (HUVECs) using Cell Titer-BlueTM.  The results indicate only minimal 
toxicity as compared to polymersomes after four hours of incubation with vesicles.   
 The results of dendrosome studies establish their the potential use as of self-
assembled dendrimeric vesicles for drug delivery purposes 
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7.2.3 Aim 3:  To study the in vitro effects of functional polymersomes using HUVECs 
and SK-BR-3 tumorigenic cells 
 The effects of PEO-b-PCL vesicles on HUVECs and SK-BR-3 cells were 
examined separately.  It was determined that the HUVECs incubated with PEO-b-PCL 
polymersomes remain 50% viable after 72 hours, even when incubated at the high 
concentration of polymer.  At short times, SK-BR-3 cells appear to tolerate the PEO-b-
PCL polymersomes, with viability as great as 50% after 12 hours.  However toxicity is 
observed at longer times, where after 72 hours only 50% of cells cultures in the lowest 
polymer concentration are viable. 
 The cellular uptake of PEO-b-PCL by HUVECs and SK-BR-3 cells was 
determined using porphyrin polymersomes.  The uptake of vesicles by these cell types was 
established over 5 hours and it was determined that the uptake is dependent upon both 
vesicles concentration and incubation time.   
 Lastly, the cytotoxic effects of drug loaded polymersomes on cell viability were 
investigated with cells cultured both separately and in co-culture.  In general, toxicity was 
a function of both drug concentration and incubation times.  Preliminary co-culture assays 
suggest that cells in co-culture appear to be less adversely affected initially by the drug 
loaded vesicles.   
 These in vitro experiments establish the potential of using polymersomes loaded 
with doxorubicin and combretastatin for the simultaneous (and independent) destruction 
of tumorigenic and endothelial cells.   
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7.2.4 Aim 4:  To demonstrate the in vivo potential of polymersomes for imaging and 
drug delivery applications using athymic nude mice with xenograft tumors 
 Using NIR-emissive porphyrin PEO-b-PBD polymersomes, the biodistribution of 
vesicles was determined both at short times (up to 12 hours) and at long times (up to 9 
days) using the eXploreOptix GEArt and LI-COR Odyssey, respectively.  These studies 
demonstrate accumulation of vesicles at the tumor site within 4 hours, with the greatest 
accumulation after 24 hours.  Furthermore, localization of the vesicles with the spleen 
and liver were observed in vivo and ex vivo studies also demonstrate accumulation in the 
kidneys and lungs.  Subsequent studies carried out using NIR-emissive porphyrin PEO-b-
PCL polymersomes show similar results.   
 The anti-tumor effects of doxorubicin loaded PEO-b-PCL polymersomes on 
tumor suppression in vivo were demonstrated using metrics such as tumor volume and 
mouse weight.  Athymic nude mice were administered one of four treatments 
(doxorubicin polymersomes, DOXIL®, unencapsulated doxorubicin, and PBS) and it was 
determined that the DOX polymersomes was able to retard tumor growth in mice as well 
as DOXIL®, and better than free DOX.  Furthermore, physical behavioral disposition of 
the treated mice, suggested that the polymersome may be a superior delivery vehicle for 
the drug.   
 The potential to image drug delivery through the use of multi-functional 
doxorubicin loaded porphyrin incorporated PEO-b-PCL polymersomes was highlighted.  
Mice were administered one of four treatments (DOX-porphyrin polymersomes, 
porphyrin polymersome, unloaded polymersomes, and free DOX).  While the results of 
the study are not nearly as promising as was desired, the study does demonstrate the 
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ability to use bioresporbable vesicles loaded with drug for imaging and treating tumors 
highlighting their potential for theranostic applications. 
7.3 SIGNIFICANCE OF RESULTS 
 Through preliminary developmental studies, multi-drug loaded PEO-b-PCL and 
multi-functional PEO-b-PCL polymersome were successfully generated.  These multi-
drug loaded vesicles demonstrate potential utility for combination therapies where the 
simultaneous co-localization of the drug is imperative for effective therapy, for example 
when administering a vascular disrupting agent and a chemotherapeutic.  If the anti-
vascular agent is administered prior to the chemotherapeutic, the chemotherapeutic may 
never reach the tumor site because of vasculature disruption.  The multi-functional 
porphyrin-doxorubicin PEO-b-PCL polymersome enables the drug loaded vesicles to be 
tracked in vivo.  This novel ability is believed to prove exceedingly useful for monitoring 
therapeutic outcomes of after administration of therapy.  In addition, this combination 
vesicle will greatly assist in drug biodistribution studies where the number of animals 
required can be greatly reduced since location of the drug over time can be tracked 
fluorometrically, obviating the need to sacrificing multiple animals at various time points 
for histological assessment on the excised organs.   
7.4 FUTURE WORK AND INVESTIGATIONS TOWARDS THE DEVELOPMENT 
OF A CLINICALLY RELEVANT FULLY-BIODEGRADABLE MULTI-
FUNCTIONAL POLYMERSOME FOR IN VIVO THERANOSTIC APPLICATIONS 
 As demonstrated throughout this thesis, bioresorbable polymersomes hold 
considerable promise to be clinically relevant nanoparticles for the simultaneous delivery 
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of dual therapeutics and imaging agents.  However, a few key modifications to the 
vesicles would enhance their clinical utility.  Furthermore, additional experimentation is 
required to bring theses nanoparticles from bench to bedside.  This section will highlight 
additional experiments deemed necessary to demonstrate the clinical applicability of 
multi-modality vesicles, future surface modifications to the vesicles, and suggest 
additional changes to experiments already performed.   
7.4.1 Suggestions to Enhance Experiments Investigating the Anti-vasculature and 
Anti-tumor Potential of Combretastatin and Doxorubicin Loaded PEO-b-PCL 
Polymersomes on HUVECs and SK-BR-3 Cells in Co-culture  
 As discussed in Chapter 5, considerable sticking was observed when carrying out 
stained co-culture cell viability assays to determine the effects of doxorubicin and 
combretastatin separately or together on co-cultured cells.  At the time of the 
experimentation, the dual color staining of cells using CellVue® stains from MTTI 
appeared to be a proper course of action for these preliminary experiments.  However, 
post experimentation, considerable cell sticking was observed with HUVECs.  It was 
determined that this sticking increases as the amount of time the nonviable cells remain in 
the wells increases; thus yielding false positive results (i.e. nonviable cells appear viable).   
 A dual-color fluorescence imaging based assay [38, 134], appears to be a 
promising alternative to the current assay.  In this assay, one type of cells in the co-
culture, the tumorigenic cells for example, will be transfected and selected such that they 
express green fluorescent protein (GFP).  The co-culture, comprised of HUVECs and 
tumorigenic cells, will be exposed to the various polymersome treatments for a defined 
period of time.  After administration of drug-loaded polymersomes, the cells will be 
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treated with propidium iodide to stain the nuclei and analyzed by dual-fluorescence 
confocal microscopy to determine the extent of treatment efficacy by examining the 
vascular network and survival of the tumor cells.   
 In addition to the dual-color fluorescent microscopy assay detailed above, if the 
morphological markers of cell death vary between the cell types, investigating 
morphological markers can be used to ascertain difference in cellular viability between 
each cell type.  In addition, the upregulation of various cellular markers on the cell can be 
examined to further determine the cellular viability of each cell type.   
 Additionally, it may be advantageous to co-culture the endothelial and 
tumorigenic on cells a three-dimensional Matrigel, as this will simulate the tumor 
environment better than cell culture plates.  
7.4.2 Suggestions for Future Surface Modifications to the Vesicles for Enhanced 
Therapeutic and Diagnostic Efficacy and Related Experiments 
 Tumor vasculature varies greatly from that of normal tissues.  The endothelial 
cells lining the vessels of solid tumors, where angiogenesis is prevalent, upregulate αv 
integrins, as well as receptors for various angiogenic growth factors [135].  These 
proteins, however, are not present or are present at very low levels in established normal 
blood vessels [135].  Thus, peptides directed at these upregulated proteins are good 
targets for cancer therapeutics.  Ruoslahti and colleagues showed that upregulated αvβ3 
integrins on tumor vasculature are active, available for binding by circulating RGD 
ligands, and expressed at levels sufficient for tumor targeting[135, 136].  Furthermore, αv 
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integrins are expressed on many human carcinoma cells as well as tumor vasculature 
[135]. 
 Peptides for homing to tumors (that can direct therapeutics to the tumor site) can 
enhance therapeutic efficacy and minimize adverse side effects [137].  This idea of 
enhanced therapeutic index with tumor-homing peptides was examined by Ruoslahti and 
coworkers who conjugated doxorubicin to an RGD peptide and administered the 
conjugated drug and free drug to nude mice with human tumor xenografts [135].  In 
addition to increased survival rate and decreased tumor size, nude mice treated with the 
dox-RGD conjugates exhibited less cardiac and liver toxicity than those treated with free 
DOX [135].  
 This data suggests that decorating the PEO brush surface of the fully-bioresobable 
polymersome loaded with combretastatin and doxorubicin with an RGD peptide capable 
of targeting tumor vasculature as well as cancer cells would enhance the localization of 
the vesicles at the tumor site and ultimately improve therapeutic efficacy. 
 Peptides targeting upregulated αv-integrins can be conjugated to the PEO brush of 
the polymersome via various covalent and modular chemistries.  Currently, Joshua Katz 
(Hammer and Burdick Laboratories) is working on the ability to functionalize the 
polymer chain ends through amidation chemistry, where by the amine of the peptide is 
conjugated to a carboxylic acid at the end of the PEO block to form an amide bond.  
Furthermore, the biotin-avidin binding represents a method of modular chemistry for 
peptide conjugation.  A biotin molecule is attached to the PEO brush of the polymersome 
surface and an additional biotin molecule is attached to the end of the peptide. The 
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biotinylated polymersome and the biotinylated peptide are joined by an avidin molecule 
[21].  It should be noted that the attachment of peptides to the vesicle surface has been 
previously attempted by P. Peter Ghoroghichian [53] with limited success in maintaining 
vesicular structure with peptide attachment.  This is likely because the conjugation of 
ligands to the polymersome surfaces can alter the composite polymer amphiphiles’ 
hydrophilic-block-to-total-mass ratio leading to a change in structural morphology (e.g. 
from vesicles to micelles) [132].  Hence peptide attachment to polymer vesicles should be 
confirmed using both cryo-TEM, to images the vesicles, and well as fluorescence 
microscopy to confirm the presence of an aqueous reservoir.   
 Once peptide attachment to vesicles is confirmed, Enzyme-linked Immunosorbent 
Assay (ELISA) can be performed to ensure binding of the RGD peptide-conjugated 
polymersome with αv integrins and to determine binding properties of the αv integrin to 
the conjugated polymersome.  Equilibrium binding of the RGD peptide-conjugated 
polymersomes to purified αv integrins will be examined using an ELISA assay.  RGD 
peptide-conjugated polymersomes, scrambled RGD peptide-conjugated polymersomes, 
and non-conjugated polymersomes will each be mixed with purified αv integrins.  After 
integrin binding, the sample will be purified to remove unbound integrin, and an antibody 
for the integrin (but not function blocking) will be added to each sample.  Again the 
sample will be purified once binding had occurred.   Lastly, a secondary antibody linked 
to an enzyme such as horseradish peroxidase (HRP) will be added and allowed to bind to 
the anti-integrin antibody.  The sample will be purified, and the enzyme will be 
developed using a substrate solution.  After a period of time, the reaction will be 
quenched and absorbance readings will be determined using an ELISA reader [53].  
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Higher absorbance values will be seen with increased enzyme in sample, thus correlating 
to increased integrin-RDG peptide binding.   
 Once these in vitro studies are completed, further in vivo work to demonstrate 
increased therapeutic outcomes as well as increased localization to the tumor site are 
necessary.  Anti-tumor potential of the peptide-decorated drug loaded polymersomes can 
be assayed as a measure of tumor volume and mouse survival.  The localization of these 
peptide conjugated vesicles can be demonstrated through vesicle tracking with the 
porphyrin fluorophore as shown in Chapter 6.   
 These enhancements and confirming studies can lead to the generation of a fully-
bioresorbable vesicle with potential to directly and simultaneous effect tumor cells and 
the endothelial cells which grow up to support their existence.   
7.4.3 Suggestions for Future Work and Experiments to Enhance In Vivo Component 
of this Thesis 
 Through the work described in this thesis, considerable advancements have been 
made in marrying the drug delivery and imaging applications of polymersomes.  
However, there are still challenges which must be overcome.  First and foremost, the 
sizing of the vesicles is an extremely labor and time intensive task and a system to 
automate the extrusion process is essential if vesicle preparation is to be scaled up for 
clinical use.   
 In addition, the loading efficiency of DOX, when loaded into porphyrin 
incorporated vesicles, must be further enhanced and better controlled so that a substantial 
amount of drug can be delivered to the tumors.  Currently, the loading is quite poor and 
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as such, only 1% of the dose deliver in the Therapeutic Studies was delivered in the 
Theranostic Studies.  The addition of a targeting agent to the vesicle should enhance the 
localization of vesicles to the tumor site, decrease systemic delivery of the drug, and 
thereby increase the amount of drug delivered to the tumor.  Once the loading efficiency 
of DOX in porphyrin-incorporated vesicles has been increased, the Theranostic Study 
described in Chapter 6 should be repeated as the potential to demonstrate the “imaging of 
drug delivery” has been demonstrated, and could be confirmed with an increase in drug 
concentration at the tumor site.   
 As eluded to in Chapter 6, it is envisioned that the bioresorbable vesicles 
generated from PEO-b-PCL diblock, might be able to link changes in fluorescence not 
only to the clearance of the vesicle, but also to degradation of the vesicle.  While PEO-b-
PBD vesicles are biocompatible, they are not known to be biodegrable. Thus, changes in 
fluorescence associated with the non-degradable PEO-PBD vesicles, would provide 
information about biodistribution and in vivo clearance of the vesicles while changes in 
fluorescence of the degradable PEO-PCL vesicles should provide information about 
clearance and biodistribution, as well as vesicle breakdown and subsequent drug delivery.  
Data in Chapter 4 demonstrated a decrease in porphyrin fluorescence as doxorubicin is 
released from the vesicle interior.  To carry out this experiment, mice should be 
administered, PEO-b-PBD and PEO-PCL vesicles with porphyrin incorporated into the 
bilayer.  The in vivo fluorescence should be tracked over time, and organs examined for 
fluorescence upon culmination of the study to determine vesicle location and breakdown.   
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 Once these studies establish the ability to demonstrate vesicle degradation in vivo 
through changes in fluorescence, the drug delivery component should be added by 
administering doxorubicin loaded vesicles in both the biocompatible and biodegradable 
formulation.  Post treatment, tumor volumes and fluoresce should be monitored in vivo at 
regularly established time points.  At the culmination of the study, organs should be 
harvested and fluorescence measured.  In addition to imaging whole organs for 
fluorescence signal from the porphyrin in the vesicles, these tumor should be sectioned, 
and sections should imaged for both DOX florescence [28] and porphyrin fluorescence.  
Ex vivo imaging of visible fluorophores is possible at sub-millimeter depths [114].  These 
studies will assist in fully capturing the essence of polymersomes for imaging drug 
delivery.   
 Lastly, in an effort to further develop multi-drug vesicles for clinical in vivo 
applications for the simultaneous delivery of drug to two different cell types, namely 
endothelial cells and tumorigenic cells, once clearance is granted for in vivo studies, in 
addition to demonstrating increased tumor suppression when combretastatin is delivered 
in combination with DOX, the tumor vasculature post delivery of the VDA should be 
examined.  Mice should be administered chemotherapeutic vesicles with and without 
combretastatin, as well as blank vesicles to compare the therapeutic effects of the dual 
drug loaded vesicles against single drug vesicles and control (non-drug loaded) vesicles.  
Tumor volumes should be monitored daily, and mouse weights recorded every other day.  
At the culmination of the study, prior to sacrificing mice, if possible, mice should be 
administered Angiosense 680 IVM and the tumor vasculature examined using the 
Olympus IV-100 described in Chapter 6 for invasive in vivo examination of the tumor 
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vasculature.  Once the vasculature dye has cleared, the mice should be sacrificed, tumors 
harvested, sectioned, and stained for vWf, CD34, CD31, which are known markers of 
blood vessels in order to get a better understanding of the effects of combretastatin on 
tumor vasculature.   
7.5 CONCLUDING REMARKS 
 Considerable progress was made in establishing the utility of polymer vesicles for 
drug delivery and diagnostic applications.  In vitro work was performed to characterize 
the effects of these vesicles on endothelial and tumorigenic cells.  However, the ultimate 
experiments in establishing the significance of these vesicles in clinical biological 
applications were performed in vivo through collaboration with Dr. Murali.  For future 
clinical use of the theranostic polymersomes, however, the efficiency of loading 
doxorubicin into porphyrin vesicles must be greatly enhanced, so that a significant dose 
of drug can be delivered to the tumor site.  Furthermore, to fully realize the potential of 
multi-drug vesicles, the attachment of a vascular homing peptide to target the vesicles to 
the tumor would probably enhance therapeutic efficacy of the drug loaded vesicles.  As a 
final permutation, to provide both dual therapeutic action as well as imaging capability, a 
vascular targeting peptide with known therapeutic value could be attached to the PEO 
brush surface of doxorubicin-porphyrin PEO-b-PCL vesicles, enabling the simultaneious 
imaging of drug delivery to both endothelial and tumorigenic cells.   
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